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Abstract 
Malaria is a disease resulting from infection with protozoan parasites of the genus, 
Plasmodium. Malaria remains a leading cause of global deaths, particularly of children living in 
sub-Saharan Africa. Despite significant research efforts, an effective strategy for inducing robust 
Plasmodium-specific immunity remains elusive. CD4+ T helper (Th) cells are critical components 
of the adaptive immune response to blood-stage Plasmodium parasites. During experimental 
malaria in mice two major Th cell types arise, T helper 1 (Th1) and T follicular helper (Tfh) cells, 
both of which are associated with improved infection outcomes. Immune mechanisms controlling 
the emergence of Th1 and Tfh cells during Plasmodium infection remain poorly characterised, due 
in part to the absence of appropriate in vivo reagents.  
To elucidate mechanisms involved in the emergence of parasite-specific Th cells, recently 
developed Plasmodium-specific CD4+ T cell receptor (TCR) transgenic T cells (termed PbTII cells) 
were assessed for their in vivo response in mouse models of malaria. Adoptively-transferred PbTII 
cells proliferated during infection in a manner dependent on MHCII-expressing cells and 
conventional dendritic cells. By the peak of infection, PbTII cells had differentiated into Th1 and 
Tfh cells, mirroring the endogenous polyclonal CD4+ T cell response, and emphasising the utility 
of this reagent for further studies of in vivo Th responses.  
Next, a relatively new technology, single-cell RNA sequencing (scRNAseq), was applied to 
PbTII cells to explore at a molecular level the process of Th differentiation in vivo. After initial 
priming events, emerging Th cells entered a state of high cell cycling, in which they expressed 
genes associated with both Th1 and Tfh subsets. This occurred prior to their commitment to a 
differentiated, and possibly terminal, Th1 or Tfh effector state. In this pre-Th state, cells remained 
'impressionable' to external signals. Using scRNAseq, inflammatory monocytes were identified as 
likely providing one such signal. Furthermore, in vivo depletion of monocytes after a period of 
initial priming resulted in a reduction in Th1 but not Tfh cell responses.  
Although numerous innate immune sensors have been implicated in the detection of blood-
stage Plasmodium infection, whether such molecules influence Th responses remains unclear. 
Therefore, PbTII cells were employed to determine T-cell extrinsic signals that might drive Th 
responses, and modest roles for individual innate immune sensing molecules were observed. 
However, interferon regulatory factor 3 (IRF3), which sits downstream of several innate sensors, 
played a strong role in the clonal expansion of PbTII cells during infection. Importantly, using Irf3
-/-
mice, IRF3 was shown to support T cell clonal expansion and promote Th1 differentiation. IRF3 
was also required for inflammatory monocytes to express MHCII, suggesting a possible 
  
ii 
contributory mechanism. Interestingly, IRF3 exerted a suppressive effect on humoral responses, by 
limiting Tfh cell and germinal centre (GC) B cell responses. Notably, IRF3-deficiency improved 
GC B cell responses, promoted stronger and longer-lasting Plasmodium-specific serum antibody 
levels, and accelerated the resolution of infection. Finally, in mixed bone marrow chimeric mice, 
IRF3-deficent B cells responded more effectively than WT counterparts, suggesting a B-cell 
intrinsic suppressive role for IRF3.  
In summary, PbTII cells have been demonstrated to be an effective tool for studying 
Th1/Tfh differentiation in vivo. During experimental blood-stage malaria PbTII cells do not commit 
to an effector state until several days after initial priming. Prior to this point, pre-Th cells remain 
receptive to external inputs, such as those supplied by myeloid cells including inflammatory 
monocytes. Finally, an innate immune transcription factor, IRF3, exhibits roles in sustaining Th1 
differentiation, and suppressing Tfh cell and B cell responses. Therefore, IRF3 represents a 
potential target for improving immunological protection against blood-stage Plasmodium parasites.  
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Chapter One: 
Literature review 
The human body is constantly at risk of infection from micro-organisms, such as the 
protozoan parasite species, Plasmodium, the causative agent of malaria. Whether infection causes 
disease depends on a delicate balance between pathogenicity of the organism and defence 
mechanisms employed by the body, including those mediated by the immune system (Parkin and 
Cohen 2001). Understanding the body’s response to infection is therefore of critical importance to 
tip the balance towards a favourable outcome for the host.  
The immune system encompasses a vast array of cells with the collective goal of defending 
the body against disease. Broadly speaking, the immune system can be divided into two arms based 
on the speed and specificity with which it responds. The first arm is the innate immune system, 
which is rapid in its response, but displays a limited capacity to distinguish between threats. It 
includes physical and chemical barriers, as well as varied cell types, for example phagocytic cells 
that engulf particulate matter, and other cells specialised in the rapid production of soluble factors. 
The highly conserved nature of this immune response across evolutionarily-distant phyla, including 
the simplest of animals, demonstrates its necessity for survival. The second arm of the immune 
system is the adaptive immune system, which generally takes longer than the innate immune system 
to mount an effective response, and is more specifically targeted towards the immune challenge 
presented. The adaptive immune system is also comprised of numerous cell types, the most 
important and prevalent of which are T cells and B cells. A key feature of the adaptive response is 
that it confers 'immunological memory', so that secondary infections are dealt with more effectively, 
via a faster and stronger host adaptive immune response. Although different cell types of the innate 
and adaptive immune systems exhibit unique and individual behaviours, in practice, highly complex 
interactions between these cells must occur for an effective immune response to infection to be 
mounted. Indeed, vaccine design and immune therapies rely on these complex interactions.  
Malaria remains a significant global health concern; at least in part due to a limited 
understanding of how to induce host immune responses that provide long-lasting protection. This 
thesis seeks to determine novel cellular and molecular mechanisms controlling adaptive immune 
responses during malaria, principally those mediated by CD4+ T helper cells. This literature review 
will provide a detailed exploration of the field of malaria immunology. It will highlight gaps in 
knowledge regarding adaptive immune responses to malaria parasites that may be filled by novel 
approaches and technologies employed in this thesis.  
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1.2 Malaria 
Malaria is the disease resulting from infection with the protozoan parasite, Plasmodium. It 
remains a leading cause of global mortality, with an estimated 214 million cases and 438,000 deaths 
in 2015, 90% of which occurred in sub-Saharan Africa. Children under the age of 5 are particularly 
at risk of severe symptoms (WHO 2015). There are five species of Plasmodium known to infect 
humans: P. vivax, P. falciparum, P. malariae, P. ovale and P. knowlesi, with P. falciparum causing 
the majority of deaths. Symptoms of malaria include fever, fatigue, anaemia, nausea and sweating. 
However, more severe complications such as respiratory distress, metabolic acidosis and coma can 
also occur during P. falciparum infection. Despite the significant global health burden posed by 
malaria, there are still no effective vaccines or immune therapies for generating long-lasting, 
Plasmodium-specific immunity. 
Part of the difficulty in generating immunity to malaria may be linked to the complex life-
cycle of the Plasmodium parasite. Plasmodium parasites are spread to humans when an infected 
female Anopheles mosquito takes a blood meal (Figure 1.1). Transmitted parasites (sporozoites) 
migrate through the skin to the liver, where they infect hepatocytes. After a single round of 
replication, parasites spread to the bloodstream and infect erythrocytes. Here, they undergo asexual 
replication, producing many daughter parasites (merozoites) from every infected red blood cell 
(RBC). All of the clinical symptoms associated with malaria occur during the blood-stage of 
infection. Furthermore, parasite burden during this stage is currenty the most accurate predictor of 
patient prognosis (Dondorp, Desakorn et al. 2005). During P. falciparum infection, parasitised 
RBCs (pRBCs) can sequester in soft tissues such as the brain, kidney, liver and lung, which may 
perturb blood flow and promote severe symptoms as mentioned above (Carter and Mendis 2002). 
Some merozoites give rise to the sexual-stage parasites (gametocytes), which migrate to peripheral 
blood vessels of the skin, and await the opportunity to be taken up by a new mosquito taking a 
blood meal. If gametocytes are successfully taken up by another mosquito, they undergo sexual 
reproduction within the midgut. The resulting sporozoites move to the salivary glands and are 
transferred to a new human host when the infected mosquito takes another blood meal.  
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Figure 1.1 Life cycle of Plasmodium spp. The parasites (sporozoites) are transmitted to a human 
host via the bite of an infected female Anopheles mosquito. Sporozoites migrate through the skin 
and take up residence in hepatocytes. Here, they undergo asexual reproduction to produce blood-
stage parasites (merozoites). Merozoites enter the blood stream and infect RBCs. Inside RBCs, 
merozoites hijack host machinery to undergo further multiplication, causing rupture of the RBC 
when it has reached capacity. The released merozoites infect new RBCs to continue multiplying, or 
alternatively, become the sexual-stage parasite (gametocytes). Gametocytes migrate to the dermis 
where they may be taken up by mosquitoes, undergo sexual reproduction and continue the life cycle 
(Long and Zavala 2016). 
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1.2.1 Progress towards a successful malaria vaccine 
Large-scale interventions in endemic regions have contributed to the decline of global 
mortality due to malaria by 48% between 2000 and 2015 (WHO 2015). These interventions include 
the use of insecticide-treated bed nets, indoor residual spraying, chemoprevention in highly-
susceptible groups including pregnant women and young children, and use of rapid diagnostic tests 
(Steketee and Campbell 2010, WHO 2015). However, insecticide and antimalarial resistance are an 
increasing threat to the control of this disease. Thus, it is generally accepted that inducing long-
lasting immunological protection in at-risk individuals, either naturally or by vaccination, will be 
necessary for the eradication of malaria (Moorthy, Good et al. 2004).  
Over 100 years ago the German microbiologist Robert Koch was the first to observe 
naturally-acquired immunity to symptomatic malaria in individuals living in endemic areas 
(Stanisic, Mueller et al. 2010). In Papua New Guinea, where individuals are exposed to hundreds of 
infectious mosquito bites each year, young children and transmigrants had higher detectable 
parasite burdens than local adults (Stanisic, Mueller et al. 2010). From this he concluded that 
protective immunity develops slowly after many years of exposure. Further observations from the 
field showed that countries with high transmission rates, such as Kenya and Gambia, have the 
lowest incidence of cerebral malaria or severe malaria (Mbogo, Snow et al. 1993, McElroy, Beier et 
al. 1994). These observations support the argument that implementing control measures to prevent 
the transmission of infection could contribute to poorer outcomes for some individuals infected with 
Plasmodium (Snow, Omumbo et al. 1997). Therefore, inducing clinical immunity to curtail the 
symptoms of malaria in people living endemic areas is of absolute necessity to reduce the burden of 
malaria on world health.  
While naturally-acquired immunity is considered 100% effective against severe disease and 
death (Doolan, Dobano et al. 2009), it requires multiple infections over a number of years to 
develop and is easily lost in the absence of continual re-infection. Thus, considerable effort has 
been devoted to the development of a malaria vaccine that induces long-term protective immunity. 
In the 1940s, immunity to malaria was induced when ducks and monkeys were vaccinated with 
killed P. lophurae and P. knowlesi respectively (Freund, Sommer et al. 1945). In the 1960s, rodents 
were also protected after immunization with irradiated sporozoites (Nussenzweig, Vanderberg et al. 
1967). Subsequently, protection was demonstrated in humans. However, this was only achieved 
after large numbers of bites from irradiated infectious mosquitoes (Clyde 1975). In the 1980s, the 
circumsporozoite (CSP) protein was discovered as a major component of the sporozoite coat, which 
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demonstrated its promise as an alternative vaccination target (Dame, Williams et al. 1984, Enea, 
Ellis et al. 1984). 
The current most advanced vaccine candidate, RTS,S, is based on the CSP protein combined 
with the hepatitis B surface antigen to target the liver stage of disease. RTS,S is given alongside the 
adjuvant, AS01, a combination of mono-phosphoryl lipid A (MPL, a toll-like receptor 4 agonist), 
QS21 (a derivative of Quill A) and lipids (Stoute, Slaoui et al. 1997, Kester, Cummings et al. 2009). 
Results from phase III clinical trials of RTS,S were modest, with an efficacy of approximately 50% 
over 12 months in children aged 5-17 months (Olotu, Fegan et al. 2013). Furthermore, efficacy 
waned during subsequent years, reaching only 0.4% by the fourth year and declining most rapidly 
in children with high exposure to infection. However, since the application of this vaccine is 
considered useful in conjunction with current vector control measures, the European Medicines 
Agency’s Committee for Medicinal Products for Human Use recently adopted a positive scientific 
opinion for its use outside the European Union (EU) (Kaslow and Biernaux 2015).  
A combination vaccine approach, in which a range of Plasmodium antigens expressed at 
different stages of infection are targeted, could offer a way forward. Hence, the discovery of other 
candidate vaccines is still an area of intense research (Seder, Chang et al. 2013, Reddy, Pandey et 
al. 2014, Ishizuka, Lyke et al. 2016). Progress in this venture is slow, since it is still unclear what 
characteristics new vaccines should have and how their effectiveness should be evaluated. This 
necessitates continued studies into the immune mechanisms mediating protection to Plasmodium 
infection (Riley and Stewart 2013). 
 
1.3 Immunity to malaria 
1.3.1 Experimental models of malaria 
Studies of the immune response to Plasmodium infection have benefitted from field 
observations, clinical trials and experimental models. Although human studies are desirable, they 
have many limitations, including lack of access to relevant tissues and the difficulty in 
demonstrating causation (Langhorne, Buffet et al. 2011). For these reasons animal models can be 
useful. Four mouse models of Plasmodium infection are routinely used for modeling the various 
manifestations of human malaria. Plasmodium berghei ANKA (PbA) is typically used to mimic 
severe and cerebral malaria as seen during P. falciparum infection of humans (Renia, Howland et 
al. 2012). C57BL6/J mice infected with PbA experience cerebral complications such as seizures, 
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paralysis, and coma, and typically succumb to the infection after approximately 6-10 days (Hunt, 
Golenser et al. 2006). P. chabaudi chabaudi AS (PcAS) infection is non-lethal, similar to human P. 
vivax and P. falciparum infections (Stephens, Culleton et al. 2012), and establishes a recrudescent 
infection (Achtman, Stephens et al. 2007) as seen in human P. vivax and P. ovale infections 
(Imwong, Snounou et al. 2007). Finally, two strains of P. yoelii, a lethal P. yoelii 17 YM (Py17XL) 
strain that causes hyperparasitemia and subsequent anaemia, and P. yoelii 17X nonlethal 
(Py17XNL) strain that models slow-resolving infection (Amante and Good 1997).  
1.3.2 Requirement for antibody-mediated protection 
Antibodies have a well-established role in protection against natural Plasmodium infection. 
Cohen and MacGregor first observed this in 1960 when they transferred purified antibodies from 
naturally-immune adults of West Africa into partially immune children, resulting in rapidly 
decreased parasitemia and alleviated symptoms (Cohen, McGregor et al. 1961). More recent 
support for the association between Plasmodium-specific antibodies and naturally-acquired 
immunity was provided by a prospective study in which antibody levels were measured in the 
serum of young Malian children each year until young adulthood, when clinical immunity is 
typically observed (Crompton, Kayala et al. 2010). Antibody levels rose each subsequent year of 
exposure to infection up until young adulthood, when it plateaued at a high level (Crompton, 
Kayala et al. 2010). However, in the absence of infection, naturally-acquired antibody titres are 
easily lost, particularly in young children (Akpogheneta, Duah et al. 2008). During experimental 
malaria, antibody mediated protection is most convincingly demonstrated in scenarios where mice 
lack B cells, such as JHD mice, which fail to control Py17XNL infection (van der Heyde, Huszar et 
al. 1994). Similar results were seen in Aicda-/- mice with mature B cells that cannot undergo 
antibody class-switching (Butler, Moebius et al. 2012).  
Protective antibody responses are likely generated against antigens expressed on the surface 
of merozoite or parasite-derived antigens on the surface of pRBCs. A meta-analysis of pool data 
from three studies on merozoite proteins determined a dose-associated response of antibodies 
against merozoite surface protein 1-19 (MSP-119), by showing a 15% reduction in symptomatic P. 
falciparum infections per doubling of the antibody levels in individuals (Fowkes, Richards et al. 
2010). Similarly, risk of symptomatic infection dropped 54% in people with measurable IgG to 
MSP-3-Ct (Fowkes, Richards et al. 2010). Parasite antigens expressed on the surface of RBC (also 
known as variant surface antigens; VSAs) that could be targets for antibodies include P. 
falciparum erythrocyte membrane protein 1 (PfEMP1) (Leech, Barnwell et al. 1984), repetitive 
interspersed family (RIFIN) proteins (Cheng, Cloonan et al. 1998, Fernandez, Hommel et al. 1999), 
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sub-telomeric variable open reading frame (STEVOR) proteins (Kaviratne, Khan et al. 2002, 
Blythe, Yam et al. 2008, Niang, Yan Yam et al. 2009), surface-associated interspersed gene family 
(SURFIN) proteins (Winter, Kawai et al. 2005) and P. falciparum Maurer’s cleft two 
transmembrane (PfMC-2TM) proteins (Sam-Yellowe, Florens et al. 2004, Lavazec, Sanyal et al. 
2006). The best studied, PfEMP1, was first identified in the sera of infected aotus monkeys and is 
now known to be involved in the adherence of pRBCs to endothelial cells. Due to the high 
variability of PfEMP1 and the many other antigens expressed on iRBCs, it is difficult to show 
PfEMP1-specific antibody responses in humans. However, using recombinant PfEMP1, a study in 
Papua New Guinea demonstrated that the magnitude of anti-PfEMP1 responses was limited and 
variant specific in young children, but in adulthood, serum antibodies were capable of recognising 
at least 20 different variants, indicating that the PfEMP1-specific antibody repertoire increases with 
age (Barry, Trieu et al. 2011). Antibodies against merozoite surface antigens or parasite-derived 
antigens on the RBCs could provide protection by blocking the invasion of free blood-stage 
parasites into new RBCs, opsonising merozoites for phagocytosis, and antibody-dependent cellular 
inhibition (Blackman, Heidrich et al. 1990, Perraut, Mercereau-Puijalon et al. 1995, Bull, Lowe et 
al. 1998), however this remains to be determined. 
1.3.3 Requirement for CD4+ T cell responses 
T cells are another key component of the adaptive immune response, and have also been 
associated with improved outcomes during Plasmodium infection. Adults co-infected with 
Plasmodium and Human Immunodeficiency Virus (HIV), which infects and destroys CD4+ T cells, 
were hospitalised with clinical malaria twice as often than those with malaria alone (Whitworth, 
Morgan et al. 2000). Additionally, individuals receiving multiple subclinical injections of P. 
falciparum acquired a level of immunity that was attributed to cellular immunity on the basis of 
increased production of a prototypical CD4+ cytokine, IFNγ, and absence of detectable 
Plasmodium-specific antibodies throughout the study (Pombo, Lawrence et al. 2002). Serum levels 
of IFNγ have also been positively associated with protection against re-infection in field studies 
(Deloron, Chougnet et al. 1991). Furthermore, IFNγ production as determined by Enzyme-linked 
ImmunoSpot (ELISPOT) assay of ex vivo cultures of lymphocytes was associated with improved 
protection against malaria during clinical trials for RTS,S (Sun, Schwenk et al. 2003, Kester, 
Cummings et al. 2009).   
In mouse models of infection, the involvement of CD4+ T cells in protection against blood-
stage Plasmodium infection is most clearly evidenced by increased parasite burden and mortality in 
T cell-depleted mice, a phenotype that can be rescued by adoptive transfer of unfractioned or 
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purified immune splenic cells (Weiss, Sedegah et al. 1993). Mice genetically deficient in IFNγ 
(Amani, Vigario et al. 2000, Su and Stevenson 2000) or the IFNγ receptor (Ifnγr-/-) (Favre, Ryffel et 
al. 1997) also fail to control infection and succumb to hyperparasitemia. In animal vaccination 
studies conducted by Pinzon-Charry et al., a  killed blood-stage parasite vaccine with the adjuvant, 
CpG-oligodeoxynucleotides induced protective CD4+ T cells in mice (Pinzon-Charry, McPhun et 
al. 2010). Even at very low doses (103 pRBCs), this vaccine induced strong proliferation of parasite-
specific CD4+ T cells within the spleen and increased serum IFNγ, IL-12, IL-10 and TNF-α levels. 
At the time of rechallenge, vaccinated mice were completely protected from the high mortality and 
severe disease experienced by control mice that received killed parasites alone. Cell-depletion 
studies ruled out the involvement of CD8+ T cells and NK cells that can also produce IFNγ. 
Importantly, the role of antibodies was also discounted due to low titres induced by vaccination and 
the failure of passive transfer of immune sera to protect naive mice from infection (Pinzon-Charry, 
McPhun et al. 2010). Experiments performed in SCID mice, demonstrated that transfer of enriched 
splenic CD4+ T cells controlled primary PcAS infections, although this was insufficient to 
completely eliminate parasites, indicating that humoral immunity is likely required for final 
resolution of infection (Meding and Langhorne 1991).  
1.3.4 Mechanisms of immune evasion 
The adaptive immune system clearly has the capacity to mount protective immune responses 
against Plasmodium infection. However, protective immunity requires many intermittent infections 
to acquire and is easily lost. The difficulty in maintaining clinical protection is hypothesised to be 
partly due to parasite evasion mechanisms. One means by which Plasmodium parasites can evade 
antigen-specific adaptive immune responses is via antigen diversity. For example, as previously 
mentioned, PfEMP1, a parasite-derived adhesion molecule expressed on the surface of pRBCs, is 
involved in sequestration of pRBCs and immune evasion. Therefore, PfEMP1 is targeted by host 
antigen-specific antibodies to block sequestration. However, PfEMP1 is encoded by the var gene, 
which has over 60 antigenically and functionally distinct variants within a single parasite genome 
(Smith, Chitnis et al. 1995, Su, Heatwole et al. 1995). Therefore, switching var gene expression can 
prevent binding of antigen-specific antibodies and enable continued sequestration. 
Numerous studies have also reported immunomodulation by Plasmodium infection. 
Reduced numbers of circulating innate immune cells have been observed in human patients infected 
with P. falciparum and P. vivax, at least partially due to cellular apoptosis (Woodberry, Minigo et 
al. 2012, Pinzon-Charry, Woodberry et al. 2013). Innate cells are critical for priming adaptive 
responses. Therefore, their clearance could have knock-on effects on long-lived immune responses. 
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Apoptosis of antigen-specific T cells has also been observed during experimental Plasmodium 
infection (Xu, Wipasa et al. 2002). Additionally, inappropriate activation of T cell inhibitory 
pathways, such as those mediated by high expression of PD1 and LAG3, may also contribute to 
functional exhaustion of T cells as observed in children exposed to P. falciparum infection in Mali 
(Butler, Moebius et al. 2012). Furthermore, PD1+ LAG3+ CD4+ T cells have been associated with 
poorer antibody and memory B cell responses during infection (Illingworth, Butler et al. 2013). 
Blocking these inhibitory receptors can result in better control of parasitemia in mice (Butler, 
Moebius et al. 2012, Hafalla, Claser et al. 2012, Horne-Debets, Faleiro et al. 2013). These potential 
immune evasion mechanisms highlight the dynamic relationship between host immune cells and 
parasites, thus adding another layer of complexity to the induction of protective immune responses 
to malaria.  
 
1.4 T cell-mediated immunity 
1.4.1 Development of antigen-specific T cells within the thymus 
The adaptive immune system is adept at recognising different pathogens and responding 
accordingly. Antigen specificity is provided through the expression of unique surface-bound 
receptors on adaptive immune cells, as postulated in the clonal selection theory first described by 
Burnet in 1957 (Burnet 1957). CD4+ and CD8+ T cells express unique T cell receptor (TCR) 
complexes composed of variable disulphide-linked α and β TCR chains non-covalently associated 
with a number of invariant CD3 polypeptides. Generation of TCRs begins in the thymus with the 
CD4-CD8- (DN) thymocyte derived from a common hematopoietic progenitor cells. The DN 
thymocyte undergoes rearrangement at the Vβ gene locus leading to expression of a functional Vβ 
chain paired with a non-variant pre-Vα chain (Groettrup, Ungewiss et al. 1993). This drives 
proliferation of the thymocyte, up-regulation of both CD4 and CD8 (DP) and cessation of 
rearrangement at the Vβ locus. The end of Vβ rearrangement is termed allelic exclusion and results 
in almost all T cells expressing a single Vβ variant (Casanova, Romero et al. 1991). The DP T cell 
then undergoes rearrangement at the α locus until a TCR is created that is competent for positive 
selection through recognition of major histocompatibility complex (MHC) molecules expressed by 
local antigen presenting cells (APCs). If the DP T cell expresses a Vα chain that does not contribute 
to recognition, it may still be expressed alongside the next iteration (Borgulya, Kishi et al. 1992). 
For this reason, almost 30% of all T cells express two Vα variants (Padovan, Casorati et al. 1993). 
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90% of DP cells will only generate 'useless' TCRs that cannot successfully bind MHC molecules, 
and undergo cell death (Klein, Kyewski et al. 2014). 
In the event of a TCR successfully recognising an MHC molecule, the affinity of the TCR 
for 'self-peptide' bound to the MHC molecule determines the fate of the T cell. If affinity is high, 
the T cell is deemed 'self-reactive' and promptly deleted. T cells with moderate affinity may 
progress to become natural T regulatory cells. Lastly, T cells with low affinity for self antigen 
migrate out of the thymus and join the naïve T cell repertoire. In a study by Liu and Bosselut, 
longer interactions between the peptide-MHC (p-MHC) complex and the TCR of these low affinity-
binders was shown to be constitutive for CD8+ T cell development, regardless of the MHC class 
type (Liu and Bosselut 2004). The significance of positive selection by recognition of self-peptide 
was evident from a study by Mandl et al. who showed that the affinity of CD4+ T cells for self-
peptide bound to MCH molecules was positively associated with its affinity for foreign bound 
antigen (Mandl, Monteiro et al. 2013).  
The resulting naïve T cell repertoire of the human body has the capacity to recognise an 
estimated 109 different antigens, making them one of the most diverse populations of cells in the 
body (Davis and Bjorkman 1988). However, this high diversity within the naive T cell repertoire 
comes at a cost to the number of each clone that can be accommodated. In fact, the frequency of 
naïve CD4+ T cells specific to any given antigen is estimated to be only 20 to 200 cells per mouse 
(Moon, Chu et al. 2007) or 1 to 10 per million CD4+ T cells in humans (Jenkins, Chu et al. 2010). 
Clonal expansion of these rare clones occurs in secondary lymphoid organs when a TCR recognises 
a peptide bound to a MHC molecule, of which there are two classes. MHC class I (MHCI) 
molecules are expressed by all nucleated cells and are recognised by CD8+ T cells. On the other 
hand, MHC class II (MHCII) molecules are expressed by specialised APCs, including DCs, 
macrophages and B cells, and are recognised by CD4+ T cells. Upon recognition of cognate 
antigens, expansion of T cells must be vigorous to provide a protective response to acute disease 
(Buchholz, Schumacher et al. 2016). Studying the development of antigen-specific T cell responses 
in vivo is of high interest, but is confounded by the low frequency with which clones exist within 
the entire T cell pool.   
1.4.2 Studying antigen specific T cell responses 
The ‘gold standard’ for circumventing the problem of low antigen-specific T cell 
frequencies is the use of peptide-bound MHC multimers or TCR transgenic mice expressing clonal 
populations of T cells with proven antigen specificity. Peptide-bound MHC multimers are a soluble 
form of MHC molecules with bound antigen (Nepom 2012). The MHC multimer commonly 
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consists of a streptavidin core bound to four biotin-conjugated MHC molecules and tagged with a 
fluorochrome for easy flow cytometry-based detection of bound T cells. Peptide-bound MHCI 
tetramers were first applied to study CD8+ T cells 20 years ago. One example of their early 
application was in determining the frequencies and functions of antigen-specific CD8+ T cells 
among peripheral blood mononuclear cells (PBMCs) of HIV patients (Altman, Moss et al. 1996). 
Since then, the system has been applied to MHCII tetramers for studying CD4+ T cell responses to a 
wide variety of diseases, including type 1 diabetes, coeliac disease, pemphigus vulgaris, rheumatoid 
arthritis, multiple sclerosis, and uveitis (Danke, Koelle et al. 2004, Danke, Yang et al. 2005, 
Mallone, Kochik et al. 2005, Oling, Marttila et al. 2005). However, MHC tetramer design requires 
prior knowledge of peptide sequences, which in conjunction with MHC molecules, bind to T cell 
clones of interest (Nepom 2012).  
The second major approach for studying antigen-specific T cell responses in vivo is the use 
of TCR transgenic T cells. TCR transgenic T cell-expressing mice are created by culturing 
immortalised T cells with antigen-loaded APCs. Responding cells are selected for and their α and β 
TCR chains sequenced. These sequences are used to create cDNA, which is then cloned into 
expression vectors and injected into blastocysts to generate transgenic founder mice (Mueller, 
Heath et al. 2002). The first TCR transgenic mouse was developed in the late 1980's towards the 
minor histocompatibility HY complex and was used to study negative selection of T cells 
(Kisielow, Bluthmann et al. 1988). Subsequent transgenic mice were used to study positive 
selection (Hogquist, Jameson et al. 1994). TCR transgenic cells have been instrumental in observing 
CD8+ T cell exhaustion in mice with persistent LCMV infection (Moskophidis, Lechner et al. 
1993), and in showing that initial encounters with APCs trigger memory programming (Kaech and 
Ahmed 2001). Similarly, LCMV-specific CD4+ T cells have been used to demonstrate the 
requirement for TCR signal strength in CD4+ T cell differentiation (Williams, Ravkov et al. 2008) 
and a role for CD4+ T cells in rescuing exhausted CD8+ T cells (Aubert, Kamphorst et al. 2011).  
TCR transgenic T cells have not only informed T cell biology, but also their interactions 
with other immune cells and contribution to immune responses. Proliferation of MHCI-restricted 
TCR transgenic CD8+ T cells were used to measure antigen presentation during acute and 
recrudescent HSV-1 infection, leading to the identification of CD103+ dermal DCs as dominant 
APCs in this model (Mueller, Heath et al. 2002, Bedoui, Whitney et al. 2009). PbA parasites 
transgenically modified to express the model protein OVA, recognized by OVA-specific TCR 
transgenic CD4+ (OTII) or CD8+ (OTI) cells have revealed a requirement for DCs in inducing CTL 
cells (Lundie, de Koning-Ward et al. 2008) and protective CD4+ T cells during Plasmodium 
infection (Haque, Best et al. 2014) respectively. A more biologically relevant MHCI-restricted TCR 
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transgenic T cell-expressing mouse that harbors CD8+ T (termed PbTI) cells responsive to a 
Plasmodium derived antigen has been generated and was able to protect recipient mice against liver 
stage Plasmodium infection (Lau, Fernandez-Ruiz et al. 2014). 
Only one TCR transgenic system to date has been used for studying Plasmodium-specific 
CD4+ T cells in vivo (Stephens, Albano et al. 2005). The authors of this paper generated CD4+ T 
cells reactive to Plasmodium MSP-1 protein (Stephens, Albano et al. 2005). These cells were useful 
in determining the role for DC subsets in antigen-presentation during malaria (Sponaas, Cadman et 
al. 2006). However, a significant caveat of this reagent was that a second Vα chain was transcribed 
alongside the transgenic Vα chain, which may have confounded results. Furthermore, the genetic 
background of these transgenic mice (BALB/c) has few available knock-out strains, thus limiting its 
application for immunological studies. Currently, no other reagent exists for studying Plasmodium-
specific CD4+ T cells in vivo. This lack of appropriate tools has hampered efforts to understand 
many aspects of CD4+ T cell responses during malaria. 
1.4.3 Antigen presentation to CD4+ T cells during malaria 
DCs are generally regarded as the most proficient APC, and as suggested above, have been 
linked to priming T cells during Plasmodium infection. DCs can be divided into two main subsets: 
plasmacytoid dendritic cells (pDCs), which express low levels of MHCII and the co-stimulatory 
integrin CD11c in steady state, and classical dendritic cells (cDCs), which express high MHCII and 
CD11c. pDCs have a key role in the production of type I interferons (TI IFN), which are 
particularly important for protection against viral infection. On the other hand, cDCs are superior at 
interacting with T cells due to their capacity to phagocytose antigen, upregulate MHCII, express co-
stimulatory molecules such as CD86, CD40 and CD80, as well as produce chemo-attractant 
molecules (Villadangos and Schnorrer 2007, Segura and Villadangos 2009, Reizis, Bunin et al. 
2011, Joffre, Segura et al. 2012). In secondary lymphoid tissues, in which T cell priming occurs, 
cDCs can be subdivided into two main groups based on their differential expression of CD8α and 
CD11b (Dudziak, Kamphorst et al. 2007). CD8α+CD11b- cDCs play a unique role in resistance to 
certain viral infections due to their ability to process non-replicating antigens for presentation by 
MHCI (termed cross-presentation), particularly to CD8+ T cells (den Haan and Bevan 2002, Iyoda, 
Shimoyama et al. 2002, Allan, Smith et al. 2003). In contrast, CD8α-CD11b+ cDCs, which also 
express Sirpα and Clec4a4 (also known as DCIR2), are more adept at presenting antigen to and 
activating CD4+ T cells, with limited capacity for eliciting CD8+ T cell activation (Dudziak, 
Kamphorst et al. 2007) 
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The requirement for cDCs in initiating T cell responses during Plasmodium infection has 
been demonstrated in a number of studies. During liver-stage infection, depletion of CD11c-
expressing cells resulted in reduced activation of CD8+ T cells (Jung, Unutmaz et al. 2002), which 
are required for killing infected hepatocytes expressing Plasmodium antigen in a contact-dependent 
manner (Cockburn, Amino et al. 2013, Cockburn, Tse et al. 2014). During blood-stage infection, 
the spleen is a major site of both parasite clearance and developing immune responses (Grun, Long 
et al. 1985, Chotivanich, Udomsangpetch et al. 2002). The number of cDCs within the spleen 
increases considerably during blood-stage infection, as does expression of MHCII, CD40 and CD80 
(Perry, Rush et al. 2004). Here, cDCs act as APCs for CD8+ T cells as well, with CD8α+ DCs the 
most prominent APC (Lundie, de Koning-Ward et al. 2008). In addition, co-culture of naïve CD4+ 
T cells with cDCs harvested at day 6 of infection with Py17XNL has been shown to induce T cell 
activation and expression of IFNγ, TNFα and IL-2 (Perry, Rush et al. 2004). Moreover, depletion of 
cDCs during PbA infection perturbs CD4+ T cell responses, resulting in alleviated immune 
pathology within the brain (deWalick, Amante et al. 2007). While both cDC populations are 
capable of priming CD4+ T cells during in vivo PcAS infection, ex vivo experiments indicate that 
CD8α- cDCs may be more effective than their CD8α+ counterparts (Sponaas, Cadman et al. 2006). 
With respect to the involvement of other APCs in T cell responses to blood-stage malaria, a study 
by Sponaas et al showed a population of Ly6C+CD11bhi monocytes were generated in the bone 
marrow during infection, migrated to the spleen and upregulated MHCII. However, monocytes 
sorted from the spleens of day 8 PcAS infected mice displayed limited capacity to induce 
proliferation or cytokine production from naïve CD4+ T cells in vitro, suggesting these cells do not 
play a significant role in priming naïve CD4+ T cells (Sponaas, Freitas do Rosario et al. 2009). 
1.4.4 Differentiation of CD4+ T cells 
Activated CD4+ T cells differentiate into a spectrum of T helper cells that provide 
specialised responses to different immune challenges. Diversity in CD4+ T cell responses was first 
reported in the early 1970’s, but it was not until a seminal study by Mosmann and Coffman in 1986 
that CD4+ T cells were subdivided into helper populations (Mosmann, Cherwinski et al. 1986). In 
this study, T cell clones were categorised into two subsets termed T helper 1 (Th1) and T helper 2 
(Th2), based on patterns of cytokine production. Other Th subsets have since been defined (Figure 
1.2). It is generally believed that the differentiation programs of these subsets are predominantly 
governed by signals derived from antigen-presenting cells (APC) and the microenvironment at the 
time of activation (Coquet, Rausch et al. 2015). However, inherent factors such as the balance of 
transcription factor expression or TCR affinity may also contribute to fate decision (Tubo and 
Jenkins 2014, Weinmann 2014). 
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Th1 cells are characterised by secretion of IFNγ and TNFα and are associated with 
inflammatory responses to intracellular pathogens. Their differentiation is driven by IFNγ and 
expression of the master transcription factor T-bet (encoded by Tbx21) (Szabo, Kim et al. 2000, 
Szabo, Sullivan et al. 2003). Th1 cells also contribute to the pathogenicity of organ-specific 
autoimmune diseases, such as autoimmune type 1 diabetes and multiple sclerosis (MS), as 
demonstrated in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE) (Szabo, 
Sullivan et al. 2003, Christen and von Herrath 2004, Sospedra and Martin 2005). Th17 cells express 
IL-17A, IL-22, IL-21 and the transcription factor RORγt. Like Th1 cells, Th17 cells contribute to 
autoimmune diseases including EAE (Sospedra and Martin 2005, Kang, Wang et al. 2013), but can 
also provide protection against extracellular pathogens (Curtis and Way 2009). Another population 
of Th cells that produce IL-22, but not IL-21 or IL-17A, are termed Th22 cells (Duhen, Geiger et al. 
2009). Th22 cells have been isolated from the skin of patients with psoriasis, atopic eczema (AE) 
and allergic contact dermatitis (ACD) (Eyerich, Eyerich et al. 2009). Th2 cells are defined by 
secretion of IL-4, IL-5 and IL-13 and expression of the transcription factor GATA3. Th2 responses 
are induced during helminth infection and provoke production of IL-10 and IL-13, which have a 
passive anti-inflammatory effect (Chen, Liu et al. 2012). Th2 cytokines have also been 
demonstrated in allergic inflammation such as asthma (Robinson, Hamid et al. 1992). Th9 cells 
produce the canonical cytokine IL-9, which promotes production of mucus during airway 
inflammation (Kaplan, Hufford et al. 2015). T follicular helper cells (Tfh) were first identified in 
human tonsils in the early 2000's and were noted for high expression of the B cell zone-homing 
marker (CXCR5) (Breitfeld, Ohl et al. 2000, Kim, Rott et al. 2001, Chtanova, Tangye et al. 2004). 
They are now further distinguished by expression of Programmed cell Death Protein-1 (PD1), 
Inducible T cell Co-Stimulator (ICOS) and the master transcription factor Bcl-6, and secretion of 
IL-21 (Crotty 2011). Differentiation of Tfh cells is promoted by IL-6 and IL-21 (Eto, Lao et al. 
2011). Tfh cells are critical for germinal centre reactions, including the differentiation of antigen-
specific B cells into memory or plasma cells and antibody production during T cell dependent B cell 
responses (Crotty 2011).  
T regulatory cells (Tregs), as previously mentioned, are essential in maintaining peripheral 
tolerance to self-antigens and limiting chronic inflammation by regulating the response of other Th 
cell subsets. Tregs are characterised by expression of the key transcription factor Forkhead box P3 
(FOXP3), CD25, and production of IL-10 and TGF-β (Wing and Sakaguchi 2014). Their 
development is driven by recognition of self-antigens, and IL-2 and TGF-β. The importance of 
Tregs in central tolerance is demonstrated in mice and humans deficient in Foxp3, who exhibit 
hyperactive T helper responses and overproduction of inflammatory cytokines (Brunkow, Jeffery et 
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al. 2001, Ochs, Ziegler et al. 2005). A subset of Tregs differentiates within the thymus, and is 
therefore named thymus-derived Tregs (tTregs). However, the differentiation of Tregs can also be 
induced in the periphery (pTregs) (Abbas, Benoist et al. 2013). A third, Th1-like, regulatory subset 
that produces IL-10, but does not express CD25 or FOXP3 has been classified as T regulatory 1 
(Tr1) cells (Groux, O'Garra et al. 1997).  
Despite categorisation of T helper cells into subsets there is likely plasticity between them 
(Zhu and Paul 2010). Some defining surface markers and cytokines are shared between subsets, 
such as IL-22 expression by both Th-17 and Th-22 cells. This crossover has led to scepticism in the 
field about whether these are unique bona fide T helper subsets (Ahlfors, Morrison et al. 2014). 
Furthermore, individual cells differentiating toward one subset may display patterns of expression 
resembling another subset. It has been proposed in a study by Nakayamada et al that differentiating 
Th1 cells first transition through a Tfh-like phenotype, by expressing Bcl6 and IL-12 (Nakayamada, 
Kanno et al. 2011). Early expression of Tfh markers by pre-Th1 cells is likely initiated by the 
activation of STAT4, but this induces transcription of Tbx21 to commit the cells to the Th1 fate 
(Nakayamada, Kanno et al. 2011). 
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Figure 1.2 CD4+ T helper cell differentiation. CD4+ T cells are primed through recognition of 
antigen bound to MHCII molecules presented by APCs. Under the guidance of external cues, 
including cytokines, as well as internal signals, primed CD4+ T cells differentiate into a spectrum of 
T helper cells, including T helper 1 (Th1), Th2, Th17, T regulatory (Treg), Th9 and T follicular 
helper (Tfh) cells (Russ, Prier et al. 2013). 
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1.4.5 T helper responses provide protection during Plasmodium infection 
Th1 responses have long been known to contribute to protective immune responses to 
blood-stage Plasmodium infection. Transfer of IFNγ-secreting CD4+ T cells into athymic 
Py17XNL-infected mice conferred protection, as manifested by suppressed growth parasite number 
and improved resolution of the infection (Amante and Good 1997). Similarly, Plasmodium-specific 
IFNγ+ Th1 cells, but not control OVA-specific CD4+ cells, allowed for resolution of PcAS infection 
in CD4+-depleted mice (Taylor-Robinson and Phillips 1994). During PbA infection, enhanced 
IFNγ+ T-bet+ CD4+ T cells in mice lacking Type I IFN signalling were associated with better control 
of infections, including lower morbidity and mortality (Haque, Best et al. 2011, Haque, Best et al. 
2014). In human infection, expansion of IFNγ-producing CD4+ T cells was observed during drug-
induced clearance of P. falciparum (Mewono, Agnandji et al. 2009). Additionally, a positive 
correlation between serum IFNγ levels and the outcome of infection has fuelled confidence in an 
association between Th1 cells and protective immunity (Deloron, Chougnet et al. 1991, Sun, 
Schwenk et al. 2003, Kester, Cummings et al. 2009). However, since IFNγ is also produced by 
other immune cells, including CD8+ T cells, natural killer (NK) cells, NK T cells and γδ T cells 
(Schlub, Sun et al. 2011, Villegas-Mendez, Greig et al. 2012), it is not clear whether IFNγ-secreting 
CD4+ T (Th1) cells play the major protective role in humans. A possible mechanism by which Th1 
cells provide protection is by IFNγ- and TNFα- mediated activation of innate immune cells, such as 
macrophages and natural killer (NK) cells (Taylor-Robinson and Phillips 1998). These cells could 
respond by secreting reactive oxygen species (ROS) that directly kill infected erythrocytes (Clark, 
Hunt et al. 1987, Taylor-Robinson and Phillips 1998). However, a prolonged proinflammatory Th1 
response can also contribute to immunopathology, as demonstrated by resistance to experimental 
cerebral malaria (ECM) of PbA infected Tbx21-/-mice (Oakley, Sahu et al. 2013). 
An important aspect of clinical immunity is the ability to suppress potentially harmful 
inflammatory responses once the infection has been cleared. The number of CD4+ FOXP3+ CD127lo 
T cells was higher in healthy Gambian individuals living in rural regions experiencing high seasonal 
malaria transmission, compared to individuals living in urban areas with low transmission (Finney, 
Nwakanma et al. 2009). These Tregs expressed an effector memory phenotype, and suppressed 
cytokine production by CD4+ T cells exposed to Plasmodium antigen (Finney, Nwakanma et al. 
2009). Of particular interest was the constant ratio between T-bet+ CD4+ T cells and Treg cells in 
individuals during the transmission and non-transmission seasons, suggesting that increased Th1 
responses to Plasmodium infection was balanced with a proportionate Treg response. The balance 
of inflammation and immunosuppression can also be observed in the outcomes of the two strains of 
P. yoelii infection. Depletion of CD25+ Treg cells in BALB/c mice with a monoclonal antibody 
  
18 
enabled complete resolution of an otherwise lethal Py17XL infection (Hisaeda, Maekawa et al. 
2004). However, depletion of CD25+ Treg cells during Py17XNL infection did not affect either the 
parasitemia or the outcome of infection (Hisaeda, Maekawa et al. 2004). 
Regulatory mechanisms provided by IL-10-producing Tr1 cells are also present during 
Plasmodium infection. IL-10 and IFNγ co-producing cells were observed in stimulated PBMCs 
from acutely infected children from The Gambia, Malia and Uganda (Walther, Jeffries et al. 2009, 
Jagannathan, Eccles-James et al. 2014, Portugal, Moebius et al. 2014). To demonstrate the function 
of Tr1 cells, Couper et al. transferred Il10-/- or wild-type (WT) CD4+ T cells into Rag1-/- mice, 
which lack T or B cells, and infected mice with P. yoelii (Couper, Blount et al. 2008). While all 
mice eventually succumbed to infection, mice receiving Il10-/- T cells experienced lower 
parasitemia, but more severe pathology associated with greater numbers of circulating IFNγ+ CD4+ 
T cells (Couper, Blount et al. 2008). This data suggests that Tr1 cells have a role in balancing 
immune-mediated clearance of parasites with immunopathology. 
The role of Tfh cells in the class switching of B cells and production of antibodies make 
them another obvious target for enhancing the immune response to Plasmodium (Perez-Mazliah and 
Langhorne 2014). Before the characterisation of Tfh cells, PcAS, a model for chronic infection was 
observed to have biphasic Th responses. While Th1 cells were observed early during blood-stage 
infection, a population of IFNγ- CD4+ T cells were shown to be necessary for B cell responses 
(Langhorne, Gillard et al. 1989). This observation coincided with the appearance of an IL-4-
producing CD4+ T-cell population at this later time of infection in both humans and mice 
(Langhorne, Gillard et al. 1989, Troye-Blomberg, Riley et al. 1990). These data were interpreted as 
an early activation of Th1 cells that controlled parasitemia, followed by a Th2 response that assisted 
in activating B cell responses to clear infection (Langhorne, Meding et al. 1989, von der Weid and 
Langhorne 1993). However, the frequency of CD4+ T cells able to help B cells to produce 
Plasmodium-specific antibodies was much higher than the frequency of IL-4-producing CD4+ T 
cells (Langhorne, Gillard et al. 1989). Furthermore, control of PcAS infection and production of 
specific IgG responses was possible even in the complete absence of IL-4 (von der Weid, Kopf et 
al. 1994). The identification of Tfh cells, specialising in B cell help, provided the answer to this 
puzzle. In recent murine studies, therapeutic blockade of PD1 and LAG3 boosted the CD4+ T cell 
response and improved parasite clearance in Py17XNL-infected mice (Butler, Moebius et al. 2012). 
Further assessment showed that the blockade resulted in a 7-fold enhancement in Tfh numbers and 
50-fold enhancement in plasmablast B cells (Butler, Moebius et al. 2012). IL-21-producing cells 
have also been identified in people living in malaria-endemic areas, and these have been associated 
with increased levels of IgG (Mewono, Matondo Maya et al. 2008, Mewono, Agnandji et al. 2009).  
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Tfh cells exhibit heterogeneity in their phenotype and behaviour during Plasmodium 
infection. In Malain malaria-exposed children, a population of circulating memory PD-1+ CXCR5+ 
Tfh cells possessed phenotypic and functional characteristics of GC Tfh cells (Obeng-Adjei, 
Portugal et al. 2015). These cells had a marked downregulation of Bcl6 permitting their exit from 
secondary lymphoid organs. Furthermore, longitudinal studies in the same children showed that 
expression of CXCR3 was preferentially induced during acute infection and skewed the response of 
these cells to more of a Th1 phenotype (Obeng-Adjei, Portugal et al. 2015). These circulating 
CXCR3+ Tfh cells had reduced ability to support antibody production by B cells compared to their 
CXCR3- counterparts. This could explain the absence of correlation between Tfh responses and 
plasma cell numbers and antibody titres or breadth in these children (Obeng-Adjei, Portugal et al. 
2015). 
1.4.6 CD4+ T cell memory to Plasmodium infection 
After the initial wave of antigen-specific proliferation in response to antigen and subsequent 
clearance of infection, the number of reactive T cells drops back to levels approximately 100-1000 
fold higher than the initial frequency (Buchholz, Schumacher et al. 2016). The remaining cells can 
last for the life-time of the host and provide a minimum 1 day advantage in responses to re-infection 
(Schlub, Sun et al. 2011). CD4+ T memory cells can be divided into central memory cells, which 
are positive for the cell adhesion molecule CD44 and the secondary lymphoid homing molecule 
CD62L, and effector memory cells, which are positive for CD44 but negative for CD62L. 
Currently, the kinetics of CD4+ memory T cell responses to Plasmodium infection in humans is 
unknown. However, in a follow-up study to the Madagascan malaria epidemic of 1987, memory 
CD4+ T cell responses to simple peptide epitopes from the Pf155/RESA antigen persisted in the 
absence of reinfection for at least 5 years, although both the frequency and magnitude of the 
responses were lower than those detected in the same individuals 3 years previously (Migot, 
Chougnet et al. 1993).  
In experimental studies, MSP-1-specific CD4+ T cells differentiated into effector and central 
memory (TEM and TCM) cells during PcAS infection (Stephens and Langhorne 2010). Furthermore, 
transfer of CD4+ T cells from immunized mice provided protection against PbA and PcAS infection 
even in the absence of B cells, suggesting that memory CD4+ T cells can provide a degree of 
protective immunity via a mechanism independent of the humoral response (Grun and Weidanz 
1981, Tsuji, Romero et al. 1990, Langhorne 1994). In contrast and as previously mentioned, several 
reports from experimental infections suggested that Plasmodium infection may lead to functional 
deletion or modulation of activated CD4+ T cells, leading to defective memory responses 
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(Hirunpetcharat and Good 1998, Xu, Wipasa et al. 2002). This has also been hypothesised to be due 
to normal contraction of effector cells, which is necessary to regulate inflammatory responses and 
thus prevent pathology (Langhorne, Ndungu et al. 2008). The exact reason why T cell memory 
responses are not consistently induced in mice and humans remains to be elucidated. 
1.4.7 CD8+ T cell during Plasmodium infection 
Plasmodium-specific CD8+ T cells contribute to both protection and immunopathogy during 
Plasmodium infection. The first scenario occurs during the pre-erythrocytic stage of infection. Upon 
infection with sporozoites, CD8+ T cells are primed by CD8α+cDCs in the skin draining lymph 
nodes (Chakravarty, Cockburn et al. 2007, Radtke, Kastenmuller et al. 2015). They then migrate to 
the liver and destroy infected hepatocytes expressing parasite-derived antigens bound to MHCI 
molecules (Chakravarty, Cockburn et al. 2007, Cockburn, Amino et al. 2013). The significance of 
CD8+ T cells in generating protection is evident from β2-microglobulin knock-out mice (β2m-/-; 
deficient of MHCI expression) that fail to generated protection after attenuated P. berghei 
sporozoite challenge (White, Snyder et al. 1996). This protection is likely mediated by a 
combination of effector mechanisms including perforin-associated direct killing and pathways 
involving IFNγ and TNFα (Butler, Schmidt et al. 2010, Cockburn, Amino et al. 2013). 
CD8+ T cells take on a more sinister role during the erythrocytic-stage of severe P. 
falciparum infection. Parasite-infected RBCs can sequester in brain, resulting in cerebral malaria. 
Studies of the mouse model of cerebral malaria, PbA, have demonstrated that antigen-specific 
CD8+ T cells migrate to brain in response to the production of chemokines such as CXCL10 by 
local cells (Nitcheu, Bonduelle et al. 2003). Here they target endothelia cells expressing parasite 
antigens with secreted IFNγ, perforin and granzyme B, with the latter two being essential for CD8+ 
T cell pathogenicity (Nitcheu, Bonduelle et al. 2003, Haque, Best et al. 2011). In support of the 
involvement of CD8+ T cells in this pathogenicity, mice depleted of CD8+ T cells are immune to 
cerebral symptoms of PbA infection, but susceptibility is restored upon adoptive transfer of PbTI 
cells (Lau, Fernandez-Ruiz et al. 2014). Given the ethical considerations, it is impossible to explore 
the development and mechanism of human CM. However, post-mortem studies of the brains of 
Malawian children with CM, have shown that, just as in ECM, small numbers of CD8+T cells can 
be found in brain capillaries (Dorovini-Zis, Schmidt et al. 2011). Likewise, a positive association 
between CXCL10 expression and CM has been found in the brains of Ghanaian children (Armah, 
Wilson et al. 2007). Further studies into the development of ECM, which can be supported by 
clinical observations, are still required for developing CM interventions. 
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1.5 Humoral immunity 
1.5.1 Antibodies 
Antibodies, Y-shaped effector proteins of B cells, are protective against many infections, 
including malaria (Chapter 1.3.2). Antibodies can be divided into five classes or isotypes- IgG, 
IgM, IgA, IgD, and IgE, with IgG further divided into IgG1, IgG2a/c, IgG2b and IgG3. The base of 
the “Y”, the Fc (crystallisable fragment) region, is common within each isotype and determines the 
function of the antibody by binding to specific Fc receptors. The arms of the “Y” are called 
fragment antigen-binding (Fab) regions and confer antigen specificity. Isotype expression changes 
during maturation and response of B cells. For instance, naïve B cells express only surface bound 
IgD and IgM, while activated B cells secrete IgG, IgE and IgA, each with more defined roles. 
Maturation of B cells occurs in lymphoid tissues such as the spleen. 
1.5.2 Micro-architecture of the spleen 
Under steady-state conditions, the spleen consists of white pulp and red pulp that can be 
visualised macroscopically. Closer examination reveals that white pulp is further divided into B cell 
follicles and adjacent T cell zones (Figure 1.3). The B cell follicle contains follicular B cells 
(IgMmedIgDhiCD21medCD23hi) and follicular dendritic cells (FDCs). FDCs express the CXCR5 
ligand, CXCL13, which acts as a major chemoattractant for B cells and Tfh cells, and may facilitate 
the movement of these cells into the follicle (Pereira, Kelly et al. 2010, Victora and Nussenzweig 
2012). The T cell zone, also known as the periarteriolar sheath (PALS), contains mostly T cells, 
which interact with passing APCs and B cells (Cesta 2006). Blood enters the white pulp through a 
central arteriole and disperses via a conduit system through which only small antigenic molecules 
can pass(Nolte, Belien et al. 2003). The white pulp is surrounded by the red pulp, which is highly 
vascular and consists of various APCs and other immune cells. Red pulp filters the blood for dead 
cells and larger foreign material (Nolte, Belien et al. 2003). The area between the red and white 
pulps is termed the marginal zone. Different subsets of macrophages, DCs and marginal zone B 
cells (IgMhiIgDlowCD21hiCD23low) reside here (Kumararatne, Bazin et al. 1981, Martin and Kearney 
2002).  
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Figure 1.3 Architecture of the spleen. The spleen is divided into red and white pulps. Red pulp 
contains an array of immune cells and specialises in filtering the blood. The white pulp areas are 
subdivided into B cell follicles and neighbouring T cell zones. These are supplied with blood 
through a central arteriole and conduit network, and are the foci of antibody production during 
infection (Batista and Harwood 2009). 
 
1.5.3 Germinal centre reactions 
 In the follicle, B cells are activated when they recognise either soluble or bound antigens 
presented by APCs via surface immunoglobulins (Ig) that serve as antigen-specific B cell receptors 
(BCRs) (Batista and Harwood 2009). This initiates proliferation and differentiation of B cells. 
Activated B cells can become extrafollicular plasmablasts, which move out of the follicle and 
provide rapid antibody production for early control of infection, or they can remain in the follicle 
and initiate germinal centre (GC) reactions. GC B cells are identified by their expression of Fas, η-
glycolylneuraminic acid (ligand of the antibody GL-7), the transcription factor Bcl-6, reduced 
expression of CD38 and affinity for peanut agglutinin (Rose, Birbeck et al. 1980, Oliver, Martin et 
al. 1997, Naito, Takematsu et al. 2007). GCs begin to develop within follicles approximately 6 days 
after antigen exposure (Jacob, Kelsoe et al. 1991). A GC is divided into two distinct regions, the 
Dark Zone (DZ) and Light Zone (LZ) (Figure 1.4). The DZ is proximal to the T cell zone and 
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consists almost exclusively of GC B cells. GC B cells in the DZ receive signals from Tfh cells that 
migrate to the border of T cell zones and B cell follicles under the direction of CXCR5 (Arnold, 
Campbell et al. 2007). In the DZ, GC B cells proliferate and undergo BCR diversification, in which 
the enzyme activation-induced deaminase (AID) deaminates cytidine residues in the variable 
regions (Batista and Harwood 2009, Dominguez-Sola, Victora et al. 2012, Meyer-Hermann, Mohr 
et al. 2012). GC B cells then migrate to the LZ, which is proximal to the marginal zone. Here they 
experience clonal selection, whereby B cells with varying BCR affinities compete for antigen 
presented by FDCs. Higher-affinity cells are selectively expanded, while lower-affinity cells are 
eliminated by apoptosis (Aguzzi, Kranich et al. 2014). Approximately 30% of positively selected 
GC B cells return to the DZ to repeat the cycle of somatic hypermutation and selection in a process 
termed 'cyclic re-entry', resulting in the progressive improvement of antigen specificity within the 
GC B cell pool (Victora, Schwickert et al. 2010). Alternatively, high-affinity GC B cells 
differentiate into plasma cells under the control of B-lymphocyte-induced maturation protein 1 
(BLIMP-1) and subsequently increase their synthesis and secretion of antibodies (Shaffer, Lin et al. 
2002). 
 
 
Figure 1.4 Germinal centre. The germinal centre is divided into two areas, the light and dark 
zones. Frozen spleen section stained with CD35 (Follicular DCs (FDCs), IgD (B cell mantel), and 
GFP-expressing germinal centre (GC) B cells. T cell zone is unstained and sits below the germinal 
centre. White dashed line shows the division between zones (Victora and Nussenzweig 2012). 
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1.5.4 B cell memory 
GC B cells typically undergo apoptosis due to high expression of the death receptor Fas and loss of 
expression of the anti-apoptotic molecule Bcl-2 (Liu, Joshua et al. 1989). However, GC B cells can 
also differentiate into long-lived antigen-producing plasma cells and quiescent memory B cells 
(MBCs) to contribute to immunological memory. There are no common markers for MBCs in mice 
other than class switching from IgD. In a study by Tomayako et al, higher expression of CD80, 
PDL2 and CD73 was observed on MBCs relative to naïve cells (Tomayko, Steinel et al. 2010). 
However, there was extensive heterogeneity within the expression of these markers (Tomayko, 
Steinel et al. 2010). In humans, CD27 marks a population of antigen-experienced B cells that are 
regarded as MBCs (Sanz, Wei et al. 2008). Longitudinal studies have identified the presence of 
long-term MBCs and antibodies specific to Plasmodium in individuals from Thailand and 
Madagascar years after infection with P. falciparum (Migot, Chougnet et al. 1995, Wipasa, 
Suphavilai et al. 2010). In a prospective study, MBCs specific to two P. falciparum antigens, 
AMA1 and MSP1, increased in frequency in responses to acute infection, but then decrease to just 
above pre-infection levels following a 6-month period of reduced exposure. The MBC compartment 
expanded in a gradual, stepwise fashion after multiple infections in subsequent malaria seasons. 
This was compared to the stable antigen-specific MBC population generated in response to tetanus 
immunisation to conclude that the Plasmodium-specific MBC compartments does not simply occur 
with age, but requires repeated antigen exposure. In line with this, the proportions of individuals 
with memory B cells induced after natural exposure or vaccination against various viruses is 
typically 60-100% (Nanan, Heinrich et al. 2001, Amanna, Carlson et al. 2007), the range of 
individuals in low to moderate endemic regions with antibodies to a given Plasmodium antigen only 
reaches 30-60% (Dorfman, Bejon et al. 2005, Weiss, Traore et al. 2010, Wipasa, Suphavilai et al. 
2010, Nogaro, Hafalla et al. 2011). Furthermore, in fatal malaria cases, there are significant changes 
in splenic architecture, including breakdown in the marginal zone, loss of B cells and reduced 
formation of germinal centres (Urban, Hien et al. 2005). This suggests that B cell responses in 
malaria patients are compromised and may lead to short-lived clinical protection to malaria 
observed in the field.  
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1.6 Innate immunity 
1.6.1 Innate immune detection of Plasmodium infection 
Malaria is a highly inflammatory disease, known to induce cyclic bursts of fever in infected 
individuals (Prakash, Fesel et al. 2006). This inflammation is clear evidence of the visibility of 
Plasmodium parasites by the innate immune system. Foreign antigen is identified by innate immune 
cells through pattern-recognition receptors (PRRs) expressed on the cell surface or within the 
cytoplasm. Among the known Plasmodium antigens recognised by innate cells, are 
Glycosylphosphatidylinositols (GPIs) that can be detected by macrophages through surface-bound 
Toll-like receptor (TLR) 2 and TLR4 (Krishnegowda, Hajjar et al. 2005). Similarly, malarial 
pigment, hemozoin (Hz) has been reported to trigger TLR9-signalling (Coban, Ishii et al. 2005). 
When cultured in vitro with human peripheral blood monocytes, Hz purified from the blood of P. 
falciparum infected humans resulted in the production of proinflammatory cytokines, chemokines 
and nitric oxide (Sherry, Alava et al. 1995, Coban, Ishii et al. 2005). In addition, Hz has been 
reported to activate the NALP3 inflammasome of macrophages (Griffith, Sun et al. 2009, Shio, 
Eisenbarth et al. 2009). However, the immunogenicity of hemozoin is debatable given observations 
by Parroche et al. that hemozoin itself is immunologically inert, but is coated with Plasmodium 
DNA that can be recognised through TLR9 (Parroche, Lauw et al. 2007). Recently, Sharma et al. 
reported that AT-rich Plasmodium DNA was detected through the intracellular Stimulator of 
Interferon Genes (STING) signalling pathway in humans (Sharma, DeOliveira et al. 2011). 
Furthermore, using PbA-infected mice, the downstream effector molecules TBK1, interferon 
regulatory factor 3 (IRF3) and IRF7 were also implicated in Plasmodium detection. Given that the 
innate immune system can clearly detect Plasmodium infection, it seems likely that innate-
signalling pathways may play a role in controlling, and possibly distorting adaptive immune 
responses during malaria. However, only one report has provided evidence of this, with MyD88, an 
signalling adaptor molecule for surface bound TLRs, promoting IFNγ and TNFα expressing CD4+ 
T cells during Plasmodium infection(Franklin, Rodrigues et al. 2007).  
 
1.6.2 Interferon regulatory factors 
IRFs are a family of nine (IRF1-9) transcription regulators, highly conserved in mice and 
humans. IRFs were first identified as transcriptional regulators of type 1 interferons (TI IFNs) and 
interferon-stimulated genes (ISGs), but have now been linked with many facets of innate and 
adaptive immunity. For example, IRF1, IRF4, IRF5 and IRF8 induce the expression of pro-
inflammatory cytokines in response to PRR activation (Tsujimura, Tamura et al. 2004, Negishi, 
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Ohba et al. 2005, Takaoka, Yanai et al. 2005, Negishi, Fujita et al. 2006). These cytokines can, in 
turn, skew the adaptive immune response. For example, IRF1 biases the response towards Th1 
differentiation, as demonstrated by defective IFN-γ production and increased IL-4 production in 
Irf1-/- mice compared to IRF1 sufficient controls (Taki, Sato et al. 1997). Similarly, Leishmania 
infection of Irf4-/- mice elicited decreased differentiation into IFNγ-producing Th1 cells compared 
to heterozygous controls (Lohoff, Mittrucker et al. 2002). On the other hand, IRF1, IRF2, IRF4 and 
IRF8 have been implicated in the development of hematopoietic cells, including DCs, NK, CD8+ T 
and B cells (Matsuyama, Kimura et al. 1993, Ogasawara, Hida et al. 1998, Lu, Medina et al. 2003, 
Suzuki, Honma et al. 2004, Tamura, Tailor et al. 2005). 
With regards to the role of IRFs in malaria, a whole genome transcriptional array conducted 
on splenic CD4+ T cells from PbA-infected mice showed prominent up- and down-regulation of 
genes encoding components of type 1 (IFN-α/β) and type 2 (IFN-γ) interferon pathways (Haque, 
Best et al. 2011). While the importance of type 2 interferons during malaria is established, the 
significance of TI IFNs required further investigation. Mice unresponsive to TI IFN signalling 
(Ifnar1-/-) had 10-fold higher levels of serum IFN-γ and significantly more IFN-γ-positive Th cells 
during PbA infection compared to mice capable of TI IFN signalling (Haque, Best et al. 2011). This 
suggested a role for TI IFNs in suppressing the development of the Th1 response. IRF7 and IRF3 
are key transcription factors regulating the expression of TI IFNs, thus their involvement in immune 
responses to Plasmodium infection was also investigated. Indeed, IRF7 was demonstrated to be 
essential of the suppressive role of TI IFNs (Edwards, Best et al. 2015). However, the same was not 
seen of IRF3 (Edwards, Best et al. 2015), highlighting a disconnection between the function of 
IRF3 and IRF7 during Plasmodium infection.  
1.6.3 Interferon Regulatory Factor 3 
IRF3 is typically associated with production of TI IFNs in response to viruses. IRF3 is 
constitutively expressed in the cytosol of most cells and activated downstream of a number of cell 
membrane or cytosolic nucleic acid detection receptors (Figure 1.5) (Cavlar, Ablasser et al. 2012). 
Phosphorylation of IRF3 by kinases such as TBK1 results in its translocation to the nucleus where it 
facilitates the expression of TI IFNs and ISGs (Fitzgerald, Rowe et al. 2003, Tarassishin, Bauman et 
al. 2013). IRF3, in association with TBK1, has been shown to be important in B cell responses to 
CpG (Oganesyan, Saha et al. 2008). Additionally, activated IRF3 mediates apoptosis of virus-
infected cells in an IFN- and p53-independent way (Weaver, Ando et al. 2001). 
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Figure 1.5 Innate signalling pathways converging on Interferon regulatory factor 3 (IRF3). 
Pathogen products such as DNA or dsRNA act as ligands for receptors expressed on the cell 
surface, in the cytosol and in endosomes, notably TLRs, mitochondrial antiviral-signalling protein 
(MAVS/IPS-1) and the DNA sensors, DDX41 and DAI. These activate specific adaptor molecules, 
which in turn interact with kinases. The kinase TBK1 phosphorylates cytosolic IRF3 resulting in its 
translocation to the nucleus, thereby facilitating its action as a transcription factor for type 1 
interferons and other interferon-stimulated cytokines. 
 
Since IRF3 appears to be a convergence point for several PRR-signalling pathways, it is 
ideally situated to influence adaptive immune responses. IRF3 has been reported to suppress Th1 
responses during viral and bacterial co-infection (Negishi, Yanai et al. 2012), but drive Th1 and 
Th17 responses in the central nervous system during EAE (Fitzgerald, O'Brien et al. 2014). During 
liver-stage PbA infection of mice, IRF3 has been reported by two independent studies to be a driver 
of TI IFN responses (Liehl, Zuzarte-Luis et al. 2014, Miller, Sack et al. 2014). Whether IRF3 is also 
involved in shaping adaptive immune responses to blood-stage malaria is currently unknown. 
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1.7 Thesis aims 
This thesis aims to explore cellular and molecular mechanisms that modulate Plasmodium-
specific CD4+ T helper responses during experimental blood-stage malaria.  
Specifically it aims to: 
1. Determine whether a newly developed Plasmodium-specific CD4+ T cell can be effectively 
used to track T helper responses. 
 
2. Resolve the process of Th1 and Tfh cell differentiation to gain molecular insight into 
mechanisms controlling Th fate decision-making. 
 
3. Investigate whether innate immune signalling pathways can influence Th1 and Tfh-
dependent immune responses during infection.  
 
1.7.1 Thesis outline 
The materials and methods used throughout this thesis are described in Chapter 2.  
The importance of CD4+ T helper cells for protection against malaria is well established. 
However, the molecular and cellular mechanisms underlying their emergence in vivo remain poorly 
delineated. A novel Plasmodium-specific TCR transgenic mouse was recently generated by 
Professor Bill Heath and Dr Daniel Fernandez Ruiz (Doherty Institute, University of Melbourne), 
but its response during in vivo Plasmodium infection was uncharacterised. In Chapter 3, CD4+ T 
cells from this transgenic mouse (termed PbTII cells) are tested for their utility in tracking Th 
responses in vivo. PbTII cells are shown to proliferate during experimental malaria in a cDC-
dependent manner. In addition, PbTII cells are demonstrated to differentiate into Th1 and Tfh 
effector cells, and also regulatory and memory populations. 
The bifurcation of PbTII cells into two Th subpopulations offered a unique opportunity to 
study the process of fate 'decision-making' of a clonal population during in vivo infection. To this 
end, in Chapter 4, single-cell RNA sequencing (scRNAseq) is applied to PbTII cells during the 
first week of PcAS infection. By applying a combination of modelling algorithms to the 
transcriptomic data, the process of Th1 and Tfh differentiation is resolved. While Cxcr5 is the only 
chemokine receptor associating with Tfh fate decision, a number of chemokine receptors, including 
Cxcr3, correlate with the Th1 fate decision. ScRNAseq analysis of myeloid populations at the time 
of PbTII bifurcation, revealed expression of CXCR3 ligands not only by cDCs, but also 
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Ly6Chiinflammatory monocytes. For the first time, the requirement for inflammatory monocytes in 
Th1 responses is confirmed on a functional level.  
Given that PRR can detect Plasmodium infection and induce innate immune responses, it is 
possible that these influence Th fate decision. In Chapter 5, the first side-by-side comparison of 
endosomal and cytosolic PRRs is performed using the PbTII cells. Minor opposing roles for TLR 
adaptor molecules, MyD88 and Trif are observed. However, a critical role for the downstream 
transcription factor IRF3 in promoting PbTII accumulation, and furthermore, in their differentiation 
towards Th1 cells is demonstrated. This requirement corresponded with a role for IRF3 in MHCII 
expression by Ly6Chi inflammatory monocytes. Conversely, IRF3 is observed to suppress Tfh 
differentiation, GC B cell responses and resulting Plasmodium-specific antibody production in a B 
cell-intrinsic mechanism. 
Chapter 6 summarises the findings outline in each of the results chapters, their relationship 
with each other and how they contribute to a wider scientific understanding of CD4+ T cell 
responses during malaria. Finally, future directions of this project will be discussed. 
  
30 
Chapter Two: 
Materials and methods 
2.1 Materials 
2.1.1 Mice 
 
Strain Description Reference 
C57BL/6J Inbred animal expressing MHC class II (MHCII) 
IA(b) 
Australian Resource 
Centre (Canning 
Vale, Western 
Australia) 
B6.SJL-Ptprca These congenic mice express the leukocyte 
surface antigen CD45.1 (also referred to as 
Ly5.1) Ptprca (protein-tyrosine phosphatase, 
receptor type c, a allele). This maker is used to 
distinguish between cells from these mice and 
those from WT C57BL/6J mice, which express 
CD45.1/Ly5.2.  
 
Australian Resource 
Centre (Canning 
Vale, Western 
Australia) 
B6.129S7-
Rag1tm1Mom(Rag1
-/-) 
Mice lack mature T and B cell populations due 
to a mutation in the recombination activation 
gene (RAG) 1. The original mutation was made 
in the 129-derived AB1 ES cell line. The 
C57BL/6J strain was generated by backcrossing 
mice carrying the mutation to C57BL/6J inbred 
mice 10 times.  
(Mombaerts, 
Iacomini et al. 1992) 
LysMCre x iDTR F1 generation of LysMCre and iDTR breeding 
generating a mouse in which a diphtheria toxin 
receptor (DTR) is expressed off the lysozyme M 
promoter, such that lysozyme M expressing 
Generated in-house 
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myeloid cells can be depleted upon diphtheria 
toxin (DT) administration. 
CD11c-DOG Mice in which DTR, ovalbumin (OVA) and GFP 
are expressed off the CD11c promoter allowing 
for depletion of CD11c expressing cells upon 
administration of DT. 
(Hochweller, 
Striegler et al. 2008) 
Irf7-/- This mouse was generated by homologous 
recombination of an Irf7 gene-targeting construct 
in E14-1S cells, and their microinjection into 
C57BL/6 blastocysts. A homozygous line was 
generated by intercrossing heterozygous mice.  
(Honda, Yanai et al. 
2005) 
Irf3-/- An Irf3 gene-targeting vector was isolated from 
the C57BL/6N genomic library and 
electroporated into CCE embryonic stem cells 
(ESCs). Positive cells were injected into 
C57BL/6J blastocysts. Irf3-/- mice were 
generated by intercrossing heterozygous mice. 
(Sato, Suemori et al. 
2000) 
Myd88-/- The Myd88 gene was disrupted by homologous 
recombination in E14.1 embryonic stem cells 
with a targeting vector containing neomycin 
resistance gene. Clones with homologous 
recombination were microinjected into C57BL/6 
blastocysts. Homozygous knock-out mice were 
born at Mendelian ratio.   
(Adachi, Kawai et al. 
1998) 
Trif-/- A targeting vector was generated by replacing 
the Trif-encoding gene with a neomycin-
resistance gene cassette. This was transfected 
into ESCs. Homologous recombinants were 
micro-injected into C57BL/6 mice and 
heterozygous progenies were intercrossed in 
order to obtain a homozygous line.  
(Yamamoto, Sato et 
al. 2003) 
Casp1−/−Casp111 Mice were obtained by backcrossing (Kayagaki, Warming 
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29mt/129mt (Casp1/1
1-/-) 
NOD/ShiLtJ Casp1/11 double knockout to 
C57BL/6 for more than 10 generations. 
et al. 2011) 
Mavs-/-(Ips1-/-) A targeting vector was designed to disrupt two 
exons harboring the CARD-like domain of IPS-
1. Homozygous knock-out mice were born at 
expected Mendelian ratio.  
(Kumar, Kawai et al. 
2006) 
B6(Cg)-
Tmem173tm1.2Cam
b/J 
A targeting vector covering the Mpys locus was 
transfected into J<8A3.N1 ESCs. Positive clones 
were injected into C57BL/6J blastocysts. 
Heterozygous mice were intercrossed to achieve 
a homozygous line.  
(Jin, Hill et al. 2011) 
Tlr3-/- To generate these mice, the first exon of the Tlr3 
gene was replaced with a neomycin-resistance 
cassette flanked by two loxP sites. Chimeric 
mice were generated by microinjecting 
embryonic stem cells from three positive clones 
into C57BL/6 blastocysts. Male chimeric mice 
were mated with female and mutation was 
confirmed by southern blot. 
(Alexopoulou, Holt 
et al. 2001) 
OTII 
 
MHC class II-restricted, αβTCR transgenic mice, 
which express CD4+ T cells that are specific for 
the OVA323–339 determinant. This mouse is on 
a Rag1-/- background eliminative the expression 
of endogenous TCRs.  
(Barnden, Allison et 
al. 1998) 
μMT KO These mice were generated by targeted 
disruption of the gene encoding the 
immunoglobulin (Ig) u-chain constant region of 
IgM. Since IgM is the first immunoglobulin 
expressed by pre-immature B cells, homozygous 
mutation of this gene results in B cell deficiency.  
(Kitamura, Roes et 
al. 1991) 
PbTII x CD45.1 
(PbTII) 
MHCII-restricted T cell receptor (TCR) 
transgenic PbTII mice were generated using 
TCR genes isolated from a IA(b)-restricted 
(Fernandez-Ruiz 
DL, Ghazanfari et al. 
2016) 
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hybridoma originally derived from a T cell line 
isolated from a C57BL/6 mouse infected with 
blood-stage P. berghei ANKA. Female PbTII 
mice were crossed with male B6.SJL-Ptprca. 
Mice were maintained as a heterozygous line and 
phenotyped by flow cytometry assessment of 
Vα2 and Vβ12 transgenes by CD4+ T cells. 
  
2.1.2 Parasites 
 
 (Stabilates stored at -80◦C) 
Parasite Description Reference 
P. berghei ANKA 
(PbA)  
 
A transgenic PbA line (231c1l) expressing 
luciferase and GFP under the control of the 
ef1-α promoter. Lethal experimental model. 
C57BL/6 mice succumb to cerebral malaria 
after approximately 1 week of infection. 
(Franke-Fayard, Janse et al. 
2005) 
P. chabaudi 
chabaudi AS 
(PcAS) 
A model of resolving infection. C57Bl/6J 
mice resolve infection with a standard dose 
within 15 days. 
(Stephens, Culleton et al. 
2012) 
P. yoelii 17X non-
lethal (Py17XNL) 
Model of resolving infection. C57Bl/6J mice 
resolve infection with a standard dose by day 
30.  
(Amante and Good 1997) 
  
2.1.3 Infections 
 
Consumable/Reagent Source 
5ml tubes  Greiner Labortechnik (Frickenhausen, 
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Germany) 
30mL tubes Sarstedt (Pookara, Australia) 
Haemocytometer Pacific Laboratory Product (Blackburn, VIC, 
Aus) 
Immersion oil  Merck (Darmatadt, Germany) 
CliniPure Haem Kwik Fixative Grale Scientific (Ringwood, VIC, Aus) 
CliniPure Haem Kwik Stain No 1 Grale Scientific (Ringwood, VIC, Aus) 
CliniPure Haem Kwik Stain No 2 Grale Scientific (Ringwood, VIC, Aus) 
Heparin 5000 IU in 5mL Pfizer (New York, NY, USA) 
Trypan Blue 0.4% Thermo Fischer Scientific 
Sodium chloride 0.9% Baxter (Toongabbie, NSW, Aus) 
1mL Syringe Terumo (Tokyo, Japan) 
26 G needle Terumo (Tokyo, Japan) 
 
2.1.4 Harvesting tissues 
 
Consumable/Reagent Source 
1mL Insulin syringe and 18 gauge needle  Terumo (Tokyo, Japan) 
10mL tubes Sarstedt(Pookara, Aus) 
1.5mL eppendorf tube VWR (Radnor, PA, USA) 
 
2.1.5 Processing spleens 
 
Consumable/Reagent Source 
Petri dishes Greiner Labortechnik (Frickenhausen, 
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Germany) 
Falcon Yellow 100uM Nylon Strainer Fischer Scientific (Waltham, MA, USA) 
Deoxyribonuclease 1 100mg Worthington Biochemical 
Corporation(Lakewood, NJ, USA) 
5ml syringe Terumo (Tokyo, Japan) 
Collagenase Type 4 100mg Worthington Biochemical Corporation 
(Lakewood, NJ, USA) 
 
2.1.6 Cell transfer 
 
Consumable/Reagent Source 
MS columns  Miltenyi Biotec (Bergisch Gladbach, 
Germany) 
LS columns Miltenyi Biotec (Bergisch Gladbach, 
Germany) 
Octomagnant Miltenyi Biotec (Bergisch Gladbach, 
Germany) 
CD4 (L3T4) Microbeads Miltenyi Biotec (Bergisch Gladbach, 
Germany) 
CD11b Microbeads Miltenyi Biotec (Bergisch Gladbach, 
Germany) 
MACS stand Miltenyi Biotec (Bergisch Gladbach, 
Germany) 
Vacuum-driven filter 500mL Merck Millipore (Darmstadt , Germany) 
 
  
36 
2.1.7 In vivo cell depletions 
 
Consumable/Reagent Source 
Diptheria toxin from Corynebacterium 
diptheriae 
Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
anti-CD4 depleting monoclonal antibody 
(clone GK5.1) 
BioXCell (West Lebanon, NH, USA) 
anti-CD20 depleting (clone 5D2) Genentech (South San Francisco, CA, USA) 
 
2.1.8 Flow cytometry reagents and materials 
 
Consumable/Reagent Source 
CELLSTAR Falcon tube (50mL) Greiner Labortechnik (Frickenhausen, 
Germany) 
18 G needle Terumo (Tokyo, Japan) 
Falcon Centrifuge tubes (5mL) Corning (Corning, NY, USA) 
RBC Lysis Buffer Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Pipette 5mL Sarstedt (Pookara, Aus) 
Pipette 10mL Sarstedt (Pookara, Aus) 
Pipette 25mL Sarstedt (Pookara, Aus) 
Corning Costar U bottom 96-well plates Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
BD FACS lysing solution BD Biosciences  (Franklin Lakes, NJ, USA) 
Foxp3 Staining Buffer Set eBioscience (San Diego, CA, USA) 
Sucrose Chem-supply (Gillman, SA, Aus) 
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Ionomycin calcium salt from Streptomyces 
conglobatus powder 
Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Phorbol 12-myristate 13-acetate (PMA) Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Brefeldin A (BFA) Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Dulbecco's Phosphate buffered saline (dPBS) Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Percoll Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
 
2.1.9 Antibodies and dyes 
 
Antibody/Dye Clone Source 
Rat α mouse CD4-BV605 RM4-5  BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Hamster α mouse TCRb-APCCy7 H57-597 Biolegend (San Diego, CA, 
USA) 
Hamster α mouse CD69- PE  H1.2F3 Biolegend (San Diego, CA, 
USA) 
Biotin Rat α mouse CXCR5 2G8 BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Rat α mouse Vα2-FITC B20.1 Biolegend (San Diego, CA, 
USA) 
Rat α mouse CXCR6- PE SA051D1 Biolegend (San Diego, CA, 
USA) 
Rat α mouse Vβ12-TCR PerCP-
eFluor710 
MR11-1 eBioscience (San Diego, CA, 
USA) 
Hamster α mouse CD279 (PD-1)- APC-
eFluor 780 
J43 eBioscience (San Diego, CA, 
USA) 
  
38 
Rat α mouse CD279 (PD-1)-APC  29F.1A12 Biolegend (San Diego, CA, 
USA) 
Rat α mouse ICOS-PE  7E.17G9  eBioscience (San Diego, CA, 
USA) 
Mouse α mouse CD45.1-FITC A20  Biolegend (San Diego, CA, 
USA) 
Mouse α mouse CD45.1-Alexa Fluor 
700 
A20 Biolegend (San Diego, CA, 
USA) 
Streptavidin- BV605  Biolegend (San Diego, CA, 
USA) 
Streptavidin-PercpCy5.5  Biolegend (San Diego, CA, 
USA) 
Streptavidin-PeCy7  Biolegend (San Diego, CA, 
USA) 
Mouse α-mouse CD45.2-Alexa Fluor 
700 
104 Biolegend (San Diego, CA, 
USA) 
Hamster α mouse CD11c-APC N418  Biolegend (San Diego, CA, 
USA) 
Hamster α mouse CD11c- PercpCy5.5 N418 eBioscience (San Diego, CA, 
USA) 
Rat α mouse MHCII(I-A/I-E)-Pacific 
Blue  
M5/114-15.3 Biolegend (San Diego, CA, 
USA) 
Rat α mouse MHCII(I-A/I-E)-APC M5/114-15.3 Biolegend (San Diego, CA, 
USA) 
Rat α mouse Ly6C-FITC HK1.4 Biolegend (San Diego, CA, 
USA) 
Rat α mouse Ly6G-PE 1A8  Biolegend (San Diego, CA, 
USA) 
Rat α mouse B220-APCCy7 RA3-6B2 Biolegend (San Diego, CA, 
USA) 
Hamster α mouse TCRβ-BV605 H57-597 BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Hamster α mouse TCRβ-APCCy7 H57-597 Biolegend (San Diego, CA, 
USA) 
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Rat α mouse CD8a-PECy7 53-6.7  Biolegend (San Diego, CA, 
USA) 
Rat α mouse CD172a (Sirpα)-FITC P84 Biolegend (San Diego, CA, 
USA) 
Rat α mouse CD11b-PercpCy5.5 M1/70  Biolegend (San Diego, CA, 
USA) 
Rat α mouse CD11b-BV421 M1/70 Biolegend (San Diego, CA, 
USA) 
Rat α mouse CD86-PE GL1 Biolegend (San Diego, CA, 
USA) 
Hamster α mouse CD80-PE 16-10A1  Biolegend (San Diego, CA, 
USA) 
Rat α mouse CD40-PE  1C10 eBioscience (San Diego, CA, 
USA) 
Rat α mouse CD38- Pacific Blue 90 Biolegend (San Diego, CA, 
USA) 
Rat α mouse B220-Alexa Fluor 700 RA3-6B2 Biolegend (San Diego, CA, 
USA) 
Rat α mouse CD138-BV605 281-2 Biolegend (San Diego, CA, 
USA) 
Rat α mouse CD80-PercpCy5.5 16-10A1 Biolegend (San Diego, CA, 
USA) 
Rat α mouse CD73-PE TY/23 BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Rat α mouse CD19-FITC 6D5 Biolegend (San Diego, CA, 
USA) 
Rat α mouse GL7-eFluor660 GL-7  eBioscience (San Diego, CA, 
USA) 
Hamster α mouse CD95 (FAS)- PeCy7 Jo2  BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Rat α mouse CD23-APC B3B4 Biolegend (San Diego, CA, 
USA) 
Rat α mouse CD21/CD35-PercpCy5.5 7E9 Biolegend (San Diego, CA, 
USA) 
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Rat α mouseIFNγ-BV421  XMG1.2 Biolegend (San Diego, CA, 
USA) 
Rat α mouseIFNγ-PeCy7 XMG1.2 Biolegend (San Diego, CA, 
USA) 
Mouse α human/mouse Tbet-eFluor660 eBio4B10 eBioscience (San Diego, CA, 
USA) 
Mouse α mouse Bcl2-Alexa Fluor 647 BCL/10C4 Biolegend (San Diego, CA, 
USA) 
Rat α human/mouse RoRγT-APC AFKJS-9 eBioscience (San Diego, CA, 
USA) 
Rat α mouse FOXP3-Alexa Fluor 647 MF-14 Biolegend (San Diego, CA, 
USA) 
Rat α mouse IL-17A- BV605 TC11-18H10.1 Biolegend (San Diego, CA, 
USA) 
Rat α human/mouse GATA3-PerCP-
eFluor 710 
TWAJ eBioscience (San Diego, CA, 
USA) 
Rat α mouse IL-10-BV421 JES5-16E3 Biolegend (San Diego, CA, 
USA) 
Rat α mouse IL-4-PE  11B11 BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Rabbit α human/mouse TCF-1- PE CD63D9 Cell Signaling Technology 
(Danvers, MA, USA) 
Hamster α mouse CXCL9-PE MIG-2F5.5 Biolegend (San Diego, CA, 
USA) 
Rat α rat/mouse Ki67-PE SolA15 eBioscience (San Diego, CA, 
USA) 
Mouse α human/mouse Bcl6-
PercpCy5.5 
K112-91 BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Mouse α human/mouse Bcl6-PE K112-91 BD Biosciences  (Franklin 
Lakes, NJ, USA) 
Hamster α mouse CD183 (CXCR3)- PE CXCR3-173 Biolegend (San Diego, CA, 
USA) 
Syto-84  Life Technologies (Carlsbad, 
CA, USA) 
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Hoechst 33342  Sigma Aldrich Pty Ltd (St Louis 
Missouri, USA) 
CellTrace Violet  ThermoFisher Scientific 
(Massachusetts, USA) 
Zombie Aqua Dye   Biolegend (San Diego, CA, 
USA) 
 
2.1.10 Plasmodium-specific ELISA 
 
Reagent Source 
Corning Costar Flat bottom 96-well plates Greiner Labortechnik (Frickenhausen, 
Germany) 
OPD Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Tween 20 
 
Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Streptavidin-HRP  BD Biosciences  (Franklin Lakes, NJ, USA) 
Anti-IgM, total IgG, IgG1, IgG2b and IgG3  Jackson ImmunoResearch (West Grove, PA, 
USA) 
 
2.1.11 Single-cell RNA sequencing (scRNAseq) 
 
Reagent Source 
C1™ IFC for mRNA seq (5-10 μm) Fluidigm (San Fransisco, CA, USA) 
C1™ Single-Cell Auto Prep Reagent Kit for 
mRNASeq 
Fluidigm (Fransisco, CA, USA) 
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Clontech SMARTer® Kit Designed for the 
C1™ System, 10 IFCs 
Takara Bio USA (formally Clontech)  
(Mountain View, CA, USA) 
Nextera XT DNA Sample Preparation Kit Illumina, (San Diego, CA, USA) 
Nextera XT DNA Sample Preparation Index 
Kit (96 indices, 384 samples) 
Illumina (San Diego, CA, USA) 
ArrayControl™ ERRC RNA Spikes Life Technologies (Carlsbad, CA, USA) 
AMPure XP beads Beckman Coulter (Brea, CA, USA) 
 
2.1.12 Media and stock solutions 
 
RPMI/PS:- 10mL penicillin; 1L RPMI prepared in-house by QIMRB core services 
PBS:- Prepared in-house by QIMRB core services 
FACS Buffer:- Bovine serum albumin (BSA) (Life Technology) 100g/L; 10%w/v Sodium Azide 
1ml/L; 0.5M EDTA in PBS pH8 (Sigma)10ml/L; 1L PBS; filtered and de-gassed through 0.2μm 
bottle-top filter at 4oC for 20 minutes. 
MACS Buffer:- BSA 100g/L; 0.5M EDTA 10ml/L; 1L PBS; filtered and de-gassed through 0.2um 
bottle-top filter at 4oC for 20 minutes. 
Fetal Calf Serum (FCS):- Fetal calf serum (Bovogene) was heat inactivated at 56oC for 1 hour. 
FACS Block:- Generated in-house by harvesting supernatant of 120/G8 hybridoma to block against 
Fc receptor.  
4% PFA:- Paraformaldehyde powder (MP Biomedicals, USA) 4g/100mL; PBS 100mL; added 
~20μL NaOH while gently heating and stirring until powder dissolves. Add HCL until pH is 7. 
Aliquots of this were stored at -20oC until use. 1-2% PFA was made with the addition of PBS just 
prior to use.  
1.6% saline:- 0.16g saline; 100mL sterile milli-Q water 
12% saline:- 1.2g saline; 100mL sterile milli-Q water 
33% Percoll:- 1:3 v:v of Percoll in PBS 
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ELISA coating buffer:-1 L PBS; 1.59g Na2CO3; 2.93g NaHCO3; adjust pH to 9.6; filtered 
ELISA blocking buffer:- 1 L PBS; 1% BSA; 0.05% Tween 20; filtered  
ELISA wash buffer:- 05mL Tween20; 1L PBS. 
PcAS and Py17XNL antigens:- prepared in house 
 
2.2 Methods 
2.2.1 Mice and ethics 
 
 Mice used for single-cell RNAseq experiments were maintained under specific pathogen-
free conditions at the Wellcome Trust Genome Campus Research Support Facility (Cambridge, 
UK). These animal facilities are approved by and registered with the UK Home Office. All 
procedures were in accordance with the Animals (Scientific Procedures) Act 1986. The protocols 
were approved by the Animal Welfare and Ethical Review Body of the Wellcome Trust Genome 
Campus.  
 All other C57Bl/6, Rag1-/-, Irf7-/-, Irf3-/-, Myd88-/-, Trif-/-, Casp1/11-/-, Mavs-/-, Tmem173-/-, 
Tlr3-/-, CD11c-Cre, LysMCre x iDTRand μMT mice (all on a C57BL/6J background) were 
maintained in-house at QIMR Berghofer Medical Research Institute. PbTII mice were maintained 
as crosses with B6.SJL-Ptprca mice at QIMR Berghofer Medical Research Institute, and typed for 
the presence of the PbTII TCR by flow cytometric assessment of peripheral blood CD4+ T cells for 
co-expression of Vα2 and Vβ12.Animal procedures here were approved and monitored by the 
QIMR Berghofer Medical Research Institute Animal Ethics Committee (approval no. A02-633M) 
in accordance with Australian National Health and Medical Research Council guidelines. 
All mice were female unless otherwise stated and used at 8-12 weeks of age. 
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2.2.2 Adoptive transfer of Plasmodium-specific CD4+ T (PbTII) cells 
 
 Spleens from PbTII mice were aseptically removed and collected into a 10mL 
polypropylene tube containing 10mL of RPMI/PS. Spleens were mechanically homogenised 
through a 100μm strainer with a 5mL syringe and transferred back into original 10mL tube. Cells 
were pelleted by centrifuge at 1200rpm for 7 minutes at room temperature. The supernatant was 
discarding before lysis of erythrocytes with 5mL of RBC lysis buffer for 5 minutes at room 
temperature. The lysis buffer was quenched by topping up the tube with freshly made ice-cold 
MACS buffer, and cells were pelleted as before, but at 4oC. The supernatant was discarded. Cells 
were resuspended in 400μL of MACS buffer and 100μL of CD4+ microbeads and incubated for 15 
minutes on ice and in the dark. In this time, the octomagnet was attached to the MACS stand and an 
MS column was attached to the magnet. The column was equilibrated with 1mL of MACS buffer. 
Cells were washed with MACS buffer, centrifuged as before and the supernatant discarded. Cells 
were resuspended in 1mL MACS buffer. Using a 1mL pipette, cells were carefully passed through a 
100μM cell strainer suspended above the MS column. The column was washed three times with 
0.5mL of MACS buffer, allowing each wash to completely flow through before the addition of the 
next. After the final wash, the column was removed from the magnet and placed in a new 10mL 
tube. 1mL of MACS buffer was added to the column then, using force, cells were eluted from the 
column with a plunger. Cells were washed with RPMI/PS, centrifuged and the supernatant 
removed. Enriched cells were resuspended in 1mL RPMI/PS and counted with a haemocytometer. 
10μL of cell suspension was stained for expression of CD4, TCRβ, Vα2 and Vβ12 and assessed by 
flow cytometric methods for purity of enriched cells (purity typically >80% CD4+TCRβ+). Cells 
were diluted to the desired concentration in RPMI/PS and injected into mice via a lateral vein using 
a 1mL syringe and 18-gauge needle.   
 
2.2.3 CellTrace violet labelling of cells 
 
 Cells were washed twice in PBS and resuspended in 1mL of PBS per 107 cells. 1μL of 1mM 
CellTrace™ Violet dye in PBS was added for each 1mL of cell suspension. Cells were incubated at 
37oC in the dark for 15 minutes. Cells were washed twice in RPMI/PS before being counted with a 
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haemocytometer and purity assessed by flow cytometry as above.  Cells were resuspended in 
RPMI/PS and injected via a lateral tail vein.   
 
2.2.4 Infections 
 
 Plasmodium chabaudi chabaudi AS (PcAS), Plasmodium yoelii 17XNL (Py17XNL) and 
Plasmodium berghei ANKA (PbA) infected red blood cells (obtained from frozen stocks) were 
passaged through a C57Bl/6J mice prior to being used. Mice were infected intravenously via a 
lateral tail vein with 1x104 (Py17XNL) or 1x105 (PcAS and PbA) freshly prepared parasitised RBC 
(pRBC) in 200μL RPMI. Blood parasite burden (parasitemia) was measured from thin blood smears 
obtained from tail bleeds. Alternatively, parasitemia was measure by taking one drop of blood from 
the tail into 250μL of RPMI containing 5U/mL heparin sulphate and stained with 5μM Syto84 to 
detect RNA, and 10ug/mL Hoechst33342 to detect DNA, for 30 minutes in the dark and at room 
temperature. Staining was quenched with 10x initial volume of RPMI and samples were analysed 
immediately by flow cytometry, using a BD FACS Canto II Cell Analyser (BD Biosciences) and 
FlowJo software (Treestar, CA, USA).  
 
2.2.5 In vivo cell depletion 
 
2.2.5.1 CD4+ T cells 
Depletion of CD4+ T cells was achieved by administering mice with 0.1mg of anti-CD4 depleting 
monoclonal antibody (clone GK5.1) or an isotype control in 200μL 0.9% saline (Baxter) by 
intravenous (i.v.) injection, one day prior to infection. 
2.2.5.2 CD11c+ dendritic cells 
Depletion of conventional CD11c+ dendritic cells was achieved using CD11c-DOG mice. Mice 
were administered 160ng of DT (Sigma Aldrich) in 200μL of 0.9% saline (Baxter). 
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2.2.5.3 LysM+ monocytes/macrophages 
Cellular depletion in LysMCre x iDTR mice was performed by intraperitoneal (i.p.) injection of 
10ng/g DT (Sigma-Aldrich) in 200μL 0.9% saline (Baxter) per mouse at 3 day post-infection. 
Control mice were given saline only.  
2.2.5.3 B cell depletion 
For B cell depletion, anti-CD20 (Genentech) or isotype control antibody was administered in a 
single 0.25mg dose via i.p. injection in 200μL 0.9% saline (Baxter), 7 days prior to infection. 
 
2.2.6 Euthanasia 
 
Mice were sacrificed by asphyxiation with 80:20 mix of CO2:O2 and doused with 80% ethanol. 
 
2.2.7 Processing tissues 
 
2.2.7.1 Spleens 
 Spleens were collected into 10mL of RPMI/PS. When assessing myeloid cell populations, 
spleens were incubated in Deoxyribosnuclease and collagenase for 25 minutes with constant 
agitation. A cell suspension was created by homogenising each spleen through a 70μm cell strainer 
with a 5mL syringe. RBCs were lysed with RBC lysing buffer (Sigma) for 5 minutes at room 
temperature and splenocytes were washed once in RPMI/PS. Cell numbers were calculated from a 
haemocytometer with Trypan Blue exclusion (Sigma-Aldrich). Following processing of tissue, 
approximately 1/20th of total splenocytes diluted in 200μL of RPMI was transferred into a U-
bottomed 96-well plate.  
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2.2.7.2 Blood 
 Whole blood was harvested via cardiac bleed using a 26-gauge insulin syringe with needle 
into a lithium/heparin tube for plasma or into Eppendorf’s containing 250μL of 1000ug heparin in 
RPMI/PS for flow cytometry. Each blood sample was pelleted at 1200rpm for 5 minutes in a bench-
top centrifuge. The supernatant of was removed with a 1mL pipette. Samples were stained as 
described below and then washed twice with FACS buffer. Red blood cells were lysed with BD 
FACS Lysing solution for 7 minutes at room temperature, while mechanically disrupting the pellet 
by pipetting up and down. Samples were washed twice as before. 
2.2.7.3 Liver 
 Mice were perfused by injecting d-PBS through the heart. Livers were collected into 5mL of 
PBS. Livers were digested in deoxyribosnuclease and collagenase for 25 minutes with constant 
agitation before being homogenised through mesh. Liver cells were transferred into a new 50mL 
FALCON tube, topped up to 50mL with cold PBS/2% FCS and pelleted for 7 minutes at 1200 rpm. 
The supernatant was removed and the cells were washed again in 40mL of PBS/2% FCS. After 
removing the supernatant, cells were resuspended in 25mL of 33% Percoll in PBS. Cells were spun 
at room temperature for 12 minutes at 1700 rpm and with the brake off. Carefully, the top layer and 
supernatant were removed from the pellet with a Pasteur pipette. RBCs were lysed with RBC lysing 
buffer for 5 minutes at room temperature and cells were washed once in RPMI/PS. Cell were made 
up to 200μL in RPMI/PS and a fraction taken for cell count by haemocytometer with Trypan Blue 
exclusion. The remaining liver cells were transferred to a 96-well plate for staining. 
2.2.7.4 Bone marrow 
 Hind limbs were removed from mice and collected into 25mL of RPMI/PS. Working 
aseptically, tissue was removed from limbs to leave only femurs. The ends of bones were removed 
with a scalpel. Using an 18-gauge needle and 10mL syringe filled with RPMI/PS, bone marrow was 
flushed from the femurs in a new 50mL FALCON tube containing 10mL of RPMI/PS. Cells were 
pelleted at 1200rpm for 10 minutes. Red blood cells were lysed with 5mL of lysis buffer for 5 
minutes. Cells were washed twice with RPMI before being counted with a haemocytometer and 
diluted to the appropriate concentration in RPMI/PS. 
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2.2.8 Bone marrow chimeric mice 
 
 Bone marrow (BM) chimeric mice were generated by injecting 2x106 syngenic BM cells 
freshly harvested from the femurs of Ptprca (CD45.1) Irf3-/-, or μMT mice (described in section 
2.2.7.4) into lethally irradiated (11Gy (137Cs source)) WT or Irf3-/- recipient mice via a lateral tail 
vein. Recipient mice were treated with Baytril (100μg/mL enrofloxacin) in drinking water 7 days 
prior to and 4 weeks following irradiation. At six weeks post-transplantation, engraftment was 
assessed by flow cytometry. BM was allowed to reconstitute for 8 weeks following transplantation 
before mice were used for experiments.  
 
2.2.9 Flow cytometry 
 
2.2.9.1 Live/Dead stain 
 Samples were washed twice by topping up wells to 200μL with PBS, centrifuging at 
1200rpm for 4 minutes at room temperature, removing supernatant by quickly flicking the plate and 
resuspending cells by gently vortexing. Cells were stained with 50μL of zombie dye diluted at 
1:400 in PBS for 15 minutes in the dark and at room temperature. Samples were washed twice with 
cold FACS buffer as before but at 4oC. 
2.2.9.2 Surface stain 
 Fc receptors were blocked by incubating cells in 100μL of FACS block for 10 minutes on 
ice. The plate was centrifuged, the block removed by quickly flicking and cells resuspended by 
gently vortexing. The samples were stained 50μL of surface monoclonal antibodies made up in 
FACS buffer for 20 minutes on ice. Cells were washed twice with cold FACS buffer. 
2.2.9.3 Secondary antibody stain 
 Secondary antibody diluted in FACS buffer was added to each sample and incubated on ice 
for 15 minutes. Cells were washed twice further.  
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2.2.9.4 Intracellular stain with eBioscience Foxp3 intracellular kit 
 Approximately 200μL of a 5mL preparation of homogenised spenocytes were transferred 
into a 96 well U-bottom plate. Cells were pelleted by centrifuge for 4 minutes at 1200rpm. To each 
sample, 200μL of 10μg/mL BFA, 10% FSC in RPMI/PS was added. For IL-10/IFNγ restimulation, 
25ng/ml of PMA and 500ng/ml Ionomycin was also added to BFA cocktail. Cells were incubated 
for 3 hours at 37oC. Cells were pelleted and washed twice with RPMI/PS, and surface stain was 
performed as above. Following surface staining, cells were fixed and permeabilised by adding 
100μL of freshly made Fix/perm solution and incubated on ice for 30 minutes, according to the 
eBioscience Foxp3 intracellular staining protocol. Cells were washed twice with Perm buffer. 
Intracellular antibodies diluted in Perm buffer were added and incubated for 1 hour on ice. Cells 
were washed twice as before.  
2.2.9.5 Detection of apoptosis 
 Following surface staining of samples, cell surface display of phosphatidylserine was 
detected using the Annexin V-PE apoptosis Detection Kit I (BD Biosciences).   
 
2.2.10 FACS acquisition 
 
 Samples were fixed in 2% paraformaldehyde and transferred into 5ml polypropelene FACS 
tubes for acquisition on a BD LSR Fortessa Cell Analyser (BD Biosciences), MoFlo XDP 
(Beckman Coulter) or a FACS Aria II (Becton Dickinson) instrument. Data were analysed using 
FlowJo software (Tree Star). 
 
2.2.11 ELISA analysis of Plasmodium-specific immunoglobulins in serum 
 
 Costar EIA/RIA 96-well flat bottom plates were coated overnight at 4oC with100μL/well of 
2.5μg of soluble whole parasite lysate/ml in bicarbonate coating buffer. Wells were washed three 
times (all washes in 0.005% Tween in PBS) and then blocked for 1hr at 37oC with 1% BSA in PBS 
(Blocking buffer). Wells were washed three times and 100μL of sera diluted to 1/400, 1/800, 1/1600 
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or 1/3200 was added before being incubated for one hour at 37oC. Following six washes, wells were 
incubated in the dark with biotinylated anti-IgM, total IgG, IgG1, IgG2b and IgG3 for one hour at 
room temperature. Unbound antibodies were washed off (six times) prior to incubation with 
streptavidin HRP in the dark for 30 minutes at room temperature. Wells were washed six times and 
developed with 100μL of OPD for 3-5 minutes in the dark before termination with an equal volume 
of 1M HCl. Absorbance was determined at 492nm using a Biotek synergy H4 ELISA plate reader 
(Biotek, USA). Data were analysed using Gen5 software (version 2) and GraphPad Prism (version 
6). 
 
2.2.12 Single-cell mRNA sequencing 
 
 Activated PbTII T cells were sorted as CD4+ TCRβ+ CD4+ and CD69+ and/or divided at least 
once as measured using the CellTrace proliferation dye. Dendritic cells were sorted as lineage 
negative, CD11chi and MHCIIhi. Naive dendritic cells were further sorted as CD8α+ and CD11b- or 
CD8α- and CD11b+. Inflammatory monocytes were identified as lineage negative, CD11bhi, Ly6Chi 
and Ly6Glo. 
 Single cell capture and processing was performed using the Fluidigm C1 system as in 
(Mahata, Zhang et al. 2014). The cell suspension obtained from sorting (made to 5000 cells/3μL) 
was loaded on to the Fluidigm C1 platform using small–sized capture chips (5-10μm cells). 1 μL of 
a 1:4000 dilution of External RNA Control Consortium (ERCC) spike-ins (Ambion, Life 
Technologies) was included in the lysis buffer. Reverse transcription and preamplification of cDNA 
were performed using the SMARTer Ultra Low RNA kit (Clontech). The sequencing libraries were 
prepared using Nextera XT DNA Sample Preparation Kit (Illumina), according to the protocol 
supplied by Fluidigm (PN 100-5950 B1). cDNA from each sample were barcoded (Illumina). 
Libraries from up to 96 single cells were pooled and purified using AMPure XP beads (Beckman 
Coulter). Pooled samples were sequenced on an Illumina HiSeq 2500 instrument, using paired-end 
100-base pair reads.  Depth was 1-6 million reads per cell. 
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2.2.13 Processing scRNAseq data and quality control 
 
 Reads were mapped to the Mus musculus genome (Ensembl version 38.75) concatenated 
with the ERCC sequences, using GSNAP (version 2014-05-15_v2) with default parameters. Gene 
expressions were quantified from the samples using Salmon (version 0.4.0) (Patro 2015). For 
quality control of the single-cell data the number of input read pairs, and the amount of 
mitochondrial gene content were assessed. Samples with fewer than 100,000 reads or more than 
35% mitochondrial gene content, as well as cells where the number of genes detected was less than 
100 + 0.008 * (mitochondrial content) were considered as failed. These were removed from further 
analysis, and the remainder of the samples were taken as individual single cells. For expression 
values, the Transcripts Per Millions (TPM's) estimated by Salmon (Patro 2015) included ERCC 
spike-ins. Thus, for analysis of the cells, ERCC's were removed from the expression table and 
TPM's scaled so they again summed to a million. This generated endogenous TPM values, 
representing the relative abundance of a given gene within a cell. Also, genes were filtered for 
expression in at least three cells at minimum level of 1 TPM prior to analysis, unless stated 
otherwise. 
 
2.2.14 Statistics 
 
 Single-cell RNAseq reads were analysed using R and RStudio software. Comparison 
between two groups was performed using non-parametric Mann-Whitney tests. Comparisons 
between multiple groups were performed using a one-way ANOVA or Two-way ANOVA with 
Tukey's test for multiple comparisons. Graphs with individual points show median value, and bar 
graphs display mean values ± SEM. p<0.05 was considered significant (p<0.05=*, p<0.01=**, 
p<0.001=***, p<0.0001=****). All statistical analyse was performed using GraphPad Prism 6 
software (San Diego, CA, USA). 
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Chapter Three: 
Assessing the utility of Plasmodium-specific TCR transgenic CD4+ T 
cells for studying T helper responses during experimental blood-stage 
malaria 
 
3.1 Abstract 
Antigen-specific T helper cell responses have well-established roles in immunological 
protection against malaria in humans and experimental mice. However, studying these responses in 
vivo has proven difficult, partly due to an absence of appropriate Plasmodium-specific reagents. 
Here, a newly generated MHCII-restricted TCR transgenic CD4+ T cell line was tested for its utility 
in studying Plasmodium-specific T helper cell responses during blood-stage infection. CD4+ T cells 
from PbTII TCR transgenic mice (PbTII cells) proliferated in response to multiple Plasmodium 
strains, in a manner dependent on cDCs and MHCII. Furthermore, PbTII cells differentiated into 
both Th1 and Tfh cells, but not other Th subsets, within the same animals during the first week of 
infection. Moreover, the PbTII Th response closely resembled the endogenous polyclonal response. 
Finally, PbTII cells also displayed Tr1, and effector and central memory phenotypes during the later 
stages of infection. Therefore, PbTII cells represent a unique in vivo tool, with extensive 
applications for studying Plasmodium-specific CD4+ T cell responses. 
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3.2 Introduction 
Epidemiological studies and in vivo modelling have implicated CD4+ Th cell responses and 
high-affinity Plasmodium-specific antibodies in the control of pRBCs (Weiss, Sedegah et al. 1993, 
Whitworth, Morgan et al. 2000, Pombo, Lawrence et al. 2002). Th1 cells, defined by expression of 
the transcription factor, T-bet, and secretion of the cytokine, IFNγ (Luckheeram, Zhou et al. 2012), 
are generated during blood-stage Plasmodium infection (Suss, Eichmann et al. 1988), and can 
control pRBC numbers (Pinzon-Charry, McPhun et al. 2010). More recently, Plasmodium infection 
of mice has been reported to elicit anti-parasitic Tfh cells (Butler, Moebius et al. 2012, Perez-
Mazliah, Ng et al. 2015), which are defined by expression of the transcription factor Bcl6, the 
cytokine IL-21, and cell-surface receptors CXCR5, ICOS and PD1 (Schaerli, Willimann et al. 2000, 
Nurieva, Chung et al. 2009, Crotty 2011). In other experimental systems, Tfh cells are known to 
migrate into B cell follicles to instruct the formation and maintenance of germinal centres, and 
thereby to drive high-affinity antibody production (Kerfoot, Yaari et al. 2011). A recent study by 
Ryg-Cornejo et al, demonstrated that in a model of severe malaria, pro-inflammatory cytokines 
perturbed Tfh responses resulting in weak GC reactions (Ryg-Cornejo, Ioannidis et al. 2015). The 
critical importance of humoral immunity for controlling pRBC is demonstrated by the inability of 
mice lacking B cells or the cellular machinery for immunoglobulin-class-switching to resolve 
infection (van der Heyde, Huszar et al. 1994, Butler, Moebius et al. 2012). Furthermore, passive 
transfer of Plasmodium-specific antibodies in humans can provide protection against severe disease 
(Cohen, McGregor et al. 1961). However, there remains a substantial gap in our current 
understanding of how Th cell responses are generated during Plasmodium infection.  
Genetically-marked TCR transgenic T cells allow for in vivo tracking of antigen-specific T 
cell clones in modified immune environments. A Plasmodium-specific TCR transgenic mouse line 
that expressed CD4+ T cells reactive against the blood-stage protein MSP-1 was used to examine 
requirements for cDC subsets in initiating CD4+ T cell responses in vitro co-culture experiments 
during PcAS infection (Sponaas, Cadman et al. 2006). One caveat of this reagent, however, was 
that it was developed on the BALB/c genetic background, in which few immunologically-related 
gene knock-out mice are currently available. This limits opportunities for identifying T-cell 
extrinsic mechanisms that control CD4+ T cell responses. For this reason, Professor Bill Heath, at 
The Peter Doherty Institute, University of Melbourne, Australia, has worked towards generating 
reagents for studying T cell responses in mouse models of Plasmodium infection. His laboratory 
firstly developed transgenic PbA parasites that expressed peptides derived from the model antigen 
chicken egg ovalbumin, for which OTI (CD8+) and OTII (CD4+) T cells could be used to study 
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antigen-specific T cell responses. While these reagents have been useful (Langhorne 1989, Lundie, 
de Koning-Ward et al. 2008, Haque, Best et al. 2011), it was preferable to develop T cell lines that 
respond to wild-type Plasmodium antigens. Thus, a CD8+ TCR transgenic line (termed PbTI) was 
developed and recently used to determine roles for CD8+ T cells during liver-stage and blood-stage 
infections (Lau, Fernandez-Ruiz et al. 2014). A similar CD4+ TCR transgenic reagent, termed 
PbTII, had been generated by the Heath laboratory, but had yet to be tested in vivo. 
In this chapter, PbTII cells were tested for their utility as reporters of Plasmodium-specific 
CD4+ T cell responses during in vivo blood-stage infection. PbTII cells proliferated upon infection 
in a manner dependent on MHCII-expressing cells and cDCs. At the peak of infection towards the 
end of the first week, PbTII cells had simultaneously differentiated in the same animals into Th1 
and Tfh effector cells. Their response resembled the endogenous polyclonal response, thus 
highlighting their usefulness for studying CD4+ T cell responses in vivo. Furthermore, PbTII cells 
exhibited regulatory and memory phenotypes during later stages of infection.  
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3.3 Results 
3.3.1 Generation of Plasmodium-specific TCR transgenic CD4+ T (PbTII) cells 
To address the lack of immunological tools for assessing CD4+ T cell responses in vivo, our 
collaborators Prof. Bill Heath and Dr Daniel Fernandez-Ruiz at The Peter Doherty Institute 
(University of Melbourne) generated a novel MHCII-restricted TCR-transgenic mouse line (termed 
PbTII). This mouse was developed by first generating an IAb-restricted hybridoma (termed D73) by 
fusing an immortalised cell line with T cells taken from the spleen of a PbA-infected mouse. Vα2 
and Vβ12 transgenes cloned from D73 were then used to generate the MHCII-restricted PbTII mice. 
More than 90% of splenic CD4+ T cells in PbTII mice co-expressed Vα2 and Vβ12 TCRs (Figure 
3.1A). In order to track these cells once transferred into recipient C57Bl/6J (CD45.2) mice, the 
PbTII mice were crossed with congenic CD45.1+ (Ptprca) mice (Figure 3.1A). 
 
Figure 3.1 Gating strategy for sorted Plasmodium-specific CD4+ TCR transgenic (PbTII) cells. 
(A) Representative plot of PbTII cells (Vα2+ Vβ12+ CD45.1+ CD4+ TCRβ+) MACS enriched from the 
spleens of PbTII-expressing mice based on CD4+ expression. Flow-through of the MACS 
enrichment is shown for comparison. 
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3.3.2 PbTII responses are specific for Plasmodium infection 
Firstly, it was important to determine whether PbTII cells responded during Plasmodium 
infection. To test this, increasing numbers of CellTrace™ Violet (CTV)-labelled PbTII cells, or 105 
CTV-labelled OTII cells as a negative control, were transferred into wild-type C57BL/6J mice, 
which were infected with PcAS or left naive. By 7 days post-infection (p.i.), which approximates to 
the peak of parasitemia in this model, PbTII cells had proliferated extensively, as determined by 
CTV dilution (Figure 3.2A). The absolute numbers of splenic PbTII cells retrieved at 7 days p.i. 
were approximately 10-fold higher than the initial transfer dose of 103 or 104 PbTII cells (Figure 
3.2A). At higher transfer numbers of 105 and 106 cells, the absolute number of splenic PbTII cells 
was approximately equivalent to the number transferred (Figure 3.2A). In contrast, non-
Plasmodium-specific OTII cells were below the threshold of detection by 7 days p.i., suggesting 
they had failed to respond to the infection (Figure 3.2A). Thus, PbTII cells proliferated during in 
vivo PcAS infection, with lower numbers of transferred cells eliciting stronger proliferative 
responses. 
To determine if PbTII proliferative responses required cDCs in vivo, splenic PbTII cells 
were enumerated in PcAS-infected CD11c-DTR recipient mice, which had received 104 PbTII cells 
and were treated with diphtheria toxin (DT) to deplete CD11chi cells, or with control saline (Figure 
3.2B). In addition, PbTII responses were examined in PcAS-infected, CD11cCre IAbf/f recipient mice 
(104 PbTII cells transferred), in which CD11c+ cells lacked expression of the MHCII molecule, IAb, 
compared to control IAbf/f littermates (Figure 3.2B). In both experimental systems, lack of cDCs or 
MHCII-expression by CD11chi cells resulted in substantial reductions in splenic PbTII numbers 
(Figure 3.2B). Together, these data strongly suggested that in vivo proliferation of PbTII cells 
during PcAS infection was dependent upon cDC-mediated MHCII-restricted antigen presentation. 
Finally, to explore the influence of PbTII cells on parasitemia, increasing numbers of PbTII 
cells were transferred into PcAS-infected WT mice, and peripheral parasitemia was monitored until 
the first peak of infection was controlled. No change in the kinetics of PcAS infection was observed 
upon transfer of PbTII cells compared with infected mice receiving no PbTII cells, demonstrating 
that PbTII cells did not influence the outcome of PcAS infection in WT mice (Figure 3.2C). 
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Figure 3.2 PbTII cells proliferate in an MHCII-dependent manner during PcAS infection. CTV-
labelled PbTII cells or non-specific control OTII cells were transferred at the indicated number into 
C57Bl6/J mice that were left naïve or infected with PcAS. (A) Representative plots of total CD4+ T 
cell population showing expansion of transferred cells and graphs depicting total numbers of 
transferred cells in the spleen of mice at 7 days p.i.. (B)Numbers of PbTII cells (104 transferred) in 
the spleens of DT treated CD11c-DTR or CD11cCreIAbfl/fl or appropriate control mice at 7 days p.i. 
(n=5-6). (C) Kinetics of infection determined by proportion of parasitised red blood cells (pRBC). 
(A) Data are a single experiment, or (B &C) representative of two independent experiments. 
Graphs show mean with SEM. * p<0.05, **p<0.01. 
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3.3.3 Th1 and Tfh are distinct effector subsets 
CD4+ T cell clones have been reported to display preferential skewing towards certain Th 
subsets (Tubo, Pagan et al. 2013). OTII cells, for example, preferentially differentiate into Tfh cells 
over Th1 cells in response to LCMV infection (Tubo, Pagan et al. 2013). Thus, it was important to 
determine whether PbTII cells differentiated into T helper cells, and the kinetics of this 
differentiation. To enable tracking of PbTII cells at earlier time points, 106 CTV-labelled PbTII 
cells were transferred into mice and splenic PbTII cell responses assessed at 1, 4 and 7 days p.i. 
with PcAS (Figure 3.3A). PbTII cells proliferated extensively by 4 days p.i. as determined by the 
loss of CTV and total numbers of splenic PbTII cells. Additionally, PbTII cells that had progressed 
through more than 5 divisions up-regulated CXCR5 expression, a marker of Tfh differentiation, and 
exhibited modest, direct ex vivo expression of IFNγ, a Th1 marker (Figure 3.3A). PbTII expansion, 
as well as IFNγ and CXCR5 expression increased up to day 7 p.i. (Figure 3.3A).  
Intra-clonal competition has previously been reported at transfer of higher numbers that can 
affect the magnitude of the T cell responses (Foulds, Rotte et al. 2006, Badovinac, Haring et al. 
2007, Bautista, Lio et al. 2009). Therefore, to characterise Th1 and Tfh responses further at peak 
infection, 104 PbTII cells were transferred. Importantly, most PbTII cells expressed either IFNγ 
(Th1) or CXCR5 (Tfh) at 7days p.i. (Figure 3.3B), in a manner similar to the polyclonal Th 
response (Figure 3.3B). Of particular note, bifurcated PbTII cells, expressing either IFNγ or 
CXCR5, also expressed canonical transcription factors T-bet or Bcl6 respectively (Figure 3.3C). To 
determine the effect of intra-clonal competition on PbTII cell responses, PbTII cells were 
transferred at numbers of 102, 104 or 106 into WT mice, where transfer 102 represents the most 
physiologically relevant frequency in naïve mice (Moon, Chu et al. 2007). Proportions of Th1 or 
Tfh cells within the PbTII population were equivalent for transfers of 102 or 104 cells, while transfer 
of 106 PbTII cells elicited lower proportions of Th1 cells and Tfh cells (Figure 3.4A). The absolute 
number of both effector populations was equally high upon transfer of 104 or 106 compared to 102 
cells (Figure 3.4A) Thus, use of 104 PbTII cells was appropriated for assessing PbTII responses at 
peak infection. Together, these data suggests that PbTII cells bifurcate into either Th1 or Tfh 
effector cells, similar to the polyclonal response. 
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Figure 3.3 Plasmodium-specific TCR transgenic CD4+ T (PbTII) cells bifurcate into Th1 and Tfh 
cells during PcAS infection. (A) CellTrace™ Violet (CTV)-labelled, CD45.1+ PbTII cells (106) 
were transferred into WT mice (n=4) prior to infection with PcAS. Representative FACS plots of 
CTV loss and IFNγ or CXCR5 expression, and numbers of splenic PbTIIs at indicated days p.i.. (B) 
Representative FACS plots and summary graphs showing proportions of PbTII cells (CD45.1+ 
CD4+ TCRβ+ live singlets) and endogenous polyclonal CD4+ T cells (CD45.1- CD4+ TCRβ+ live 
singlets) expressing IFNγ or CXCR5 in PcAS-infected mice 7 days p.i. (receiving 104 PbTII cells) 
compared to naïve controls (106 PbTII cells). (C) Left: representative FACS plots (gated on 
CD45.1+ CD4+ TCRβ+ live singlets) and a summary graph showing T-bet and Bcl6 expression by 
splenic PbTII cells (CD45.1+) from naive and 7-day PcAS-infected mice (n=5). Right: 
representative histograms of IFNγ and CXCR5 expression by T-bethi Bcl6lo (red), Bcl6hi T-betlo 
(blue) PbTII cells compared to those from naive mice (grey). Data are representative of two 
independent experiments. Statistics:  Mann-Whitney U test; *** p<0.001; ****p<0.0001.  
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Figure 3.4 Differentiation of PbTII cells during PcAS infection. PbTII cells were transferred at 
the indicated doses into PcAS-infected WT mice. Proportions and absolute numbers of T-bet+ IFNγ+ 
(Th1) or CXCR5+ Bcl6+ (Tfh) splenic PbTII cells at day 7 p.i.. 
 
3.3.4 PbTII display the capacity to differentiate into T regulatory 1 cells 
Regulatory responses by Tregs and Tr1 cells have been observed in human and experimental 
malaria studies (Langhorne, Gillard et al. 1989, Amante, Stanley et al. 2007, Couper, Blount et al. 
2008, Finney, Nwakanma et al. 2009, Walther, Jeffries et al. 2009, Berretta, St-Pierre et al. 2011). 
Similarly, IL-4 positive Th-2 cells have been implicated in immune responses to malaria 
(Langhorne, Gillard et al. 1989). Therefore, PbTII cells were assessed for their capacity to 
differentiate into regulatory T cells and other Th subsets during PcAS infection. While 
approximately 4% of the recipient polyclonal CD4+ T cells expressed FOXP3 at peak infection 
(Figure 3.5A), no such FOXP3 expression was observed from the PbTII cells (Figure 3.5A). 
Notably, however, after peak infection, ex vivo restimulation of PbTII cells resulted in co-
expression of IL-10 and IFNγ by approximately 5% of PbTII cells (Figure 3.5B), evidence of Tr1 
effector function as seen from polyclonal CD4+ T cells in this infection (Montes de Oca, Kumar et 
al. 2016). Finally, neither endogenous polyclonal CD4+ T cells nor PbTII cells expressed Th2 
markers, IL-4+ and GATA3+, or Th17 markers, IL-17A and RORγT at peak infection (Figure 3.5C). 
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Together, this demonstrates that during PcAS infection, PbTII cells have the capacity to 
differentiate into Tr1 cells, but not Treg, Th2 and Th17 cell subsets.  
 
 
Figure 3.5 PbTII cells differentiate into regulatory cells during PcAS infection. PbTII cells were 
transferred into C57Bl/6J mice infected with PcAS (104/mouse) or left uninfected (106/mouse). 
(A)Representative FACS plots (gated on CD4+ TCRβ+ live singlets) and proportion of Treg 
(FOXP3+) cells within the PbTII (CD45.1+) or polyclonal CD4+ T cell population (CD45.1-) at 7 
days p.i.. (B) Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets) and 
summary graph of ex vivo restimulated IL-10 and IFNγ co-expression by splenic PbTII cells (106 
transferred) in naive (n=2) or day 9-infected mice (n=6). (C) Representative FACS plots (gated on 
CD45.1+ CD4+ TCRβ+ live singlets)  of IL-4+ GATA3+ (Th2) and IL-17+ RORγt+ (Th17) splenic 
PbTII cells at 7 days p.i. (n=6). Data show mean and SEM and are representative of two 
independent experiments. Statistics:  Mann-Whitney U test; *p<0.05. 
 
 
CD45.1
F
O
X
P
3
GATA3
IL
-4
0.010
RORγt
IL
-1
7
0.030
Naive PcAS
0.323.54
P
o
ly
c
lo
n
a
l
P
b
T
II
0
1
2
3
4
5
%
 F
O
X
P
3
+
*
A
C
Naive PcAS
IL-10
IF
N
γ
B
1.484.78 6.8114.0
N
a
iv
e
 
P
c
A
S
0
2
4
6
8
%
 I
L
-1
0
+
 I
F
N

+
  
62 
3.3.5 PbTII cells migrate to the liver and display a Th1 phenotype 
 Next, it was of interest whether effector PbTII cells could migrate to peripheral tissues such 
as the liver, in which CD4+ T cell responses have previously been identified during blood-stage 
malaria (Mastelic, do Rosario et al. 2012). Indeed, PbTII cells were observed in the liver at peak 
infection, although roughly 100-fold fewer compared to the number within the spleen (Figure 3.6A 
and Figure 3.3A). Of the PbTII cells within the liver, approximately 50% expressed IFNγ (Figure 
3.6B). Conversely, no CXCR5 expression was detected (Figure 3.6B). Together, these data show 
that PbTII cells can migrate to the liver, and display a Th1, but not Tfh effector phenotype. 
 
Figure 3.6 IFNγ+ PbTII cells migrate to the liver. PbTII cells (106) were transferred into mice that 
were infected with PcAS (n=4) or left naive (n=1). (A) Absolute numbers of PbTII cells in the liver 
at day 7 p.i.. (B) Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets) and 
proportions of IFNγ and CXCR5 expression by PbTII cells in the liver at day 7 p.i.. Numbers on 
plots show proportion of PbTII population within respective quadrants. Data show mean with SEM 
and are a single experiment.  
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3.3.6 PbTII cells develop into memory cells after acute PcAS infection 
Memory T cells have been associated with long-lasting protection against Plasmodium 
infection in mice and humans (Grun and Weidanz 1981, Tsuji, Romero et al. 1990, Migot, 
Chougnet et al. 1993, Langhorne 1994, Stephens and Langhorne 2010). However, it has been 
challenging to definitively track memory T cell responses. To determine if PbTII cells survived 
beyond the first week of infection, and could convert into memory phenotypes, PbTII cells were 
assessed after peak parasitemia had been controlled. PbTII cells were detected in the spleens of WT 
recipient mice by 37 days p.i. with PcAS (Figure 3.7A), and depending on the number of cells 
transferred, exhibited both effector memory (CD62Llo CD44hi) and central memory (CD62Lhi 
CD44hi) phenotypes (Figure 3.7B). Thus, PbTII cells exhibited the potential to form splenic 
memory responses after acute PcAS infection. 
 
Figure 3.7 PbTII cells develop into memory cells after acute PcAS infection. 104 or 106 PbTII 
cells were adoptively transferred to C57Bl/6J mice (n=3-4) infected with PcAS. (A) Enumerated 
splenic PbTII cells at 37 days p.i.. (B) Representative FACS plots of CD62L and CD44 expression 
by recipient polyclonal CD4+ T cells (gated on CD45.1- CD4+ TCRβ+ live singlets) or PbTII cells 
(gated on CD45.1+ CD4+ TCRβ+ live singlets) and summary graphs showing proportions of central 
memory (CD62L+ CD44+) (TCM) and effector memory (CD62L
-CD44+) (TEM) splenic PbTII cells. 
Numbers in plots are proportion of population within respective quadrants. Data are a single 
experiment. 
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3.3.7 PbTII cells show cross-species reactivity to Plasmodium infection 
Lastly, PbTII cells were assessed for their ability to respond to two other commonly used 
rodent Plasmodium strains- Py17XNL and PbA. During Py17XNL infection, transfer of fewer than 
105 cells did not give rise to a reliable PbTII response. Thus, 105 cells were determined to be the 
optimal dose in this model. Similar to PbTII responses during PcAS infection, PbTII cells expanded 
and bifurcated into IFNγ+ T-bet+ Th1 cells or CXCR5+ Bcl6+ Tfh cells in WT mice by day 11 of 
Py17XNL infection, which was also seen in the endogenous polyclonal response (Figure 3.8A). 
Finally, transfer of 106 PbTII cells was found to be the optimal transfer dose during PbA infection. 
PbTII cells proliferated, and began to differentiate into Th1 cells, but not Tfh cells by day 4 p.i. 
during PbA infection (Figure 3.8B), in accordance with polyclonal CD4+ T cell responses and 
previous reports (Ryg-Cornejo, Ioannidis et al. 2015). These results together demonstrate the 
reactivity of PbTII cells in several murine models of malaria, and furthermore highlight possible 
differences in magnitude of Th responses mounted during infection with these three strains. 
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Figure 3.8 PbTII cell expansion and Th1/Tfh differentiation during P. yoelii 17XNL and P. 
berghei ANKA blood-stage infection. (A) Representative FACS plots of polyclonal CD4+ T cells 
(gated on CD45.1- CD4+ TCRβ+ live singlets) and PbTII cells (105 transferred) (gated on CD45.1+ 
CD4+ TCRβ+ live singlets), showing proportions expressing IFNγ or CXCR5, as well as absolute 
numbers of splenic PbTII cells 11 days p.i. with Py17XNL, compared to uninfected WT mice. (B) 
Representative FACS plots of polyclonal CD4+ T cells (gated on CD45.1- CD4+ TCRβ+ live 
singlets) and PbTII cells (106 transferred) (gated on CD45.1+ CD4+ TCRβ+ live singlets), showing 
proportions expressing IFNγ or CXCR5, as well as absolute numbers of splenic PbTIIs 4 days p.i. 
with PbA. Data pooled from two independent experiments. Statistics: Mann-Whitney U test; 
*p<0.05; **p<0.01; ****p<0.0001. 
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3.4 Discussion 
Antigen-specific CD4+ T helper responses protect against blood-stage Plasmodium infection 
in humans and experimental mice. However, studying the emergence of these responses in vivo is 
difficult due to the low frequency of antigen-specific T cells in the naive repertoire, and that T cell 
priming occurs in the spleen, which is not easily visualised in humans. Murine TCR transgenic T 
cells are therefore a powerful reagent, as they allow for in vivo tracking of T cell priming and 
differentiation. Moreover, their responses to manipulation of the external immune environment can 
be assessed via transfer into genetically altered recipient mice. Unfortunately, few TCR transgenic 
reagents have been available for assessing CD4+ T cell responses during Plasmodium infection. 
Here, the utility of a recently developed Plasmodium-specific TCR transgenic CD4+ T cell line for 
following T helper responses during in vivo blood-stage malaria was investigated.  
Adoptively transferred PbTII cells proliferated extensively, and differentiated into two T 
helper subsets- Th1 and Tfh cells, during PcAS infection. The response of PbTII cells was critically 
dependent on MHCII-expressing CD11c+ cells. This is consistent with previous in vivo and ex vivo 
studies showing important roles for cDCs in priming CD4+ T cells during Plasmodium infection 
(deWalick, Amante et al. 2007, Sponaas, Freitas do Rosario et al. 2009, Haque, Best et al. 2014). 
While IL-17A and IL-17F-producing Th17 cells and IL-4-producing Th2 have been identified 
during experimental blood-stage Plasmodium infection (Langhorne, Gillard et al. 1989, Keswani 
and Bhattacharyya 2014), whether these subsets have a significant role in protective immunity has 
not been demonstrated. Here, no evidence of Th2 of Th17 differentiation was observed from PbTII 
cells or endogenous polyclonal CD4+ T cells at peak infection. Thus, in the spleen during PcAS 
infection at least, these subsets do not appear to contribute to immune responses.  
Although experimental malaria and field studies have reported the involvement of Treg cells 
in immune responses to infection (Hisaeda, Maekawa et al. 2004, Finney, Nwakanma et al. 2009), 
PbTII cells did not express FOXP3 at peak infection. Since a subset of FOXP3+ Tregs develop in 
the thymus from moderate affinity of their TCR for self-antigen, it is not surprising that PbTII cells, 
with forced expression of a Plasmodium reactive TCR, display limited capacity to become 
regulatory cells. Interesting, however, PbTII cells did have the capacity to co-produced the 
regulatory cytokine IL-10 and the proinflammatory cytokine IFNγ+, a phenotype that has been 
termed 'Tr1' and has also previously been observed in human and experimental malaria (Couper, 
Blount et al. 2008, Walther, Jeffries et al. 2009). This population appeared to emerge from the 
IFNγ+ populations at a time point after the emergence of the Th1 response, suggesting that it could 
represent a continuation from the Th1 phenotype. A study by Cardone et al. has proposed that CD46 
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expression mediates the switch from the Th1 phenotype to a Tr1 phenotype in purified human CD4+ 
T cells (Cardone, Le Friec et al. 2010). However the relationship between Th1 and Tr1 cells has not 
been demonstrated within a clonal population or in vivo. Thus, these observations from PbTII cells 
offer the prospect of exploring whether Tr1 cells do emerge from Th1 cells during in vivo infection.  
After the acute infection, PbTII cells displayed both TCM and TEM phenotypes within the 
spleen. Memory T cells contribute to long-term immunity to malaria (Grun and Weidanz 1981, 
Tsuji, Romero et al. 1990, Langhorne 1994), but are also hypothesised to be functionally deleted or 
modulated during Plasmodium infection (Hirunpetcharat and Good 1998, Xu, Wipasa et al. 2002). 
PbTII cells would be useful for examining how these populations of memory T cells develop, and 
also how their development can be boosted in the future to improve long-term protection by 
vaccines or other immune-interventions. In addition to circulating TEM and lymphoid-resident TCM 
populations (Sallusto, Geginat et al. 2004), another tissue resident memory T cells (TRMs) have been 
shown to reside in peripheral tissues. The best described TRMs are CD8
+ and have been shown to 
provide local immune responses in the skin (Mackay, Rahimpour et al. 2013), ganglia (Gebhardt, 
Wakim et al. 2009), intestinal mucosa (Kim, Reed et al. 1997), brain (Wakim, Woodward-Davis et 
al. 2010) and thymus (Hofmann, Oschowitzer et al. 2013). CD4+ TRMs have also been described in 
the skin (Glennie, Yeramilli et al. 2015), genital tract (Iijima and Iwasaki 2014) and lungs (Teijaro, 
Turner et al. 2011). In the liver, CD44hi antigen-specific CD8+ TRMs were identified in mice at 45-
days after immunization with irradiated P. yoelii sporozoites (Tse, Cockburn et al. 2013). These 
memory cells displayed differential gene expression compared with antigen-specific memory CD8+ 
T cells in the spleen, suggesting they represented a distinct population from central memory T cells. 
Whether an equivalent tissue-resident CD4+ T cell population exists within the liver is unknown. 
Here, PbTII cells are also shown to exist within the liver during blood stage-infection. A large 
proportion exhibited a Th1 phenotype, but none differentiated into Tfh cells, in alignment with the 
role of Tfh cells in germinal centre formation within secondary lymphoid organs (Crotty 2011). 
Given the ideal localisation of liver-resident TRMs to contribute to memory responses against liver-
stage infection (Tse, Cockburn et al. 2013), assessing PbTII memory responses in the liver would be 
of high interest, specifically for vaccine development targeting liver-stage of infection.  
A particularly interesting observation from these data was that adoptive transfer of PbTII 
cells did not modulate the kinetics of the infection. A possible explanation is that PbTII cells are not 
involved in the clearance of pRBCs. However, this does not seem likely given the strong Th1 
response of PbTII cells at peak infection and the demonstrated contribution of Th1 responses in 
clearance of pRBCs (Taylor-Robinson and Phillips 1994, Amante and Good 1997, Haque, Best et 
al. 2011, Haque, Best et al. 2014). Another explanation could be that endogenous CD4+ T cells in 
  
68 
WT mice infected with PcAS are already adequate for the number of macrophages to phagocytose 
the pRBCs (Clark, Hunt et al. 1987, Taylor-Robinson and Phillips 1998)and for the number of B 
cells that contribute to resolution of infection (Butler, Moebius et al. 2012). In order to test this 
hypothesis, further experiments could include transfer of PbTII cells into Rag1-/- mice that do not 
have endogenous T or B cell responses. PbTII cells would not be expected to differentiate into Tfh 
cells in the absence of B cells within this system (Kerfoot, Yaari et al. 2011), but it would allow for 
functional assessment of Th1 PbTII cells. Alternatively, PbTII cells could be transferred into CD40 
ligand-deficient mice, in which endogenous T cells lack the ability to receive co-stimulatory signals 
and can therefore not undergo activation (Grewal, Foellmer et al. 1996).  
Here, increasing doses of PbTII cells were tested for their responses compared with an 
approximately physiologically relevant number of 102 PbTII cells (Moon, Chu et al. 2007). 
Compared to 102 transferred cells, 104 resulted in similar PbTII cell responses by peak PcAS 
infection; however transfer of 106 PbTII cells resulted in reduced expansion and proportions of T 
helper populations. This suggests that transfer of 104 cells is a practical method for studying 
physiologically relevant responses during PcAS infection. At transfer doses in the order of 106 cells, 
however, PbTII cells experienced intra-clonal competition, possibly due to processes such as 
competition for contact with APCs or for physical room within the spleen. This phenomenon of 
intra-clonal competition has been observed within multiple TCR transgenic cells (Langhorne, 
Gillard et al. 1989, Langhorne and Simon 1989). It was particularly interesting that the Th1 
response was impaired to a greater extent at higher PbTII transfer doses than the Tfh response, 
suggesting that Tfh cells are more impartial to clonal competition. This observation is consistent 
with the concept that Tfh differentiation is the default pathway for activated CD4+ T cells(Crotty 
2014). A study by Eto et al. provides support for this idea by showing that unlike other 
differentiation of Th subsets, which require the presence of a key cytokine, Tfh differentiation can 
be induced by multiple redundant signals during viral challenge (Eto, Lao et al. 2011). A highly 
reliable Tfh response is biologically conceivable given that subsequent GC development and 
affinity maturation are central processes of the adaptive immune response. 
By using a single T cell clone, these data have provided the evidence that the magnitude of 
Th responses for a given TCR is different between models. The optimal responses were observed 
upon the transfer of 106, 104 and 105 cells respectively for PbA, PcAS and Py17XNL infections. 
However, a direct comparison between the Th responses induced by these different strains cannot 
be definitively performed since the parasite antigen triggering PbTII cells, and whether this antigen 
differs between Plasmodium strains, has not yet been determined. Nevertheless, relative to 
endogenous CD4+ T cell responses, it can be inferred that the greater the endogenous Th response, 
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the fewer PbTII cells required. TCR transgenic cells can exhibit some preference in their 
differentiation toward a particular Th subset (Tubo, Pagan et al. 2013). This was not the case with 
PbTII cells, since they could bifurcate into both Th1 and Tfh cells during in vivo Py17XNL and 
PcAS infections, in a manner that closely resembled the endogenous polyclonal responses. During 
PbA infection, PbTII cells gave rise to Th1 cells before the animals succumbed to disease 7-9 days 
after infection. As with the endogenous polyclonal response, CXCR5-expressing PbTII cells failed 
to develop in this model. The absence of a polyclonal Tfh response during PbA infection has been 
reported recently (Ryg-Cornejo, Ioannidis et al. 2015). Although the antigen to which PbTII cells 
respond is yet to be determined, the cross-reactivity of this line suggests that the target epitope is 
expressed by at least three common rodent infective strains. Whether PbTII cells also respond to 
human infective Plasmodium species such as P. falciparum, or to other life stages of the parasite, 
such as the liver-infective sporozoite stage, will be of future interest. Further studies will be 
required to determine the exact antigen recognized by PbTII cells. 
In conclusion, the utility of a novel TCR transgenic tool for studying Plasmodium-specific 
CD4+ T cell responses during experimental blood-stage malaria has been demonstrated. PbTII cells 
proliferated in a cDC- and MHCII-dependent manner. They developed into Th1 and Tfh cells, Tr1 
cells and later TEM and TCM cells. Therefore, this reagent provides an opportunity for examining 
multiple aspects of CD4+ T cell biology during experimental models of malaria in mice.    
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Chapter Four: 
Single-cell RNA-sequencing resolves a CD4+ T helper cell fate 
bifurcation 
 
4.1 Abstract 
CD4+ T helper cells are critical for immunity to blood-stage Plasmodium infection. During 
experimental malaria in mice T helper 1 (Th1) and T follicular helper (Tfh) subsets emerge, which 
have both been associated with better infection outcomes. In vitro experimentation and 
mathematical modelling have proposed asymmetric cell division and internal stochastic events as 
possible mechanisms controlling T cell differentiation fates. However, molecular mechanisms 
controlling this process in vivo remain unclear. In Chapter 3, TCR transgenic PbTII cells were 
shown to concurrently differentiate, or bifurcate, into Th1 or Tfh effector cells during infection. 
Here, to study this process at molecular resolution, a single-cell RNAseq (scRNAseq) approach was 
adopted. Emerging Th cells entered a state of high cell-cycling after initial priming, in which they 
expressed markers of both Th1 and Tfh subsets. This occurred prior to a commitment to a 
differentiated, and possibly terminal, Th1 or Tfh effector state. Furthermore, expression of 
chemokine receptors prior to bifurcation suggested that CD4+ T cells were receptive to chemokine-
expressing cells at this point. While B cells were shown to sustain PbTII Tfh responses, additional 
scRNAseq analysis of myeloid populations supported roles for cDCs and Ly6Chi inflammatory 
monocytes in interacting with un-committed, activated PbTII cells. Depletion of Ly6Chi monocytes 
after PbTII activation, and prior to bifurcation, demonstrated their support of Th1 but not Tfh 
responses. In summary, Plasmodium-specific CD4+ T cells do not commit to an effector state until 
several days after initial activation, before which they are indistinguishable at the transcriptional 
level. In particular, activated PbTII cells required support from B cells and myeloid populations to 
sustain commitment to Tfh and Th1 effector states respectively.  
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4.2 Introduction 
CD4+ T cells exhibit substantial functional diversity in response to many immune 
challenges, including blood-stage Plasmodium infection. Naive CD4+ T cells are activated upon 
recognition of antigenic peptides presented by MHCII molecules on the surface of APCs. They 
proceed to undergo clonal proliferation and differentiate into a range of T helper (Th) cell subsets, 
classified according to their expression of cytokines, transcription factors and surface molecules. T 
cells typically display skewed effector phenotypes in response to an immune challenge. For 
example, intracellular infections induce differentiation of TNFα- and IFNγ- producing Th1 cells, 
whereas helminth infections and allergy are characterised by the emergence of IL-4-, IL-5- and IL-
13- secreting Th2 cells. As discussed in Chapter 3, two subsets concurrently emerge during 
Plasmodium infection: Th1 cells, which are considered important for macrophage-mediated 
clearance of infected red blood cells (Clark, Hunt et al. 1987, Taylor-Robinson and Phillips 1998), 
and Tfh cells, which assist in the production of high-affinity antibodies (Perez-Mazliah, Ng et al. 
2015). While Th1 and Tfh cells are established to be protective during malaria, the molecular and 
cellular mechanisms underlying their development are not fully understood.  
Recent in vivo data suggested that the unique TCR of a single naïve CD4+ T cell imparts a 
genetically programmed preference towards a particular Th fate (Tubo, Pagan et al. 2013). This 
study performed limiting dilution-mediated single-cell adoptive transfer of naïve transgenic T cells 
into mice, and showed that clonal cells gave rise to a limited range of effector subsets in response to 
Listeria monocytogenes infection. However, extracellular factors such as exposure to cytokine 
signals also profoundly influence the magnitude of the response, and skew differentiation towards 
particular Th fates. For example, extracellular IFNγ can promote a Th1 response, while IL-4 
promotes Th2 development. Additionally, the stochastic balance of several master transcription 
factors known to be expressed in CD4+ T cells, such as Blimp1, T-bet and Bcl6, drive and stabilize 
particularly Th fates (Szabo, Kim et al. 2000, Liu, Yan et al. 2012, Tubo and Jenkins 2014). This 
supports a view of Th development as a choice between clearly distinct states. However, the 
molecular relationship between Th subsets, particularly between Tfh and other Th fates remains 
unclear in vivo.  
Intra-vital microscopy has demonstrated that naïve CD4+ T cells make stable engagements 
with cDCs during initial priming events in secondary lymphoid tissue (Celli, Lemaitre et al. 2007). 
Thereafter, further pMHCII contact is required to sustain expansion of the responding T cell 
population (Obst, van Santen et al. 2005). A recent study by Groom et al. suggested that 
chemokines CXCL9 and CXCL10 facilitated interaction between adoptively-transferred antigen-
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loaded cDCs and activated CXCR3+ CD4+ T cells in lymph nodes, and furthermore, were 
associated with Th1 differentiation (Groom, Richmond et al. 2012). The generation of Tfh cells is 
also a multi-step process. After the initial priming events, internal upregulation of Bcl6 drives the 
expression of Tfh-associated genes, including CXCR5 to promote migration of pre-GC Tfh cells to 
the T-B cell border of the follicle. Here, Tfh cells are critical for supporting GC formation and B 
cells are imperative for sustaining Tfh effector cells, for example via ICOS:ICOSL signalling (Choi, 
Kageyama et al. 2011). Whether interactions with different endogenous myeloid cells modulate the 
decision of a primed T cell towards either Th1 or Tfh fates in vivo is yet to be explored. 
Flow cytometry has been instrumental in studying CD4+ Th cells and their relationship with 
disease. However, even the most advanced machines only allow for the simultaneous assessment of 
15-20 parameters. Furthermore, this methodology depends almost completely on high-quality 
antibodies, a reliance that tends to bias analyses towards better-known molecules. More recently, a 
mass spectrometry-based flow cytometry method, CyTOF, has extended the number of assessable 
parameters to ~50 (Newell and Davis 2014). CyTOF allowed for dissection of the relationship 
between the CD8+ T cell phenotype, function and antigen-specificity by simultaneously assessing 
several markers for each quality (Newell, Sigal et al. 2012). Similarly, this technique was applied to 
murine myeloid cells taken from various tissues (Becher, Schlitzer et al. 2014). In this study, 
machine-learning dimensional reduction of all parameters was used to cluster the cells in a semi-
unbiased way according to their similarity. Nevertheless, CyTOF still requires the generation of 
antibodies against target molecules and is therefore poorly suited for the discovery of novel 
molecules that control Th biology.   
Single-cell genomics is a relatively new technique that possesses extraordinary potential for 
studying cellular processes in many fields including immunology. The origins of single-cell 
genomics stem from gene expression profiling of single cells using microarrays (Tang, Lao et al. 
2011). However, the advent of next-generation sequencing has taken this field even further by 
allowing for sequencing of mRNA from individual cells, a process termed single-cell RNA 
sequencing (scRNAseq) (Tang, Barbacioru et al. 2009, Islam, Kjallquist et al. 2011, Ramskold, Luo 
et al. 2012). In initial studies, technical and economical limitations restricted sequencing to only a 
handful of cells (Lao, Tang et al. 2009, Tang, Barbacioru et al. 2009). However, continual 
improvements in the efficient physical isolation of individual cells, amplification of the genome of 
single cells to acquire sufficient material for downstream analyses, cost-effectiveness of this process 
and development of computational and analytical approaches to make sure the data is fully 
exploited and correctly interpreted, continue to drive more elaborate studies. ScRNAseq has begun 
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to provide novel information into the biology and response of immune cells that would never have 
been possible with population-level methods.  
A key area in which scRNAseq has provided new information is in cellular heterogeneity. 
This was done to explore heterogeneity within CD11c+ mouse myeloid cells (Jaitin, Kenigsberg et 
al. 2014), and within cells engaged in the tumour microenvironment (Kim, Lee et al. 2016). 
Furthermore, scRNAseq allows for the identification of rare and potentially biologically important 
cells, as demonstrated in a paper by Shalek et al., which showed that rare DCs respond to immune 
stimuli early and drive the response of the core DC population via paracrine signalling (Shalek, 
Satija et al. 2014). Another significant advantage of scRNAseq is the assessment of covariance of 
genes. This means that if genes share similar or even inverse patterns of expression, it can be 
reasoned that they are involved in related-biological processes, possibly leading to the identification 
of novel gene interactions. For example, a subset of in vitro-induced Th2 cells were shown to 
activate genes in the steroid synthesis pathway, and inhibit Th differentiation in a Cyp11a1 enzyme-
dependent manner (Mahata, Zhang et al. 2014). Due to the in-depth profile of cells provided by 
scRNAseq, the description of other transcriptional features, such as splice variants (Shalek, Satija et 
al. 2013) and allele-specific expression (Tang, Barbacioru et al. 2011) is also possible. 
Studying immune processes, such as the response kinetics of T cells, has previously proven 
difficult due to the extensive heterogeneity within even a clonal population of cells. Population-
level transcriptomic approaches such as RNAseq on pooled cell samples tend to mask heterogeneity 
amongst responding cells. Instead, flow cytometry-based methods are commonly adopted to take 
discrete 'snapshots' of a response through time. However, given the heterogeneity in the response 
kinetics of individual cells in any snapshot, studying intermediate states is challenging. This issue 
can be solved with single-cell RNAseq combined with computational analysis. In a study by 
Gaublomme et al. scRNAseq data was used to model the transition of IL-17A+ Th17 cells through a 
pre-Th1 effector state during acute EAE (Gaublomme, Yosef et al. 2015). To separate transitional 
states and identify novel transcription factors mediating their development, the authors combined 
dimensional reduction and unbiased clustering by Principal Component Analysis (PCA) with 
annotation with known gene lists describing Th states. The model was then mined for novel genes 
corresponding to different states. However, prior cell-sorting according to expression of the 
canonical Th17 cytokine, IL-17A, limited this analysis to changes within an already differentiated 
Th17-like cell population. This approach has not yet been applied to study the early processed of Th 
differentiation in vivo.  
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Our collaborator, Dr Sarah Teichmann leads the single-cell genomics department at the 
Wellcome Trust Sanger Institute, Hinxton, UK. Her team features computational biologists and 
immunologists, who use single-cell genomic approaches to study aspects of T cell biology. An 
example of the strength of this integrated approach was demonstrated by the development of 
TraCeR, a computational method that determines full-length TCR sequences from sequencing data 
for single T cells, thus allowing for assessment of clonality and paving the way for following the 
development of effector responses from single clones (Stubbington MJT 2015). In another study, Dr 
Teichmann's team integrated in-depth transcriptome profiling, bioinformatic data analysis and 
functional validation via flow-cytometry and live-imaging of single-cells to demonstrate the 
relationship between cell-cycling and differentiation of Th2 cells (Fujii, Kumazaki et al. 1996). 
In this chapter, the single-cell genomics expertise of Dr Sarah Teichmann and Dr Tapio 
Lonnberg, and computational knowledge of Valentine Svennson (Wellcome Trust Sanger Institute, 
UK) were employed to resolve the concurrent emergence of Th1 and Tfh PbTII cells during 
experimental malaria. PbTII cells entered a state of high cell-cycling and metabolic activity prior to 
commitment to differentiation. In this state, they expressed a range of chemokine receptors, 
suggesting that they were impressionable to signals from chemokine-expressing cells. ScRNAseq 
analysis of myeloid cells predicted a role for inflammatory monocytes in "coaching" PbTII cells 
towards a Th1 fate, likely via the CXCR3-signalling axis. This association was confirmed in vivo by 
timed depletion of inflammatory monocytes. 
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4.3 Results 
4.3.1 Unbiased separation of Th1 and Tfh effector cells 
To study the concurrent differentiation of antigen-specific CD4+ T cell during in vivo blood-
stage Plasmodium infection, scRNAseq was performed on PbTII cells during PcAS infection. To 
achieve this, CD4+ T cells were enriched from the spleens of PbTII mice, labelled with the 
proliferation dye CTV (Figure 3.1A) and adoptively transferred into C57BL/6J mice before 
infection with PcAS. A transfer dose of 106 cells per mouse was adopted to enable ease of 
retrieving the cells at early time points of infection. At days 2, 3, 4 and 7 p.i., activated PbTII cells, 
defined by expression of CD69 or dilution of CTV, were sorted by flow cytometry cell sorting 
(FACS) (Figure 4.1A). Single cells were processed using the Fluidigm C1 platform, which allows 
for automated cell lysis, reverse transcription of mRNA and pre-amplification of cDNA, thus 
limiting technical variance. For quality control, External RNA Control Consortium (ERCC) spike-
in RNAs were added at a known concentration to each sample at the time of cell lysis. The cDNA 
for each cell was harvested and further amplified via polymerase chain reaction (PCR), during 
which unique barcodes were added. The cDNA libraries were pooled and cleaned for mRNA of a 
minimum length of 100 base pairs (bp). The pooled cDNA libraries were subjected to 100 bp 
paired-end Illumina Next-Generation sequencing. Unlike single-end sequencing, paired-end 
sequencing allows for both ends of the reference gene to be sequenced, thus improving the quality 
of the reads. Additionally, paired-end sequencing allows for detection of genomic rearrangement 
and repetitive sequence elements, as well as gene fusions and novel transcripts (Fullwood, Wei et 
al. 2009). Transcripts were mapped to the Mus musculus genome and normalised to the ERCC 
spike-in measurements. Finally, cell filtering was performed to attain transcriptional data from only 
high quality cells (Figure 4.2A). 
Firstly, to determine whether this scRNAseq could characterise responding PbTII cells, 
dimensionality reduction was performed using PCA on all reads for cells from day 7 p.i.. PCA uses 
weighted combinations of each of the gene expression measurements to create composite 
parameters that maximally represent the relationship of the cells with a minimal number of new 
parameters. This analysis showed clear separation of two populations of PbTII cells along PC2 (Fig 
4.2B). Using established makers of either effector fate, these two populations were shown to 
correspond to Th1 or Tfh phenotypes (Fig 4.2C) as observed by flow cytometric assessments in 
Chapter 3 (Fig 3.4B).  
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Figure 4.1 Sorting strategy for PbTII cells. (A) PbTII cells (CD45.1+ CD4+ TCRβ+) were 
adoptively transferred into WT congenic (CD45.2+) recipient mice. At indicated days, early 
activated (CD69+) and/or proliferated (CTVlo) PbTII cells were cell-sorted from spleens of PcAS 
infected mice, or naïve PbTII cells (CD69loCTVhi) at the indicated days p.i.. 
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Figure 4.2 Single-cell mRNA-sequencing of activated antigen-specific PbTII CD4+ T cells. (A) 
Experimental setup. PbTII cells were transferred from a single donor to multiple recipients. n is the 
number of recipient mice per time point. Also shown are the numbers of single cells from which 
high-quality mRNAseq data was successfully recorded. (B) PCA of single PbTII cells at 7 days 
post-infection with PcAS. The arrows represent the Pearson correlation with PC1 and PC2. Cell 
size refers to the number of detected genes. The size of the data points also represents cell size. 
“Th1 signature” and “Tfh signature” refer to cumulative expression of genes associated with Th1 
or Tfh phenotypes (Hale, Youngblood et al. 2013). PC, Principal Component. (C) Expression of top 
50 genes with largest PC2 loadings of day 7 cells (D). The genes were annotated as Th1- or Tfh-
associated based on public datasets (Marshall, Chandele et al. 2011, Liu, Yan et al. 2012, Hale, 
Youngblood et al. 2013, Stubbington MJT 2015). PC, Principal Component. (B) and (D) were 
generated by T. Lonnberg. 
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4.3.2 Deducing concurrent Th trajectories during a Mixture of Gaussian Processes model 
To assess overall heterogeneity within PbTII cells, PCA was then performed on the entire 
PbTII cell dataset across all time points (Fig 4.3A). Although timepoint information was not used in 
this analysis, cells clustered largely in accordance with the days at which cells were sorted (Fig 
4.3A). This suggested that the gene expression variation between single PbTII cells could be used to 
recreate the progression from a state of naivety through to terminal differentiation. To model the 
dynamics of the differentiation of these cells, a temporal mixture model that builds on two 
modelling approaches, a Gaussian Process Latent Variable Model (GPLVM) and an Overlapping 
Mixtures of Gaussian Processes (OMGP) model, was developed and applied (Lawrence 2010). 
GPLVM first reconstructed a progression trajectory (termed “psuedotime”) from the observed data, 
thereby establishing an order for the cells (Figure 4.3B). Although this model used the sample time 
as prior information, the inferred temporal ordering does not strictly adhere to these experimental 
time points. For this reason, cells sorted at day 4 p.i. were mixed with some of the cells from day 3 
and day 7 at either end of the day 4 pseudotime distribution (Fig 4.3B). This was consistent with the 
idea that bulk assessments of cells at specific time points fail to take into account the heterogeneity 
and differential kinetics of responses made by individual cells.  
Next, OMGP was used to determine whether multiple independent trends could be occurring 
(Lawrence 2010). Using this approach, two co-emerging trends or trajectories were identified 
(Figure 4.3C). Cells following these alternate trajectories transcribed previously described Th1/Tfh 
signature genes (Hale, Youngblood et al. 2013), indicating they corresponded to the emergence of 
Th1 and Tfh cells (Fig 4.2C). To determine the time point at which these Th1 and Tfh trajectories 
separated or 'bifurcated', they were followed backwards from the ends of the Th1 and Tfh trends, 
where trend assignment was clear, to a point where trend assignments became completely 
ambiguous. The point at which bifurcation initiated was amongst late day 4 p.i. cells relative to 
pseudotime (Fig 4.3C). In a separate repeat experiment performed by Dr Tapio Lonnberg, 
scRNAseq was performed on PbTII cells at day 0, 4 and 7 during PcAS infection. Consistent with 
the original dataset, PbTII cells at day 7, but not day 4 p.i. were easily clustered into two 
populations that corresponded with Th1 and Tfh gene signatures (data not shown). Furthermore, 
bifurcating genes in the original dataset were also expressed by day 7 p.i. cells and were able to 
independently separate Th1 and Tfh populations (data not shown). Together, this data demonstrates 
that the process of pseudotime inference coupled with time series mixture modelling is effective at 
modelling the co-development of two Th effector populations during infection and could likely be 
applicable more generally for studying cellular processes in scRNAseq data.  
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Figure 4.3 Computational delineation of Th1 and Tfh differentiation trajectories. (A) Principal 
component analysis of normalised mRNA expression data of single PbTII cells. (B) Unbiased 
ordering of single PbTII cells using a Bayesian Gaussian Process Latent Variable Model and 
assuming a 1-dimentional latent space (“pseudotime”). The blue line depicts the progress of 
pseudotime. The text labels illustrate features of typical cells on that region of the pseudotime, and 
are proved purely as a visual aid. (C) Inference of two simultaneous trends through pseudotime 
using Overlapping Mixtures of Gaussian Processes (OMGP). The red and blue lines depict the 
distinct trends, corresponding with characteristics of Th1 and Tfh differentiation, respectively. The 
black dots correspond to the first instance when the two trajectories can be separated with 
confidence. The colours of data points represent their relationship with the Th trends. (B) and (C) 
were generated by V. Svensson and T. Lonnberg. 
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 Next, PbTII cells at the point of bifurcation were characterised. Bifurcating PbTII cells 
expressed the highest number of genes, indicative of high transcriptional activity, compared to those 
at all other points in pseudotime (Fig 4.4A). These cells also expressed high levels of the cell-
cycling gene Mki67 (encoding Ki-67) (Fig 4.4B). High expression of Ki-67 before the emergence of 
Th effector markers was confirmed on protein level by flow cytometry (Fig 4.4C). Cell cycle 
activity was further supported by computational allocation of cells into cell cycle stages (Scialdone, 
Natarajan et al. 2015), and flow cytometric confirmation of DNA content and cell size (Figure 
4.4D-E). Bifurcating PbTII cells also had increased expression of genes associated with aerobic 
glycolysis (data not shown), an indication of increased metabolic requirements being met by 
glucose metabolism and increased mTORC1 activity. Consistent with this was the observed 
elevated levels of ribosomal protein S6 phosphorylation (p-S6) at day 4 p.i. (Figure 4.4F). These 
data suggested that PbTII cells entered an uncommitted state of high metabolic activity and cell-
cycling prior to a commitment to either Th1 or Tfh differentiation.  
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Figure 4.4 Bifurcation of T cell fates is accompanied by changes in transcription, proliferation 
and metabolism. (A) The relationship of Th1-Tfh bifurcation point and the number of detected 
genes per cell. (B) The expression level of the proliferative marker Ki-67 (encoded by the Mki67 
gene) across pseudotime. (C) Representative FACS plots showing kinetics of CellTrace™ Violet 
(CTV) dilution and Ki-67, IFNγ or CXCR5 expression, with summary graphs showing % of PbTII 
cells expressing these markers (after 106 PbTII cells transferred) in uninfected (Day 0) and PcAS-
infected mice at indicated days post-infection (n=4 mice/time point, with individual mouse data 
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shown in summary graphs; solid line in summary graphs indicates results from third order 
polynominal regression analysis). Data are representative of two independent experiments. (D) 
Experimental and computational analysis of cell cycle speed of PbTII CD4+ T cells activated in 
response to PcAS. The allocation of cells to cell cycle phases was performed by flow cytometry 
using Hoechst staining and computationally using the Cyclone algorithm (Luscher 2012). The 
relative cell-cycle speed was determined by measuring the fraction of cells in S, G2, or M phases. 
(E) Cell size estimation using FSC (Forward Scatter) measurements of PbTII cells. (F) Cellular 
metabolic activity of PbTII cells in naive mice (n=3) and at days 4 and 7 p.i. (n=6) as determined 
by flow cytometric assessment of ribosomal protein S6 phosphorylation (p-S6). Flow cytometric 
data are representative of two independent experiments. Statistics are one-way ANOVA and Tukey's 
multiple comparisons tests ***p<0.001. NS, not significant. (A), (B) and (D) were generated by T. 
Lonnberg. 
 
4.3.3 Mechanisms underlying the differentiation of Th1 and Tfh cells 
 Molecular mechanisms possibly controlling Th1/Tfh fate decision were next explored. To 
this end, the concordance of each gene with bifurcation was calculated as a 'bifurcation statistic'. 
The relationship of genes with the direction of bifurcation was determined from the correlation 
between their expression and trend assignment (Figure 4.5A). The overall pattern in gene 
correlation was an up-regulation of gene expression during progression towards a Th1 fate (Figure 
4.5A-B). Among the top genes contributing to the Th1 trend were established genes including Ifng 
and Il18ra. In accordance with a recently published report by Shaw et al., Id2 was also among the 
top genes associating Th1 commitment (Shaw, Belanger et al. 2016). However, novel genes were 
also present including Gna15 and Mxd1, representing genes of interest for Th1 fate commitment. 
Likewise, Tfh associated genes included established Tfh genes Cxcr5, Bcl6, IL21 and Tcf1 (encodes 
TCF7) as previously reported (Choi, Gullicksrud et al. 2015, Xu, Cao et al. 2015). Novel genes 
were also associated with the Tfh fate (Figure 4.5A-B). Assessment of transcription factor Id2 
revealed that it continued to increase in expression until differentiation, suggesting that it could be 
involved in stabilising fate commitment (Figure 4.5C). Interestingly, Tcf1 expression was high in 
the naive state as expected, and was retained only in cells heading towards Tfh commitment. Using 
flow-cytometry, the association between TCF7 protein expression and Tfh (CXCR5+) and naive 
states, but not the Th1 state, was confirmed (Figure 4.5D).  
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Figure 4.5 Unique gene expression signatures corresponding with Th1 and Tfh differentiation. 
(A)Identification of genes associated with the differentiation of Th1 or Tfh cells. For every gene, the 
correlation of its expression with pseudotime (x-axis) and Tfh trend assignment (y-axis) are shown. 
Statistical significance was determined using the bifurcating score. Genes satisfying the 
significance threshold of FDR<0.002 are represented in colours according to the functional 
classification of the genes. FDR, False Discovery Rate, estimated by performing the same analysis 
with permuted data. (B) The genes with strongest association with Th1 (left) or Tfh (right) 
differentiation. The genes were filtered using the bifurcation score as in (B). The genes were then 
ranked in descending order of association with either Th1 or Tfh trend. (C) The expression of Id2 
(upper panel) and Tcf7 (lower panel) across pseudotime. The curves represent the Th1 (red) and 
Tfh (blue) trends when weighing the information from data points according to trend assignment. 
The colour of the data points represents the strength of the relationship with the Th1 trend. (D) 
Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets) showing TCF-1 (gene 
product of Tcf7) expression in CXCR5+ (blue gate) and IFNγ+ (red gate) PbTIIs at 7 days post-
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infection (n=4) (isotype control shown in black in FACS histogram), compared to naïve PbTIIs 
(grey gate) (n=1). Summary graph shows mean & standard deviations for geometric mean 
fluorescence intensity of TCF-1 expression in gated PbTII populations.  Statistics: Mann-Whitney U 
test, *p<0.05. (A), (B) and (D) were generated by T. Lonnberg. 
 
 
4.3.4 IFNγ and IL-10co-producing PbTII cells emerge from Th1 cells 
 Expression of the regulatory cytokine, Il-10, emerged after bifurcation and exhibited similar 
kinetics and Th1 fate association as Ifnγ (Figure 4.6). Assessment of Ifnγ andIl-10 expression by 
PbTII cells at day 7 p.i. revealed a population of co-producing cells, commonly referred to as Tr1 
cells, emerging from Ifnγ+ cells (Figure 4.6).  
 
 
Figure 4.6 IL-10/IFNγ co-producing PbTIIs begin to emerge from Th1 cells late in pseudotime. 
The expression of IFNγ (upper panel) and Il-10 (lower panel) across pseudotime. The curves 
represent the Th1 (red) and Tfh (blue) trends when weighing the information from individual PbTII 
cells according to trend assignment. Dot plot of Ifnγ and Il-10gene expression PbTIIs from day 7 
p.i., with green box showing Il-10 producers as co-expressors of Ifnγ.Figure generated by T. 
Lonnberg. 
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4.3.5 PbTII cells are receptive to chemokine signals at bifurcation 
 Included in the top genes corresponding to either Th1 or Tfh trajectories were a number of 
chemokine receptors. Among the highest ranked genes for the Th1 fate were Cxcr6, Ccr2, Ccr5, 
Ccr4 and Cxcr3 (Figure 4.5A). In contrast, the only bifurcating chemokine receptor associated with 
Tfh fate development was Cxcr5 (Figure 4.5A). When investigating the kinetics of chemokine 
expression, two waves could be identified (Figure 4.7A). Cxcr6, Ccr2, and Ccr5 were among a late 
wave, whose expression began after bifurcation and continued to increase with differentiation 
(Figure 4.7A). The kinetics of CXCR6 expression and association with the Th1 phenotype was 
confirmed on the protein level (Figure 4.7B-C). In contrast, Cxcr5, Cxcr3 and Ccr4 were among an 
early wave, whose transcription and translation into protein peaked around the time of bifurcation 
(Fig 4.7A and 4.7D). The difference in the timing of peak expression of these chemokine receptors 
was reasoned to be due to differences in their function. For instance, while the late stage bifurcating 
genes Cxcr6, Ccr2 and Ccr5 might be important for trafficking and effector function of CD4+ T 
cells, earlier expression of Cxcr5, Cxcr3 and Ccr4 might be involved in cell-to-cell interactions that 
promote differentiation of activated PbTII cells prior to bifurcation (Figure 4.8). 
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Figure 4.7 Chemokine signals underlying Th fate commitment. (A) The expression kinetics of the 
chemokine receptor genes Cxcr5, Cxcr3, Ccr4, Ccr2, Ccr5, and Cxcr6 across pseudotime. The 
curves represent the expression patterns associated with the Th1 (red) and the Tfh (blue) trends. (B) 
Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets) showing kinetics of 
CellTraceTM Violet (CTV) dilution and CXCR6 expression, with summary graphs showing 
proportion of PbTII cells expressing CXCR6 (after 106 PbTII cells transferred) in un-infected (Day 
0) and PcAS-infected mice at indicated days p.i. (n=4 mice/time point, with individual mouse data 
shown in summary graphs; solid line in summary graphs indicates results from third order 
polynominal regression analysis). (C) Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ 
live singlets) showing CXCR6 expression in T-bethi (red gate) or Bcl6hi (blue gate) PbTII cells, 
compared to naïve PbTIIs (grey) at 7 days p.i.. Summary graph shows mean & standard deviations 
for geometric mean fluorescence intensity of CXCR6 expression in gated PbTII populations (n=4 
mice). Data are representative of two independent experiments. Statistics: Mann-Whitney U test 
*p<0.05. (A) was generated by T. Lonnberg. 
 
 
Figure 4.8 Bifurcation of PbTII cells into Th1 and Tfh effector cells. A model summarizing the 
expression patterns of Id2, Tcf7, and chemokine receptors during Th1-Tfh cell fate determination. 
The size of the cell represents proliferative capacity and the colour of receptors and transcription 
factors represent differences in expression level. 
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4.3.6 B cells support Tfh responses 
Since CXCR5 drives migration and retention of Tfh cells in B cell areas (Breitfeld, Ohl et al. 
2000, Kim, Rott et al. 2001, Chtanova, Tangye et al. 2004), the role of B cells in supporting Tfh fate 
commitment in PbTII cells was explored. To this end, an anti-CD20 depleting antibody was used to 
deplete B cells from mice prior to infection with PcAS. Tfh responses were significantly reduced in 
B cell-depleted mice compared to control-treated mice (Figure 4.9). In contrast, Th1 cell 
proportions were comparatively improved in B cell depleted mice (Figure 4.9). These data revealed 
that B cells were crucial for Tfh differentiation, but not Th1 differentiation of PbTII cells.  
 
 
Figure 4.9 B cells are essential for Tfh responses in PbTII cells during PcAS 
infection.Representative FACS plots (gated on CD4+ TCRβ+ CD45.1+ live singlets) and summary 
graphs of splenic PbTII cells, showing absolute and relative numbers exhibiting Tfh (Bcl6+ 
CXCR5+) and Th1 (T-bet+ IFNγ+) phenotypes in WT mice (receiving 104 PbTII cells) treated with 
anti-CD20 monoclonal antibodies to deplete B-cells, or control IgG, and infected for 7 days with 
PcAS. Naïve mice received 106 PbTII cells. Individual mice data are (n=5) shown in summary 
graphs. Results are representative of two independent experiments. Mann-Whitney U test *p<0.05; 
**p<0.01.  
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4.3.7 ScRNAseq assessment of myeloid cells during PcAS infection 
Given that B cells were essential for Tfh commitment, it was hypothesised that myeloid cell 
might provide alternative, competing support for Th1 commitment. Therefore, scRNAseq was 
performed on splenic CD8α+ CD11b- cDCs, CD8α- CD11b+ cDCs, and Ly6Chi inflammatory 
monocytes prior to the bifurcation of PbTII cells and from the same PcAS infected mice (Fig 4.1A 
and Fig 4.10). This approach was particularly appropriate given the possibility that subsets of the 
myeloid cell-types were providing unique signals to uncommitted PbTII cells. 
Firstly, PCA of all cDCs separated naïve CD8α+ cells from their CD8α- counterparts along 
PC2 (Fig 4.11). Differential gene expression analysis of these two naïve subsets, using the 
algorithm Monocle (Trapnell, Cacchiarelli et al. 2014), showed generally higher expression of 
genes within the CD8α- subset (Fig 4.12A-C). Among these were genes known to associate with 
either subset, including Cd8α, Irf8, Clec4a4 and Sirpα. However, new associations were identified 
including co-stimulatory molecule Cd80 with CD8α- cells and Cxcl9 with CD8α+ cells, suggesting 
differences in the steady-state condition of these two subsets. While naïve CD8α+ and CD8α- cDCs 
were easily discernible on the transcriptional level, no obvious clusters were evident amongst day 3 
p.i. cDCs (Fig 4.11) suggesting a convergence of these cells during infection. Nevertheless, using 
only differentially expressed genes between naïve CD8α+ and CD8α- cDCs, day 3 p.i. cDCs were 
clustered into two approximately equal clusters, as per the mixing ratio of CD8α+ to CD8α- prior to 
processing and sequencing (Fig 4.12D). These results demonstrate the un-biased separation of naïve 
cDCs by single-cell transcriptomics, and a general convergence at a transcriptomic level upon 
activation, as previously reported (Jaitin, Kenigsberg et al. 2014). 
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Figure 4.10 Sorting strategy for myeloid cells.Representative FACS plots showing sorting strategy 
for CD8α+ and CD11b+ cDCs, and Ly6Chi inflammatory monocytes from the spleens of naive and 3-
day PcAS-infected mice. 
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Figure 4.11 Principal Component Analysis of cDCs from naïve and infected mice. Principal 
Component Analysis (PCA) of mRNA reads (filtered by minimum expression of 100 TPM in at least 
2 cells) from 131 single splenic naïve CD8α+ and CD8α- and mixed day 3 PcAS-infected cDCs. 
PC1-PC6 shown. Axis labels show proportional contribution of respective PC. 
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Figure 4.12 Differential gene expression between single splenic CD8α+ and CD8α- cDCs. (A) 
Results of differential gene expression analysis between naïve splenic CD8α+ and CD8α- cDCs, for 
all genes expressed in greater than 2 cells. (B) Complete list of differentially-expressed genes 
between naïve CD8α+ and CD8α- cDCs, which were expressed in >10 cells of either subset with a 
qval <0.2 as determined in (A). (C) Heatmap of naïve cDCs ordered by PC2 (Figure 4.10) and 
expression of genes from (B) ordered by PC2 loading in (Figure 4.10). (D) Heatmap examining 
hierarchical clustering of mixed CD8α+ CD11b- and CD8α- CD11b+ day 3-infected cDCs (cell-
sorted and mixed at a ratio of 50:50 prior to scRNAseq) using differentially expressed genes from 
(B) ordered by PC2 loading shown in (Figure 4.10). 
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PCA conducted on all genes in cDCs also separated naïve cells from day 3 p.i. cells along 
PC6 (Figure 4.11 and 4.13A). To explore genes contributing to changes in these cDC states, 
differential expression analysis was performed on naïve versus day 3 p.i. cDCs. This identified 30 
differentially expressed genes, 29 of which were upregulated during infection (Figure 4.13B and 
4.14). Among these upregulated genes were interferon-related transcription factors Irf1 and Stat1, 
and CXCR3 ligands Cxcl9 and Cxcl10. Notably, expression patterns varied for individual genes. 
For example Stat1 and Irf1 were both expressed in naïve cells, but further upregulated during 
infection (Figure 4.13C and 4.15). Cxcl9 was expressed in naïve CD8α+ cells and also upregulated 
during infection. On the other hand, Cxcl10 was not expressed in naïve cells, but was expressed 
upon infection (Fig 4.13C and 4.15). These results showed that cDCs experienced up-regulation of 
several genes during infection but little down-regulation, and furthermore, suggested that cDCs 
were capable of interacting with CXCR3+ T cells via expression of Cxcl9/10 as previously reported 
(Groom, Richmond et al. 2012).  
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Figure 4.13 cDCs influence Th bifurcation in uncommitted PbTII cells. (A) Principal Component 
Analyses of mRNA reads (filtered by minimum expression of 100 TPM in at least 2 cells) of 131 
single splenic CD8α+ and CD11b+ CD8α- cDCs from a naïve mouse, and mixed cDCs from a day 
3-infected mouse, showing PC combinations best separating populations cells. (B) Volcano plots 
showing fold-change and confidence for differentially expressed genes between naïve and infected 
cDCs- genes filtered on expression in >10 cells; genes satisfying qval<0.05 are represented in 
colours according to functional classification displayed (Full list is included as Figure 4.13). (C) 
Expression heatmaps for significantly (qval<0.05) differentially expressed genes in (B): cells and 
genes are ordered according to PC6 score and loading respectively as in (A). 
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Figure 4.14 Differentially-expressed genes between single naïve and day 3 PcAS-infected cDCs. 
List of differentially-expressed genes, expressed in >10 cells (qval<0.05) between naïve and day 3-
infected cDCs. Mean TPM fold-change in gene expression is relative to naïve levels. 
 
 
 
Gene name Log2(Fold Change) qval 
Pianp -7.262625898 1.14E-37 
Tgtp1 4.359998594 4.84E-11 
Tgtp2 2.78069932 1.68E-10 
Ifi47 3.557446068 4.23E-10 
Kdm6b 4.254218426 1.22E-09 
Actb 1.621695106 1.01E-07 
Igtp 4.003078626 1.43E-07 
AC124762.1 3.062289012 3.69E-07 
Gm15427 -0.977819831 1.51E-06 
Stat1 2.491431703 1.92E-06 
U6 -3.307885729 8.27E-06 
Snora31 0.926874728 9.92E-06 
Nlrc5 2.091145817 1.43E-05 
Gm12250 5.431395825 1.61E-05 
Zbp1 4.871392677 5.59E-05 
Gbp4 3.405248926 0.000181786 
R3hdm4 2.1863913 0.000251891 
Slc39a1 3.199473697 0.000708528 
Gm10800 0.641967923 0.00083472 
Cxcl10 3.425848442 0.001808979 
Alkbh5 3.19927987 0.001977138 
Cxcl9 2.422667011 0.002384972 
Dtx3l 1.744309287 0.004686724 
Wtap 2.846340387 0.004866485 
AC131780.3 1.105647313 0.005073109 
Gbp3 1.396086788 0.005888858 
Wac 2.867605317 0.008312287 
Pml 2.963358709 0.013544203 
Arf4 1.885252908 0.015554393 
Irf1 1.437877607 0.022724835 
Gbp2 2.124613484 0.045504232 
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Figure 4.15 Expression of immune-related molecules by myeloid cells. Heatmaps showing 
normalised mRNA expression of select (A) chemokines, (B) costimulatory molecules and (C) 
cytokines and respective receptors (rows) by single splenic cDCs and Ly6Chi monocytes (columns) 
from naïve or 3-day PcAS-infected mice.  
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4.3.8 Ly6Chi monocytes support Th1 fate, but not Tfh fate, commitment 
Ly6Chi inflammatory monocytes have been shown to migrate from the bone marrow to the 
spleen during blood-stage Plasmodium infection, and furthermore, up-regulate MHCII expression 
(Sponaas, Freitas do Rosario et al. 2009). Therefore, it was hypothesised that they also played a role 
in mediating Th cell responses. Firstly, PCA of all monocyte scRNAseq data allowed for unbiased 
separation of naïve and day 3 p.i. cells along PC2 (Figure 4.16 and 4.17A). Differential gene 
expression analysis of naïve versus day 3 p.i. cells identified approximately 100 genes, which 
unlike cDCs, were both up- and down-regulated during infection (Figure 4.17B and 4.18). This 
highlights a significant difference in the directionality of gene expression during infection between 
cDCs and monocytes. Among the top upregulated genes were chemokines including Cxcl2, Ccl2 
and Ccl3. Of particular interest, ~40% of up-regulated genes by monocytes were in common with 
those up-regulated in cDCs (Figures 4.13C and 4.17C), including Stat1, Irf1 and Cxcl10. This 
suggested possible similarities in the functions of monocytes and cDCs during infection. 
Furthermore, monocytes up-regulated an array of immune-interaction related genes including Tnf, 
Cd40, Pdl1, Ccl4, Ccl5, Cxcl16, Cxcl9, and Cxcl11, providing evidence of complex interactions and 
multiple roles for these cells during infection (Figure 4.15). Assessment of the kinetics of one of 
these chemokines, Cxcl9, a ligand for CXCR3 that was highly expressed by non-bifurcated PbTII 
cells (Figure 4.6), showed similar expression in both cDCs and Ly6Chi monocytes (Figure 4.19). 
Expression of CXCL9 in both myeloid populations was evident by day 4 p.i., which corresponded 
to the start of PbTII bifurcation (Figure 4.3C and 4.19). Thus, these results indicated that, like 
cDCs, Ly6Chi monocytes possessed the ability to signal to CXCR3+ uncommitted PbTII cells. 
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Figure 4.16 Principal Component Analysis of Ly6Chi monocytes from naïve and infected mice. 
Results of Principal Component Analysis, using scRNAseq mRNA reads (filtered by minimum 
expression of 100 TPM in at least 2 cells), from 154 single splenic Ly6Chi monocytes from naïve 
and infected mice. PC1-PC6 shown. Axis labels show proportional contribution of respective PC. 
Arrows demonstrate the correlation between number of expressed genes and PCs. 
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Figure 4.17 Ly6Chi monocytes display similar functional capacity as cDCs. (A) Principal 
Component Analysis of mRNA reads, filtered by minimum expression of 100 TPM in at least 2 cells, 
of 154 single Ly6Chi monocytes from naïve and infected mice, showing PC combinations best 
separating populations of Ly6Chi monocytes from naïve and infected mice. (B) Volcano plots 
showing fold-change and confidence for differentially expressed genes between Ly6Chi monocytes in 
infected versus naïve mice - genes filtered on expression in >10 cells; genes satisfying qval<0.05 
are represented in colours according to functional classification displayed. (C) Expression 
heatmaps for significantly (qval<0.05) differentially expressed genes in Ly6Chi monocytes, between 
naive and infected mice: cells and genes are ordered according to PC2 as in (A). 
  
102 
Gene names Log2 (Fold Change) qval 
Gbp2 5.343418344 2.14E-33 
Egr1 5.025006039 1.11E-25 
Ifi47 3.25317286 6.85E-20 
Cxcl10 9.85360446 8.78E-20 
Irf1 3.970316816 3.93E-17 
Tgtp1 12.50667977 9.12E-17 
Tgtp2 3.857804903 7.32E-15 
Stat1 2.746907486 2.36E-10 
Gbp4 5.769038177 1.34E-09 
Igtp 2.698204505 1.46E-09 
Fam26f 4.706888987 1.56E-08 
Ifi205 2.558201091 6.71E-08 
Gbp7 2.716164761 9.43E-07 
U2 3.961441106 9.47E-07 
U2 3.961231475 9.48E-07 
U2 3.961976492 9.48E-07 
U2 3.961489939 9.48E-07 
Gbp6 7.596693594 1.30E-06 
Irgm1 2.554582038 2.23E-06 
Gbp3 3.654656366 3.14E-06 
Serpina3g 10.47471346 4.62E-06 
Nfkbiz 3.217801159 7.52E-06 
Gm17334 3.707732087 8.59E-06 
Gbp5 5.768713305 9.75E-06 
D4Wsu53e -1.288040437 1.86E-05 
Ceacam1 -1.486635161 1.94E-05 
Gpcpd1 -3.576733856 1.98E-05 
Hpgd -2.92213678 2.11E-05 
Pim1 2.213701378 2.51E-05 
Cd244 -2.007720552 3.26E-05 
Cd40 1.698069689 7.05E-05 
Cd274 5.404622826 8.55E-05 
Cd300lb -1.80189338 0.000103172 
Kdm6b 2.709769407 0.000130236 
CT572998.1 4.259284122 0.000138539 
Nfkbia 2.509585516 0.000147245 
Cxcl2 5.033164709 0.000187925 
Ccl3 5.803174704 0.00021635 
Pira2 -2.108050548 0.000224494 
Susd3 -1.732317859 0.000287997 
Nfic -4.21991054 0.000325979 
Ogt -1.844048384 0.000337242 
Mll3 -2.637985297 0.000371892 
Mast3 -9.017849562 0.000378042 
Ptpre -1.633894765 0.000403653 
Ccrl2 4.814048545 0.000416755 
Lilra6 -2.054712791 0.000437711 
Atp2b1 -1.48633724 0.000471865 
Ptplad2 -1.122982025 0.00083638 
Dnm1l -2.684877387 0.000891606 
Stk4 -1.035914887 0.001069216 
Hmgb2 -0.207565085 0.001163912 
Mar-01 -1.991700596 0.001322837 
Ifit2 3.957433264 0.00143919 
Klf4 -2.630782711 0.001586378 
Calm2 -0.875337793 0.001609773 
Itfg3 -1.448044803 0.002167052 
Dnase1l3 3.164154469 0.002213986 
Nrp2 3.684929824 0.002518771 
Zbp1 1.922148464 0.003888078 
Gbp9 1.57174886 0.003914237 
Tsc22d3 -1.148850425 0.00396859 
Rell1 -2.692054659 0.004025406 
Srsf2 -1.228632903 0.004077318 
Jun 2.221736196 0.005316553 
Hnrnph1 -2.226101504 0.005488455 
Itgb2 -1.023709661 0.005808116 
Ifit3 2.666797336 0.005902332 
Eif4a2 -1.392997137 0.006046446 
Rps6ka1 -1.7229663 0.006594323 
Rtp4 2.192950173 0.006616606 
Sfr1 -0.700341246 0.006695782 
Fam107b -1.630418866 0.007788727 
Tmem164 -1.105130173 0.007980954 
Mnda 1.139858542 0.009659075 
Glg1 -0.769603966 0.010631512 
Irgm2 3.514642515 0.011006151 
Emilin2 -1.779653439 0.011571272 
Tlk1 -2.156357298 0.011857332 
Tmem126b -6.422066301 0.014667174 
Lrp1 -1.509844249 0.01681349 
Zzef1 -4.023332903 0.017752319 
Pik3cg -1.615162871 0.01892715 
Camk1d -0.381536785 0.019708425 
Cd84 -1.748595178 0.019823417 
Vps13c -1.655458694 0.020838227 
Cd300ld -4.309443608 0.021491441 
Atf3 2.585532022 0.021661981 
Emr4 -1.483345739 0.022678297 
Cx3cr1 -2.061113213 0.02338043 
Nedd8 -0.453894943 0.024468547 
Tubb6 -1.63027126 0.025148487 
Ndrg1 -1.902455843 0.028273704 
Mknk2 -1.739508433 0.0286694 
Pqlc3 -1.400220797 0.029203455 
Nfam1 -1.189024309 0.030856908 
Fam89b -1.853036401 0.031955789 
U2 8.954028155 0.032731379 
U2 8.953370271 0.032731379 
Foxj2 -4.788634353 0.033617561 
H2-Q10 2.322965089 0.036776651 
Ccl2 5.211788278 0.038421772 
Idh1 -1.68740312 0.040729371 
Gm12250 2.676296613 0.043565984 
Fam46a -0.638461732 0.043914316 
Ankrd44 -0.778489063 0.045666952 
Pdcd4 -0.894788719 0.047438862 
	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Differentially-expressed genes between single Ly6Chi monocytes from naïve and day 
3 PcAS-infected mice. List of differentially-expressed genes, expressed in >10 cells (qval<0.05) 
between Ly6Chi monocytes from naïve and day 3-infected mice. Mean TPM fold-change in gene 
expression relative to naïve levels. 
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Figure 4.19 Kinetics of CXCL9 expression by myeloid cell populations. Representative FACS 
histograms and proportions of splenic CD8α+ cDCs, CD8α- cDCs and Ly6Chi monocytes expressing 
CXCL9 in naive and infected mice between 2-7 days p.i. with PcAS- individual mouse data plotted 
with line at mean; data representative of two independent experiments (n=4 mice/time 
point/experiment). 
 
 To test the requirement for cDCs and Ly6Chi monocytes in supporting Th1 differentiation, 
CD11c-DOG and LysMCre x iDTR systems were employed. In these respective systems CD11c-
expressing cDCs and Ly6Chi monocytes were depleted upon administration of DT at day 3 p.i., a 
time when adoptively-transferred PbTII cells had been primed, but were yet to differentiate (Figure 
4.3C and 4.20A). Of note, other CD11c-expressing cells including B cells are also depleted from 
DT-treated CD11c-DOG mice (Hochweller, Striegler et al. 2008). In addition to robust monocyte 
depletion from the LysMCre x iDTR mice, in an experiment performed by Ismail Sebina, ~30% of 
CD68+ macrophages, but not marginal zone macrophages, were also depleted in these mice (data 
not shown). No effect was observed for cDCs, T cells or B cells in DT-treated LysMCre x iDTR mice 
during infection (data not shown). 
At day 7 p.i., PbTII cells recovered from DT-treated LysMCre x iDTR mice had significantly 
lower proportions and a trend towards reduced absolute numbers of Th1 PbTII cells compared to 
saline-treated controls (Figure 4.20). Tfh proportions were comparably improved (Figure 4.20). 
Similarly, depletion of cDCs resulted in a slight, but not significant decrease in Th1 proportions and 
total numbers, and an increased proportion of Tfh PbTII cells (Figure 4.20). Together, these data 
supported a model in which progression of activated, uncommitted PbTII cells towards a Tfh fate 
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was dependent upon B cells, and a Th1 fate was enforced by DCs and more substantially by 
chemokine-expressing Ly6Chi inflammatory monocytes (Figure 4.21). 
 
Figure 4.20 Ly6Chi monocytes support Th1 responses. (A) Scheme depicting experimental design: 
PbTII cells were transferred into WT, CD11c-DOGmice, LysMCre x iDTR mice 1 day prior to 
infection. At 3 days p.i., mice were treated with diphtheria toxin (DT) or control saline, with PbTII 
Th responses assessed at 7 days p.i.. (B) Representative FACS plots (gated on splenic PbTII 
cells)showing proportions, and (C) absolute numbers of Th1 (T-bethi IFNγ+) and Tfh (CXCR5+) 
PbTII cells in DT or saline-treated LysMCre x iDTR mice and DT treated WT and CD11c-DOG 
mice. LyMCre-iDTR data are representative of three independent experiments, and CD11c-DOG 
data represents a single experiment. Numbers depict proportions within respective gates. Statistics: 
Mann-Whitney U Test. ****p<0.0001. NS, not significant. 
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Figure 4.21 PbTII differentiation is influenced by chemokine-producing cells. Summary model 
proposing chemokine interactions between non-bifurcated PbTII cells and myeloid cells support a 
Th1 fate, while the Tfh fate is sustained by B cells. 
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4.4 Discussion 
Th cells control immune responses during infection, cancer and auto-immunity. Therefore, 
understanding the process of Th differentiation is of paramount importance. Previous techniques 
have struggled to study this process at a genomic level in vivo due to the extent of heterogeneity 
within the responding T cell pool. Here, scRNAseq was applied to PbTII cells during in vivo blood-
stage PcAS infection. Using a newly developed computational approach, the process of 
differentiation was modelled from this data, revealing two alternate trajectories corresponding to 
Th1 and Tfh differentiation. 
 Significant findings of this study are novel genes corresponding to either Th differentiation 
trajectory. Top hits included previously established genes such as Ifng, Id2, Tcf1 and Cxcr5, 
supporting the biological accuracy of this model. In addition, novel genes, such as Mxd1 and Asap1, 
associating with Th1 and Tfh differentiation were identified and could represent possible targets for 
tailoring Th differentiation. A possible direction for future work is the exploration of the roles 
played by these genes in Th differentiation by PbTII cells.  
Several studies have followed the cell fate decision to determine contributing factors. 
Limiting dilution studies conducted in the laboratory of Marc Jenkins showed that single transferred 
T cells gave rise to both Th1 and Tfh effector cells, as seen from PbTII cells. In addition, their study 
showed that clonal cells tended to generate a similar pattern of effector cells, consistent with the 
idea the unique TCRs predispose T cells toward a particular fate (Tubo, Pagan et al. 2013). 
Marchingo et al. employed in vitro culture of CD8+ T cells with different combinations of stimuli 
and in vivo validation to further explore the role of the TCR in cell fate (Marchingo, Kan et al. 
2014). They showed that early TCR signalling and costimulatory signals imprinted the T cell with a 
defined division fate. In vitro work by Pham et al. further showed that interactions with stromal 
cells and chemokine receptor signalling resulted in the assymetric cell division of T cell and 
differential inheritance of fate determinants by daughter cells (Pham, Shimoni et al. 2015). In this 
way, the microenvironment influenced fate decision of developing cells. The current study has 
added to this body of work by showing that PbTII cells express many genes prior to fate 
commitment, including chemokine receptors that can facilitate either Th1 or Tfh differentiation. 
This suggests that uncommitted CD4+ T cells require external signals, such as those provided 
through chemokine receptors, to skew gene expression towards one of the effector fates. Without 
knowing the true identity of the cells tested here, it is difficult to know exactly when this 
commitment occurs. However, the modelling of the expression data suggests that bifurcation occurs 
several days after priming and at approximately the same time as peak gene expression, suggesting 
that as the cell fate solidifies, gene expression becomes more specific.  
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Among the chemokine receptors that peaked in expression around bifurcation, only Cxcr5 
associated with Tfh trend assignment. Since CXCR5 permits T cells to enter the B cell follicle, this 
association supports the requirement of B cells in Tfh responses (Kerfoot, Yaari et al. 2011). 
Indeed, Tfh responses, but not Th1 responses, were significantly impaired upon B cells depletion. 
The initial differentiation of Tfh cells has been reported to occur independently of B cells (Kerfoot, 
Yaari et al. 2011). In a separatestudy, differentiation of Tfh cells was demonstrated to rely on 
CD8α- cDCs within the interfollicular zone via enhanced ICOSL and OX40L expression in 
response to targeted Yersinia pestia and OVA antigens (Shin, Han et al. 2015). Here, scRNAseq of 
cDCs at the time of PbTII bifurcation revealed expression of ligands for CXCR3, but not CXCR5, 
suggesting they preferentially support Th1 differentiation (Groom, Richmond et al. 2012). 
Furthermore, timed depletion of CD11c-expressing DCs resulted in a trend towards decreased Th1 
responses, but no change in Tfh responses. T, this suggests that B cells in the follicle are the 
primary support for Tfh responses during Plasmodium infection, however other cells may be 
involved at different stages of Tfh differentiation.  
For the first time, inflammatory monocytes were shown to adopt a similar transcriptional 
profile to cDCs, suggesting similar roles during in vivo Plasmodium infection. Previous ex vivo 
studies dismissed the role of inflammatory monocytes in priming CD4+ T cell responses during 
malaria (Sponaas, Cadman et al. 2006), but did not determine whether they provided support for Th 
differentiation. By using a timed-depletion system in vivo, inflammatory monocytes were 
demonstrated to provide support to activated PbTII cells. While Th1 responses were impaired in 
these monocyte-depleted mice, the absolute number of Tfh PbTII cells was unchanged, suggesting 
that monocytes have a role in enforcing rather than driving Th1 commitment at the expense of Tfh 
differentiation. An important caveat was the partial depletion of splenic CD68+ macrophages in the 
LysMCre x iDTR transgenic system. Therefore, a role for these macrophages in supporting Th1 fate 
cannot be discounted. Nevertheless, inflammatory monocyte-mediated support for Th1 responses is 
consistent with viral and fungal infection studies (Hohl, Rivera et al. 2009, Nakano, Lin et al. 2009, 
Wuthrich, Ersland et al. 2012). 
Together, these data support a model in which cDCs prime naïve antigen-specific T cells, 
driving them to proliferate and reach a state of high cell-cycling and stochastic gene expression. 
PbTII cells then become receptive to chemoattractant signals from multiple cell types in different 
zones of the spleen. For example, B cells support Tfh commitment, while cDCs and inflammatory 
monocytes enforce Th1 fate commitment. These signals are not necessarily competing. While this 
study has focused on intercellular singling as a central mediator of Th fate commitment, upstream 
intracellular balances of gene expression likely also contribute. Follow up studies into the spatial 
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positioning of activated T cells within secondary lymphoid tissue and their direct interaction with 
chemokine-expressing cells may further solidify this model. 
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Chapter Five: 
Interferon Regulatory Factor 3 balances Th1 and Tfh-dependent 
immunity during blood-stage Plasmodium infection 
 
5.1 Abstract 
Innate immune signalling pathways are activated during blood-stage Plasmodium infection 
and serve to elicit an inflammatory response. Given that innate immune cells can modulate parasite-
specific CD4+ T helper cell differentiation, as described in Chapter 4, it was hypothesized that 
molecules associated with innate immunity were also involved. To date, however, this has been 
largely unstudied during Plasmodium infection. Using non-lethal, resolving models of blood-stage 
malaria, endosomal and cytosolic signalling pathways were compared for their role in mediating 
PbTII cell responses. While no major roles were identified for individual pathways, IRF3, which 
sits at the convergence point for multiple pathways, was shown to influence PbTII responses. In 
particular, IRF3 promoted proliferation and differentiation of Th1 cells, which was associated with 
MHCII expression by Ly6Chi inflammatory monocytes and early parasite control. Conversely, IRF3 
also acted within B cells to suppress anti-parasitic humoral immune responses, such as the 
development of germinal centre B cells, Ig-class switching and Tfh cell responses. Importantly, 
IRF3-mediated suppression of humoral immunity was associated with impaired resolution of 
infection. Thus, a novel role for an innate immune transcription factor, IRF3, was delineated in 
governing the balance between Th1 and Tfh-dependent immunity during experimental blood-stage 
malaria 
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5.2 Introduction 
Pattern Recognition Receptor (PRR) pathways have been implicated in innate immune 
recognition of pRBC-derived molecules such as haemozoin and Plasmodium DNA, via TLRs, 
NOD-like receptors (NLRs), and cytosolic DNA detection via STING (encoded by 
Tmem173)(Krishnegowda, Hajjar et al. 2005, Parroche, Lauw et al. 2007, Kalantari, DeOliveira et 
al. 2014). In these studies, the biological importance of PRR-related molecules was inferred in vivo 
based on systemic inflammatory cytokine production. However, few studies have explored in vivo 
roles for PRR-related molecules in driving adaptive immune responses during Plasmodium 
infection (Franklin, Rodrigues et al. 2007).   
IRFs were originally discovered, and are best known for roles in driving production of Type 
I IFN, and expression of Interferon-stimulated genes (ISGs) (Tamura, Yanai et al. 2008). However, 
it is becoming increasingly clear that IRFs perform many distinct roles in vivo. For instance, while 
IRF7 is a master controller of Type I IFN responses (Honda, Yanai et al. 2005), IRF1, 2, 4 and 8 
play crucial roles in the development and immunological responses of haematopoietically-derived 
immune cells. IRF3 has been reported to perform several functions, including the production of 
IFNβ and the suppression of tumour growth via apoptosis in response to DNA-damage. 
Furthermore, an in vitro report described a role for IRF3 in B cells responding to CpG (Oganesyan, 
Saha et al. 2008), while TBK1, a primary activator of IRF3, was reported to restrain B cells from 
immunoglobulin class-switching and IgA-mediated pathology in mice (Jin, Xiao et al. 2012). 
Finally, IRF3 is positioned at a convergence point for multiple PRR-signalling pathways, including 
those mediated by TRIF-dependent TLRs, MAVS, and STING (Servant, Grandvaux et al. 2002), 
which highlights its capacity to integrate and convey innate immune signals to the adaptive immune 
system. In support of this, IRF3 has been reported to play context-dependent roles in controlling Th 
responses. During viral and bacterial co-infection, IRF3 suppressed Th1 responses by competing for 
binding to the IL12β promoter in macrophages (Negishi, Yanai et al. 2012). Conversely, IRF3 
drove Th1 and Th17 responses in the central nervous system during experimental autoimmune 
encephalomyelitis (Fitzgerald, O'Brien et al. 2014). Therefore, IRF3 displays significant potential to 
influence Th and B cell responses, and indeed is likely activated in response to pRBCs (Sharma, 
DeOliveira et al. 2011); yet the consequences of this for adaptive immunity to malaria remain 
unexplored.  
Here, the role of PRR pathways in modulating PbTII responses to in vivo infection is first 
tested. Minor roles for the TLR adaptor molecules, MyD88 and Trif are identified. However, most 
strikingly, a critical role for IRF3 for the expansion of Plasmodium-specific CD4+ T cells and for 
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promoting their differentiation towards the Th1 fate is observed. Additionally, IRF3 suppresses Tfh-
mediated humoral responses, in a likely secondary mechanism, leading to poorer Plasmodium-
specific antibody production and ultimately, poorer resolution of infection.   
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5.3 Results 
5.3.1 Individual PRRs play only modest roles in controlling Plasmodium-specific CD4+ T cell 
responses during blood-stage infection 
Numerous PRRs have been reported to participate in early innate immune responses to 
blood-stage Plasmodium parasites in vivo. Nevertheless, their role in generating antigen-specific 
CD4+ T cell responses remains unclear. Therefore, PbTII cells were employed to explore roles for 
TLRs, cytosolic DNA/RNA detection, and inflammasomes in mediating CD4+ T cell responses. 
PbTII cells were transferred into WT control mice, or those deficient in TLR-signalling (Trif-/-, Tlr3-
/-, and Myd88-/-), or cytosolic DNA/RNA detection (Mavs-/- and Tmem173-/-). After infection with 
PcAS, it was noted that PbTII cells expanded equivalently in mice lacking either MAVS or STING 
compared to WT controls (Figure 5.1A), suggesting that cytosolic nucleic acid detection was not 
essential for the activation of Plasmodium-specific CD4+ T cell responses. Similarly, PbTII 
expansion occurred at wild-type levels in mice deficient in Caspase1/11, suggesting that 
inflammasome function is dispensable for this response (Figure 5.1A). No requirements were 
observed for TLR3, a detector of endosomally located nucleic acids, nor its signalling adaptor, 
TRIF, in mediating PbTII proliferative responses (Figure 5.1A). Instead, TRIF suppressed PbTII 
responses, while MyD88 played a modest supportive role (Figure 5.1A). Thus, while this approach 
revealed modest opposing roles for the TLR adaptors, TRIF and MyD88, it did not identify a 
specific PRR-pathway that was critical for driving parasite-specific CD4+ T cell responses. Instead, 
IRF3, a convergence point for multiple PRRs, was identified as an important mediator of this 
process (Figure 5.1A). To excluded the possibility of non-specific expansion of PbTII cells upon 
transfer, physiologically-relevant numbers were transferred into naive C57Bl6/J, Irf3-/-, Myd88-/-, 
Mavs-/-, Trif-/-andTmem173-/-, and PcAS-infected WT or Irf3-/-mice. PbTII numbers remained at 
approximately one-tenth of the transferred number in all of the naive mice compared to significantly 
increased numbers in infected mice by day 8 post-transfer (Figure 5.1B), thus confirming the 
Plasmodium-specific expansion of PbTII cells even in immunologically perturbed environments. 
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Figure 5.1 PbTII responses are partially modulated by MyD88- and TRIF-mediated signalling, 
but further dependent on IRF3. (A) Enumeration of PbTII cells transferred into naïve mice (106) 
or WT, Mavs-/-, Tmem173-/-, Casp-1/11-/-, Tlr3-/-, Trif-/-, Myd88-/-and Irf3-/- mice (104) at 7 days p.i. 
with PcAS. (B) Enumeration of PbTII cells (104, indicated by the horizontal dotted line) transferred 
into male or female naive C57Bl/6, Irf3-/-,Myd88-/-, Mavs-/-, Trif-/-and Tmem173-/- mice at day 8 post-
transfer, or WT and Irf3-/- at day 7 p.i. with PcAS. (A) Data are pooled from two independent 
experiments. (B) Data are from a single experiment of male and female mice. Mann-Whitney 
test.*p<0.05, **p<0.01, ****p<0.0001. 
 
5.3.2 Haematopoietic cells employ IRF3 to drive Plasmodium-specific Th responses 
Next, the effect of IRF3 on Plasmodium-specific Th differentiation was explored. PbTII 
cells were transferred into Irf3-/-or WT mice, and T-bet/IFNγ co-expression (Th1) or Bcl6/CXCR5 
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co-expression (Tfh) by splenic PbTII cells was assessed at peak PcAS infection. In addition to 
reduced numbers of splenic PbTII cells observed in Irf3-/- mice compared to WT controls (Figure 
5.1A), there was a substantial qualitative defect in the proportion of PbTII cells developing into Th1 
cells (Figure 5.2A). Conversely, Irf3-/- mice had greater proportions of Tfh cells amongst the PbTII 
populations (Figure 5.2A). Importantly, IRF3 also supported polyclonal Th1 responses and 
dampened Tfh responses during PcAS infection (Figure 5.2B).  
To explore which host cells might employ IRF3 to drive PbTII responses, bone marrow 
(BM) chimeric mice were generated, in which haematopoietically-derived cells lacked IRF3 (via 
reconstitution of lethally irradiated WT mice with Irf3-/-or control WT BM cells; Irf3-/->WT, or 
WT>WT controls). In generating these chimeras, flow cytometric assessment of pooled bone 
marrow cells was first performed. There were no major differences in the presence of long-term or 
short-term haematopoietic stem cells (HSC), or multipotent progenitor cells within the Kit+Sca-1+ 
HSC compartment between WT and Irf3-/- BM, suggesting no major HSC defect caused by IRF3-
deficiency (Figure 5.3A). After generating the chimeras, no differences were observed in bulk 
splenic B-cells, or in modest plasmablast responses between un-infected Irf3-/->WT chimeras and 
WT>WT controls (Figure 5.3B). Slight increased numbers of GC B cells were noted in the Irf3-/-
>WT chimeric mice. However, there were no significant differences in absolute numbers of splenic 
neutrophils, monocytes, cDCs or T cells in Irf3-/->WT chimeras compared to WT>WT controls 
(Figure 5.3C). These data suggested that lethally-irradiated WT mice given Irf3-/- HSC reconstituted 
the spleen as effectively as with WT HSC, with only minor perturbations in the B-cell 
compartment. Assessment of PbTII responses in PcAS-infected Irf3-/->WT mice and WT>WT 
controls revealed that haematopoietic cells required IRF3 to fully support PbTII expansion and Th1 
differentiation, while promoting Tfh differentiation (Figure 5.2C). Therefore, our data indicated that 
haematopoietic cells, but not CD4+ T cells themselves, employed IRF3 to drive Plasmodium-
specificTh1 responses and suppress Tfh responses. To confirm a requirement for IRF3 within 
haematopoietic cells in supporting polyclonal Th1 responses, as shown earlier for PbTII cells 
(Figure 5.2C), Irf3-/->WT BM chimeric mice, and WT>WT controls were similarly employed. We 
observed that PcAS-infected Irf3-/->WT BM chimeric mice displayed a 50% reduction in splenic 
Th1 responses (Figure 5.2D), but a 60% increase in Tfh responses (Figure 5.2D), and increased 
parasitemias (Figure 5.2E) compared to WT>WT BM chimeric controls. Together, our results and 
previous data demonstrate that while IRF7 and Type I IFN-signalling suppress Th1-immunity 
(Haque, Best et al. 2011, Haque, Best et al. 2014, Edwards, Best et al. 2015), haematopoietically-
derived, non-CD4+ T cells require IRF3 to fully support early Th1 responses and anti-parasitic 
immunity during non-lethal blood-stage Plasmodium infection. 
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Figure 5.2 IRF3 promotes early protective Th1 responses during blood-stage Plasmodium 
infection. (A) Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets), 
proportions and absolute numbers of splenic PbTII cells exhibiting Th1 (T-bet+ IFNγ+) and Tfh 
(CXCR5+ Bcl6+) phenotypes in WT and Irf3-/- mice at 7 days p.i. with PcAS compared to un-
infected WT mice. (B) Representative FACS plots (gated on CD4+ TCRβ+ live singlets), proportions 
and absolute numbers of splenic polyclonal CD4+ T cells exhibiting Th1 and Tfh phenotypes in WT 
and Irf3-/- mice at 7 days p.i. with PcAS. (C) Numbers of splenic PbTII cells in Irf3-/->WT BM 
chimeric mice or WT>WT chimeric controls (receiving 104 PbTII cells) 7 days p.i. with PcAS, as 
well as proportions and absolute numbers exhibiting Th1 and Tfh phenotypes. (D) Proportions of 
splenic polyclonal CD4+ T cells exhibiting Th1 and Tfh phenotypes at 7 days p.i. with PcAS. Data 
are representative of two independent experiments. (E) Parasitemia in Irf3-/->WT BM chimeric 
mice or WT>WT chimeric controls at 7 days p.i. with PcAS (data pooled from two independent 
experiments). Statistics: Mann-Whitney U test; *p<0.05, **p<0.01, ****p<0.0001. 
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Figure 5.3 Phenotypic characterisation of Irf3-/->WT bone marrow chimeric mice. (A) FACS 
gating strategy for long-term haematopoietic stem cells (LT-HSC; Lin- Kit+ Sca1+ CD150+ CD48-), 
short-term HSCs (ST-HSC; Lin- Kit+ Sca1+ CD150+ CD48+) and multipotent progenitors (MPP; 
Lin-Kit+ Sca1+ CD150- CD48+) in BM cells from WT and Irf3-/- mice (pooled from n=6/group). (BD) 
WT or Irf3-/- BM cells were transferred into lethally-irradiated WT mice, and after 8 weeks, splenic 
WT Irf3-/-
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immune populations were assessed (n=6). (B) Representative plots (gated on live singlets) showing 
proportions and absolute numbers of splenic B cells, plasmablasts (B220+ CD19+ IgDlo CD138+) 
and GC B cells (B220+ CD19+ Fas+ GL-7+). (C) Representative FACS plots of various myeloid cell 
populations, including proportions and absolute numbers in the spleens of un-infected Irf3-/->WT 
and WT>WT chimeric mice; Ly6G+ CD11b+ neutrophils (Ly6Ghi Ly6Clo B220- TCRβ- live singlets), 
inflammatory monocytes (Ly6Chi Ly6Glo B220- TCRβ- live singlets), cDCs (CD11chi MHCIIhi B220- 
TCRβ- live singlets) and CD4+ or CD8+ T cells (CD4+ TCRβ+ or CD4- TCRβ+ live singlets). 
Experiment performed once. Statistics: Mann-Whitney U test, *p<0.05. 
 
5.3.3 IRF3-mediated Th1 support correlates with MHCII-expression by inflammatory 
monocytes 
The observation of poorer accumulation of PbTII cells in the absence of IRF3 (Fig 5.1A) led 
to the consideration of a defect in early activation. However, flow cytometric assessment of 
expression of the early activation marker CD69 showed that CTV-labelled PbTII cells were 
comparably activated at day 2 p.i. in WT or IRF3 deficient mice (Figure 5.4A). In further 
experiments in which 106 PbTII cells were transferred for ease of detection, it was noted that a 
greater proportion of PbTII cells in WT mice had divided at least once by day 4 p.i. as evident by 
the loss of CTV compared to PbTII cells transferred into Irf3-/- mice (Figure 5.4B). When more 
physiologically relevant numbers were transferred and the possibility for intraclonal competition 
minimised, a trend towards reduced Th1 responses was observed by day 4 p.i., which reached 
statistical significance by day 5 p.i. (Figure 5.4C). IRF3 did not support accumulation of PbTII cells 
by preventing apoptosis, since no differences in PbTII cells from infected WT and Irf3-/-recipients 
was evident, either in expression of the anti-apoptotic protein Bcl-2 (Figure 5.4D), or cell-surface 
display of phosphatidylserine (Figure 5.4E). Therefore, this data suggested that IRF3 supports 
splenic PbTII responses by sustaining their proliferation, rather than mediating early T cell 
activation or preventing T cell apoptosis.  
 
  
118 
 
Figure 5.4 Requirements for IRF3 in early activation of PbTII cells. (A) CTV labelled PbTII cells 
(106) were transferred into WT and Irf3-/- mice one day prior to infection with PcAS. (B) 
Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets) of CTV positivity and 
CD69 expression, and proportion of unproliferated PbTII cells (CTVhi) that are CD69+ at 1, 2 and 
3 days p.i. with PcAS. (C) Absolute numbers and proportions exhibiting a Th1 (IFNγ+ T-bet+) or 
Tfh (CXCR5+ Bcl6+) phenotype. (D) Representative histograms (gated on CD45.1+ CD4+ TCRβ+ 
live singlets), and expression of Bcl2 expression by PbTII cells in WT or Ir3-/- mice at 2, 3 and 4 
days p.i. with PcAS relative to naive PbTII cells (n=4). (E) Representative plots (gated on CD45.1+ 
CD4+ TCRβ+ live singlets) of 7AAD and Annexin V-positivity by PbTII cells in WT or Irf3-/- mice at 
7 days p.i. with PcAS and plot showing staining of FSCAlo dead/dying cells for comparison. (A) 
Data are representative of replicate experiments. (B-E) Data from experiments performed once 
(n=4). Geom Mean: Geometric mean. Statistics: Mann-Whitney test. *p<0.05, **p<0.01. NS, not 
significant. 
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5.3.4 Conventional dendritic cell activation during Plasmodium infection is independent of 
IRF3 expression 
Next, it was hypothesized that haematopoietic myeloid cells employed IRF3 to support 
proliferation and Th1-differentiation of activated CD4+ T cells. CD4+ T cells require continual 
antigen presentation for each new round of division (Obst, van Santen et al. 2005). Moreover, 
prolonged MHCII-mediated signals have been demonstrated to encourage Th1-differentiation in 
vivo (Celli, Lemaitre et al. 2007). Thus, the activation and signalling capacity of conventional 
dendritic cells, which are essential for CD4+ T cells response (Fig 3.2B), was assessed during the 
course of PcAS infection (Haque, Best et al. 2014). In WT mice, cDCs experienced peak expression 
of cell surface MHCII, or co-stimulatory molecules, CD86 or CD40 followed by a sharp decrease in 
expression (Figure 5.5A and Figure 5.5B). Splenic cDCs in Irf3-/- mice also demonstrated 
comparable expression of these markers suggesting an equivalent capacity to support CD4+ T cell 
responses (Figure 5.5B). These results did not support a role for IRF3 in cDC-mediated PbTII 
activation during PcAS infection. 
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Figure 5.5 Activation kinetics of conventional dendritic cells during PcAS infection. (A) Gating 
strategy for CD11c+ MHCII+ dendritic cells and Ly6Chi CD11b+ inflammatory monocytes. (B) 
Expression of MHCII, CD86 and CD40 by CD8α+ and Sirpα+ CD11c+ MHCII+ dendritic cells from 
WT or Irf3-/-mice at 1-4 and 7 days p.i. with PcAS. Data are representative of two independent 
experiments. Geom Mean: geometric Mean fluorescence intensity.  
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5.3.5 IRF3 drives MHCII signalling by inflammatory monocytes to support accumulation of 
PbTII cells 
Inflammatory monocytes migrate from the bone marrow to the spleen during blood-stage 
infection and are reported to be involved in the clearance of pRBC (Sponaas, Freitas do Rosario et 
al. 2009). In other in vivo infection systems, inflammatory monocytes are also reported to support 
Th1 responses (Leon, Lopez-Bravo et al. 2007, Flores-Langarica, Marshall et al. 2011). 
Furthermore, CD4+ T cell proliferation after experimental vaccination depended on both 
inflammatory monocytes in association with IRF3 (Marichal, Ohata et al. 2011). Therefore, Ly6Chi 
monocytic responses were assessed first in WT mice infected with PcAS (Figure 5.5A). Strikingly, 
splenic Ly6Chi CD11b+ inflammatory monocytes dramatically up-regulated cell surface MHCII 
expression up until peak PcAS infection, to a level close to that seen on cDCs from naive mice 
(Figure 5.6A and 5.6B). Ly6Chi inflammatory monocytes in Irf3-/-mice, however, displayed a 
profound defect in MHCII upregulation compared to WT controls (Figure 5.6B). This defect in 
MHCII expression and total numbers of MHCII expression cells in Irf3-/- mice was evident at the 
same time PbTII cells displayed reduced expansion (Figure 5.4C and 5.6C). Finally, Irf3-/->WT BM 
chimeras confirmed the haematopoetic requirement for IRF3 in driving MHCII expression by 
inflammatory monocytes (Figure 5.6D). Taken together, these data suggested that IRF3 did not 
influence initial priming of CD4+ T cells, but instead promoted inflammatory monocytic responses 
that might sustain Th1 responses during infection.  
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Figure 5.6 Inflammatory monocytes express MHCII in an IRF3-dependent manner. (A) 
Expression kinetics and numbers of MHCII+ by inflammatory monocytes during PcAS infection in 
WT mice. (B) Representative histograms, proportion of MHCII+ and mean expression of MHCII by 
Ly6Chi CD11b+ Ly6G- inflammatory monocytes from naïve or WT and Irf3-/- monocytes at 7 days p.i. 
with PcAS. Histogram also shows MHCII expression by cDCs from naïve WT mice as a 
comparison. (C) Proportions, geometric mean fluorescence and absolute numbers of MHCII+ 
splenic Ly6Chi monocytes at days 5 and 7 p.i. with PcAS. (D) MHCII expression and proportions of 
MHCII+ Ly6Chi CD11b+ Ly6G- monocytes from lethally irradiated WT BM chimeric mice 
reconstituted with WT or Irf3-/- bone marrow. Data are representative of two independent 
experiments. Geom Mean: geometric mean fluorescence intensity. Mann-Whitney test. *p<0.05, 
**p<0.01. NS, not significant. 
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5.3.6 IRF3 suppresses humoral immunity during blood-stage Plasmodium infection 
Although IRF3 supported splenic PbTII numbers (Figures 5.3A), of those recovered from 
Irf3-/- mice, a greater proportion had become Tfh cells compared with WT controls (Figure 5.2A). 
This data indicated that IRF3 was not required for Tfh differentiation, and in fact regulated humoral 
responses. Since Tfh responses are known to support affinity maturation of B cells and the 
production of antibodies (Arnold, Campbell et al. 2007), it was next hypothesized that IRF3 played 
another role during the later stages of infection in suppressing humoral immunity. In support of this, 
Irf3-/-mice exhibited improved resolution of PcAS infection compared to their WT counterparts (Fig 
5.7A). Since Plasmodium-specific antibodies have been shown to contribute to the clearance of 
Plasmodium infection, antibody titres were assessed in WT and Irf3-/- mice throughout the course of 
PcAS infection. Higher levels of total IgG, IgM, IgG1, IgG2a, IgG2b and IgG3 were seen in Irf3-/- 
mice throughout infection (Fig 5.7B). Furthermore, increased GC B cell responses were observed in 
Irf3-/- mice compared to WT controls at 7 and 14 days p.i. with PcAS (Fig 5.8A and 5.8B).  Using 
Irf3-/->WT BM chimeric mice, the observed suppression of GC B cells was shown to be due to a 
hematopoietic role for IRF3 (Figure 5.8C). Finally, memory B cell responses were significantly 
stronger at day 40 p.i. in Irf3-/- mice, determined by the co-expression of CD38 and CD80 (Figure 
5.8D) (Tomayko, Steinel et al. 2010). Together, these results support a role for IRF3 in suppressing 
Tfh-mediated GC B cell, antibody and memory responses during non-lethal blood-stage 
Plasmodium infection. 
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Figure 5.7 IRF3 limits Plasmodium-specific antibody responses. (A-B) Time-course analysis of 
(A) parasitemia and (B) parasite-specific IgM, total IgG, IgG1, IgG2b, IgG2c and IgG3 in sera 
(diluted 1 in 400) in WT and Irf3-/- mice (n=6/group) infected with PcAS. Data are pooled from 
two independent experiments. Mann-Whitney test. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. 
 
A Total IgGIgM IgG1
IgG2b IgG2c IgG3
B
Days post-infection
0 1 0 2 0 3 0 4 0
0
1
2
3
*
* * * *
* * * *
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
2 .0
O
D
 (
4
9
2
n
m
)
* * * *
*
* *
* * * *
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
2 .0
* * *
* * *
*
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
* * *
* * *
* * * *
* * *
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
2 .0
* * *
* * * *
* *
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
* * *
* * * *
0 1 0 2 0 3 0 4 0 5 0
0 .1
1
1 0
D a y s  p o s t - in fe c t io n
P
a
ra
s
it
e
m
ia
 (
%
 p
R
B
C
s
)
W T
I r f3
- /-
* *
* *
* *
* *
* *
* *
* *
* *
* *
* *
* *
*
*
* *
*
* * *
  
125 
 
Figure 5.8 IRF3 limits Plasmodium-specific antibodies GC B cells and Tfh cell differentiation. 
(A) FACS gating strategy for splenic B-cells. (B) Representative FACS plots (gated on B220+ 
CD19+ live singlets) showing proportions and absolute numbers of splenic GC B cells (Fas+ GL7+) 
in WT and Irf3-/- mice, at indicated days p.i. with PcAS. (C) Absolute numbers of splenic GC B cells 
(Fas+ GL7+) in Irf3-/->WT BM chimeric mice and WT>WT chimeric controls at 7 days p.i. with 
PcAS. (D) Representative FACS plots (gated on IgDlo B-cells) showing proportions and absolute 
numbers of splenic B cells exhibiting a CD38hi CD80hi memory phenotype in WT and Irf3-/- mice at 
73 days p.i. with PcAS, compared with naïve WT mice. Data (B) & (C) are representative and (D) 
pooled from two independent experiments. Statistics: Mann-Whitney U test; *p<0.05, **p<0.01, 
***p<0.001. 
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5.3.7 IRF3 expression by B cells impairs development of humoral immune responses 
Given that IRF3 and its upstream kinase TBK1 were previously reported to operate within B 
cells (Oganesyan, Saha et al. 2008, Jin, Xiao et al. 2012); a possible B cell-intrinsic function for 
IRF3 during blood-stage Plasmodium infection was next explored. To this end, mixed BM chimeric 
mice were generated in which only B cells were IRF3-deficient. This was achieved by 
reconstituting lethally-irradiated WT mice with a mixture of BM cells (80% from B-cell deficient, 
μMT, mice and 20%either from Irf3-/-or WT control mice) (Figure 5.9A). B cell-specific IRF3-
deficient chimeras displayed no defect in the production of Plasmodium-specific serum IgG, by 15 
days p.i with PcAS, compared to WT control mixed BM chimeras, suggesting that B cells did not 
depend on IRF3 to suppress high-affinity IgG production (Figure 5.9B). However, it was observed 
that when B cells lacked IRF3, polyclonal Tfh responses were modestly increased by 15 days p.i. 
(Figure 5.9C). Together, these data pointed towards a subtle role for IRF3 in B cells, not in 
suppressing bulk GC B cell responses, but in modulating interactions between B cells and Tfh cells. 
To expose subtle roles for IRF3 in B cells, a competitive chimeric approach was adopted, in 
which mixtures of WT and Irf3-/- BM were used to reconstitute lethally-irradiated WT mice (Figure 
5.9D). In preliminary experiments, 50:50 ratios of BM cells yielded expected ratios within T cell 
and myeloid cell compartments (data not shown), but the B cell compartment was skewed heavily 
towards Irf3-/- B cells (data not shown). In subsequent experiments we employed 70:30 mixtures of 
WT and Irf3-/-BM, and again yielded marked skewing only of B cells (not T cells or myeloid cells) 
towards an Irf3-/-genotype (Figure 5.9E and data not shown). These data suggested that in the 
context of BM transplantation, IRF3 specifically suppressed B cell development from 
haematopoietic stem cells (HSC). Nevertheless, WT and Irf3-/-B cells in mixed BM chimeric mice 
displayed similar capacities to populate follicular, extra-follicular and marginal zone compartments 
in the spleen, as assessed by expression of CD23 and CD21 (Figure 5.9F). Next, mixed BM 
chimeric mice were infected with PcAS, and early GC B cell formation was examined (Figure 
5.9G). Firstly, it was noted that uninfected controls exhibited background GC B cell responses, 
although this had not generated Plasmodium-specific IgG (Figure 5.9B), and was likely the result of 
total body irradiation and BM engraftment. More importantly, in this competitive environment, Irf3-
/-B cells possessed an advantage in generating early GC B cell responses compared to WT B cells in 
the same animals (Figure 5.9G). Taken together, this approach revealed that IRF3 acted in B cells, 
not only to restrain B cell development from HSC, but also to suppress GC B cell responses during 
blood-stage Plasmodium infection.    
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Figure 5.9 IRF3 within B cells dampens maturation and GC B cell responses during infection. 
(A) Schematic of lethally-irradiated WT mice reconstituted with 80% μMT and 20% WT or Irf3-/- 
bone marrow. (B) PcAS-specific total IgG and (C) proportion of CXCR5+ ICOS+ CD4+ TCRβ+ cells 
in chimeras described in (A) at 15 days p.i. (pooled from two independent experiments). (D) 
Schematic of lethally-irradiated WT mice administered 70% WT (CD45.1) and 30% Irf3-/- (CD45.2) 
bone marrow-derived cells. (E) Representative plots (gated on B220+ CD19+ live singlets) and 
pooled proportions of WT and Irf3-/- B220+CD19+ cells, and (F) their localisation to the extra-
follicular, follicular and marginal zone within the spleens of naïve chimeric mice described in (D) 
at 12 weeks post-transplant. (G) Representative plots (gated on CD45.1+/CD45.1- B220+ CD19+ 
live singlets) and enumeration of Gl7 and Fas co-expression by B splenocytes in chimeric mice 
described in (D) at 15 days p.i. with PcAS. (F-G) Data are representative data of two independent 
experiments. Statistical analyses are Mann-Whitney test except (D), which is a one-way ANOVA 
corrected with Tukey’s multiple comparison test. *p<0.05, ****p<0.0001. NS, not significant. 
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 To further explore the role of IRF3 in suppressing humoral immunity during experimental 
malaria, a second model of resolving infection, Py17XNL, was employed. While WT mice 
recovered from Py17XNL infection after 30 days, as expected, mice deficient of T and B cells 
(Rag1-/-) succumbed to hyperparasitemia, highlighting the importance of adaptive immune 
responses in controlling this infection. Irf7-/- mice experienced significantly lower burdens of 
infection and faster resolution compared to WT mice, consistent with recent reports in other murine 
malaria models (Haque, Best et al. 2014, Edwards, Best et al. 2015). IRF3 deficient mice, however, 
showed reduced control of the initial ascent in parasite burden, but improved resolution of infection 
compared to WT mice (Figure 5.10A). As in the PcAS system, improved resolution of Py17XNL 
infection by Irf3-/- mice was associated with higher titres of Plasmodium-specific total IgG, IgM, 
IgG1, IgG2b, IgG2c and IgG3 levels, which were maintained up to day 81 p.i. compared to WT 
levels (Figure 5.10B). Furthermore, GC B cell proportions and total numbers were significantly 
improved in the absence of IRF3 (Figure 5.10C). Lastly, memory B cell responses as determined by 
proportions and total numbers of CD80+ and CD38+memory B cells were markedly improved in 
Irf3-/- mice compared to their WT counterparts at day 81 p.i. (Figure 5.10D). Thus, IRF3 dampened 
GC B cell responses, antibody titres and resolution of infection in a second model of slow resolving 
Plasmodium infection. 
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Figure 5.10 IRF3 limits humoral immune responses during Py17XNL infection. (A) Time-course 
analysis of parasitemia in Irf3-/-, Irf7-/, Rag1-/- and C57Bl/6 mice (n=5-6) infected with Py17XNL; 
cross indicates ethically-motivated euthanasia of heavily infected mice. (B) Time-course analysis of 
parasite-specific IgM, total IgG, IgG1, IgG2b, IgG2c and IgG3 in sera (1/400 dilution) in Irf3-/- and 
WT mice (n=6/group) infected with Py17XNL. (C) Representative FACS plots (gated on B220+ 
CD19+ live singlets) and graphs showing proportions and absolute numbers of splenic B cells 
exhibiting a GC B cell phenotype (Fas+ GL7+) in infected Irf3-/- and WT mice, at 7 and 14 dpi with 
Py17XNL, compared to un-infected WT controls. (D) Representative FACS plots (gated on IgDlo 
B220+ CD19+ live singlets) and graphs showing proportions and absolute numbers of splenic B 
cells exhibiting a CD38hi CD80+ memory phenotype in naïve WT or infected WT and Irf3-/- mice at 
81 dpi with Py17XNL. Data representative of (A, C & D) or pooled (B) from two independent 
experiments. Statistics: Mann-Whitney U test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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5.3.8 IRF3 contributes to disease severity during lethal experimental malaria 
Since IRF3 suppressed Tfh-mediated humoral responses during non-lethal Plasmodium 
infections, whether IRF3 could also modulate the outcome of lethal infection was explored. To this 
end, PbA, a model of severe and cerebral malaria was employed. WT mice infected with PbA 
succumbed to cerebral symptoms between 7 and 10 days p.i. (Figure 5.11). Mice deficient of 
granzyme B experienced no cerebral symptoms as expected (Haque, Best et al. 2011), confirming 
the role of cytotoxic cytokines in these ECM, but succumbed to the infection at approximately day 
15 p.i. (Figure 5.11). As expected, Rag1-/- mice were also immune to cerebral malaria (Amante, 
Haque et al. 2010), but were unable to resolve the infection. Strikingly, in the absence of IRF3, 
mice experienced no cerebral symptoms and furthermore, were able to completely clear infection 
after approximately 30 days (Figure 5.11). These results further support a role for IRF3, in 
suppressing the antibody-mediated resolution of blood-stage infection.  
 
 
Figure 5.11 IRF3 impairs resolution of PbA infection in mice. Time-course analysis of PbA 
parasitemia in C57Bl/6, Irf3-/-, Rag1-/- and Gzmb-/- mice (n=6). Grey box denotes time-frame of 
cerebral symptoms experienced by WT mice. 
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5.4 Discussion 
In this study, whether PRR-signalling pathways direct Plasmodium-specific CD4+ T cell 
responses during non-lethal, experimental malaria have been assessed. Modest opposing roles for 
MyD88 and TRIF-dependent signalling were identified, but more importantly, a complex, biphasic 
role for the innate immune transcription factor, IRF3, which is ubiquitously expressed by immune 
cells and sits at the convergence point of multiple PRRs, was discovered. Over the course of 
infection, IRF3 was initially critical for driving Th1 responses, activating monocytes, and 
controlling pRBC, but later suppressed B cell responses, limited Plasmodium-specific antibody 
production, and delayed resolution of infection.   
Naturally-acquired immunity to malaria requires multiple infections over many months to 
years to fully develop. Nonetheless, protective immunity against blood-stage Plasmodium parasites 
can be generated in humans, and thus efforts to accelerate its onset will likely be beneficial. The 
innate immune system plays a crucial role in sculpting adaptive immune responses. However, few if 
any molecular mechanisms have been reported via which innate immune responses drive adaptive 
immunity to malaria. Several endosomal and cell-surface PRRs, and their associated signalling 
adaptors, have been implicated in Plasmodium sensing in vivo. Parasite RNA activated the 
cytoplasmic receptor, MDA5, during the liver stage of infection (Liehl, Zuzarte-Luis et al. 2014). 
TLR2 and TLR4 signalled in response to Plasmodium glycosylphosphatidylinositol (GPI) moieties 
(Krishnegowda, Hajjar et al. 2005). TLR9 detected malaria haemozoin, possibly in complex with 
parasite DNA (Coban, Ishii et al. 2005). Finally, the STING/TBK1/IRF3 axis was activated, 
predominantly in vitro, by AT-rich Plasmodium DNA motifs (Sharma, DeOliveira et al. 2011). 
Despite these reports, only a single study has suggested that a PRR-signalling adaptor, in this case 
MyD88, could elicit Th cell responses during Plasmodium infection (Franklin, Rodrigues et al. 
2007). For the first time, PbTII cells have allowed for the delineation of a modest contributory role 
for MyD88, and a similarly modest suppressive role for TRIF-signalling. However, these data did 
not support roles for caspase 1/11-dependent inflammasomes or the STING pathway in driving 
CD4+ T cell responses. Given reports that these pathways are activated in vivo, it is speculated that 
myeloid cells other than those involved in T cell responses, for example certain macrophage 
subsets, employ STING and inflammasome pathways to trigger inflammatory cytokine production 
during infection.   
Another possibility is that functional redundancy exists between these PRR pathways, such 
that in any given innate immune cell, the absence of one pathway is readily compensated for by the 
activation of another. Such functional redundancy could ensure robust innate immune defense 
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against a spectrum of microbial challenges in a genetically diverse population. The concept of 
functional redundancy of PRR signalling pathways in response to pRBCs is indirectly supported by 
the fact that IRF3, which can integrate multiple PRR signals, was crucial for monocyte activation 
and Th1 responses. Thus, IRF3 constitutes one of the first described innate immune targets for 
driving CD4+ T cell responses during malaria, and as such could be investigated as a molecular 
target for novel adjuvants in candidate malaria vaccines.  
The finding that IRF3 drives Th1 responses contrasts with previous reports that Type I IFN 
signalling via IFNAR1 and the transcription factor IRF7 suppressed Th1-immunity to malaria. 
Indeed, while IFNAR1-signalling suppressed monocytic responses in this previous work (Haque, 
Best et al. 2014, Edwards, Best et al. 2015), IRF3 was essential here for driving activation of 
inflammatory monocytes. Therefore, the findings here adds to an increasing body of work showing 
that IRF3 acts very differently to its related IRF family member, IRF7, and re-enforces the view that 
IRF3 does not simply induce Type I IFN responses, but plays a number of other roles in multiple 
immune cells.   
In order for CD4+ T cells to differentiate into Th1 cells, they are reported to require 
sustained MHCII signalling, after an initial period of cDC-activation (Celli, Lemaitre et al. 2007). 
Therefore, one possible mechanism by which IRF3 supports Th1 responses is by driving 
inflammatory monocytes to provide MHCII-mediated signals to activated CD4+ T cells. Indeed, 
data reported in Chapter 4 indicate that monocyte/macrophages are specifically required to support 
Th1 responses during Plasmodium infection. Moreover, a link between IRF3 and inflammatory 
monocyte-mediated Th support was previously demonstrated in the observation by Marichal et al 
that the adjuvanticity of alum during experimental vaccination was strongly dependent on IRF3 and 
inflammatory monocytes (Marichal, Ohata et al. 2011). Therefore, it is proposed that IRF3 allows 
inflammatory monocytes in the spleen to support Th1 differentiation in activated Plasmodium-
specificCD4+ T cells. 
The involvement of IRFs in eliciting Type I IFN responses to pathogens and controlling 
development of haematopoietically-derived immune cells is well documented (reviewed by 
(Battistini 2009) and (Tamura, Yanai et al. 2008)). While IRF4 and IRF8 are well established to 
control many aspects of B lymphocyte biology, whether IRF3 acts in B cells is less clear. IRF3 
activation occurs in CpG-treated B cells in vitro (Oganesyan, Saha et al. 2008). Furthermore, the 
IRF3-related kinase, TBK1 acts within B cells to suppress pathogenic IgA production in mice (Jin, 
Xiao et al. 2012). Results discussed here demonstrated a B cell-intrinsic role for IRF3, which 
suppresses B cell development from HSC after lethal irradiation and bone marrow transplantation. 
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Furthermore, IRF3 acted in B cells to suppress GC B cell responses and Tfh cells during infection. 
Thus, this work provides the first direct in vivo evidence that IRF3 can act within B cells to 
suppress their function. One caveat of the BM chimeric approach was the significant amount of 
non-Plasmodium-specific GC B cell activity, likely generated in response to irradiation and bone 
marrow transplantation. Thus, in the future, transgenic tools such as inducible B cell-specific IRF3-
deficient mice will enable more stringent testing of how IRF3 controls B cell function in vivo. 
Nevertheless, in this study, improved Plasmodium-specific IgG production, GC B cell and Tfh 
responses were seen when IRF3-mediated suppression of humoral immunity was lifted. Thus, we 
propose IRF3 as a B cell-intrinsic regulator of humoral responses during Plasmodium infection, 
which acts to limit production of parasite-specific antibodies.  
Here, for the first time, PbA-infected Irf3-/- mice were shown to be resistant to ECM, but 
more importantly, completely resolved infection. PbA infection in C57Bl/6J mice is characterised 
by the sequestration of pRBCs into soft tissues leading to the fatal cerebral pathology. The Th1 
cytokine, IFNγ, contributes to sequestration by increasing the expression of leukocyte adhesion 
molecules on the cerebral microvascular endothelium (Hunt and Grau 2003). Additionally, previous 
studies have shown CXCR3-mediated Th1 traffic to the brain correlated with the onset of cerebral 
symptoms (Hansen, Bernard et al. 2007). A role for IRF3 in promoting Th1 responses during PbA 
infection, as evident in non-lethal infections, could explain the absence of ECM in Irf3-/-mice. 
However, this mechanism was not tested, and the possibility of IRF3 having a T cell-independent 
role in mediating ECM cannot be ruled out. In addition to resistance to ECM, Irf3-/- mice may be 
the first knock-out line to clear PbA infection. Given the observed role of IRF3 in suppressing 
Plasmodium-specific antibodies during PcAS and Py17XNL infections and the reported importance 
of antibodies in resolving infection, it is speculated that IRF3 also plays a role in suppressing the 
development of Plasmodium-specific antibodies during PbA infection.  It will be important in 
future experiments to determine the precise molecular and cellular mechanisms by which IRF3 
limits humoral immunity. Such information may reveal a novel immune-target to boost humoral 
immunity to malaria.  
In summary, a biphasic role for IRF3 was revealed during non-lethal experimental malaria. 
Firstly, IRF3 acted to drive Th1 responses, likely via up-regulation of MHCII on inflammatory 
monocytes, which resulted in better control of pRBC numbers during the early phase of infection. 
During later stages of infection, IRF3 performed a separate function within B cells to suppress GC 
B cell and Tfh responses, which was associated with limited production of Plasmodium-specific 
antibodies and delayed resolution of infection. Given its unique position downstream of several 
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PRR pathways, and its potential role in B cells, IRF3 represents a unique molecular target for 
modulating cellular and humoral immunity to malaria. 
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Chapter Six: 
Final discussion 
 Malaria remains a leading cause of global deaths due to infection. While extensive research 
efforts support roles for CD4+ T cells and antibodies in providing immunity to human and 
experimental malaria, how these responses can be induced in vivo is poorly understood. To address 
this gap in knowledge, this thesis aimed to determine novel cellular and molecular determinants 
mediating adaptive immune responses during malaria, with particular focus on Th responses. The 
three objectives of this thesis were to:  
 
1. Determine whether a newly developed Plasmodium-specific CD4+ T cell can be effectively 
used to track T helper responses. 
 
2. Resolve the process of Th1 and Tfh cell differentiation to gain molecular insight into 
mechanisms controlling Th fate decision-making. 
 
3. Investigate whether innate immune signalling pathways can influence Th1- and Tfh-
dependent immune responses during infection.  
 
6.1 PbTII cells represent an effective tool for studying in vivo CD4+ T cell 
responses 
CD4+ T cell responses during Plasmodium infection have been difficult to study partly due 
to the absence of appropriate antigen-specific tools (Stephens, Albano et al. 2005). In Chapter 3 of 
this thesis, a malaria-specific TCR transgenic mouse, which contains CD4+ T (PbTII) cells specific 
for Plasmodium, was tested in vivo for its responsiveness. PbTII cells proliferated and differentiated 
into Th1 and Tfh cells, which resembled the endogenous polyclonal response.  
 In addition to Th1 and Tfh effector subsets, PbTII cells were also observed to differentiate 
into IL-10 and IFNγ co-producing cells, referred to as Tr1 cells. Tr1 may be important for 
controlling immunopathology caused by potent inflammatory responses during both experimental 
and human infections(Couper, Blount et al. 2008, Walther, Jeffries et al. 2009, Freitas do Rosario, 
Lamb et al. 2012, Jagannathan, Eccles-James et al. 2014, Portugal, Moebius et al. 2014, Montes de 
Oca, Kumar et al. 2016). Modelling of PbTII scRNAseq data revealed that Tr1 cells emerged from 
the end of the Th1 differentiation branch, supporting the idea that Tr1 cells are direct descendants of 
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Th1 cells (Cardone, Le Friec et al. 2010). Further scRNAseq and computational analysis of PbTII 
cells could elucidate the relationship betweenTh1 and Tr1 cells, with the objective of identifying 
novel approaches for balancing parasite control and immunopathology during infection.  
 Immunological memory relies on long-term memory cells that are induced by previous 
infections. Memory responses during Plasmodium infection are difficult to induce and, 
unfortunately, difficult to maintain, as evidenced by the difficulty in developing naturally-acquired 
immunity and in the modest results from leading vaccine strategies(Stanisic, Mueller et al. 2010, 
Olotu, Fegan et al. 2013). Here, PbTII cells developed into both effector and central memory (TCM 
and TEM) phenotypes late in infection. Further studies determining the longevity of these responses 
in vivo will demonstrate the utility of PbTII cells for examining memory responses. In addition, the 
transition between effector cells and memory cells during in vivo infection could be studied through 
modelling scRNAseq data of PbTII cells. Possible findings could include identification of unique 
subsets of effector cells that are inclined to become memory cells,or novel molecular mechanisms 
associating with this transition. Such information will be imperative to improving strategies to boost 
immunological memory in individuals at risk of infection.  
6.2 Modelling of scRNAseq analysis of PbTII cells reveals the emergence of Th 
fates in vivo 
 Studying the emergence of Th responses in vivo has previously been confounded by 
extensive heterogeneity within cell populations at any given time, and different response kinetics. In 
Chapter 4, computational modelling of PbTII scRNAseq data was used to resolve the co-emergence 
of Th responses during PcAS infection. This allowed for the identification of gene expression 
profiles corresponding with either Th1 or Tfh differentiation, including expression of a range of 
transcription factors, receptors and genes with unclassified function. A critical next step in this 
research is to confirm with functional studies the relationship between these genes and 
differentiation. As a proof of concept, preliminary studies have focussed on CXCR3, which 
associated with Th1 differentiation.Blockade of CXCR3 during infection resulted in skewed 
differentiation of PbTII cells towards a Tfh state. Ongoing work has applied CRISPR-Cas9 
technology to delete Cxcr3 from PbTII cells to further demonstrate the requirement of CXCR3 
signalling for Th1 differentiation.   
 An initial hypothesis of this thesis was that innate immune cells shape Th responses during 
Plasmodium infection. The first evidence to support this hypothesis was the identification of two 
waves of Th-associate chemokine receptor expression - one that peaked late in differentiation and 
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an earlier wave that peaked around bifurcation. This suggests that while receptors expressed after 
bifurcation might mediate migration and effector function of PbTII cells, those peaking at 
bifurcation could allow T cells to sense chemokine-expressing cells. Of thechemokines expressed 
early, only Cxcr5 associated with commitment to Tfh fate decision. CXCR5 promotes the migration 
of Tfh cells to the B- and T-cell bordered where they provide ‘help’ to B cells for production of 
high-affinity antibodies(Crotty 2011). As demonstrated here and previously, B cells are also 
necessary to sustain the Tfh phenotype(Kerfoot, Yaari et al. 2011). On the other hand, Th1 fate 
commitment was associated with expression of several chemokine receptors that peaked at 
bifurcation. Among these wasCxcr3, which has previously been demonstrated facilitate cDC - T 
cell interactions and promote Th1 responses(Groom, Richmond et al. 2012). 
 Ly6Chiinflammatory monocytes are known to migrate to the spleen during Plasmodium 
infection(Sponaas, Cadman et al. 2006). They were inferior primers of naive CD4+ T cells 
compared to cDCs (Sponaas, Cadman et al. 2006), however their interaction with activated T cells 
had not been explored. Here, scRNAseq analysis supported a novel role for Ly6Chi monocytes in 
sustaining Th1 responses throughCXCR3:CXCL9/10 chemokine axis. Using the LysMCre x iDTR 
system to deplete monocytes/macrophages after PbTII cells had been primed but were yet to 
differentiate, strong evidence has been provided for their involvement. Comparison of scRNAseq 
analysis of monocytes with cDCs revealed an overlap of approximately 40% of genes differentially 
unregulated during infection. This suggests that monocytes have a similar function to cDCs during 
PcAS infection. To explore whether monocytes can act as APCs, preliminary studies have 
investigated PbTII responses in LysMcre x IAbf/fmice, in which monocytes do not express MHCII. 
While early activation of PbTII cells to infection was not perturbed in these mice, total number of 
Th1 cells at peak infection was significantly reduced. These data supports a model in which naive 
CD4+ T cells are primed by cDCs, and require additional antigen stimulation thereafter to sustain 
their response(Obst, van Santen et al. 2005). Since Th1 cells provide 'help' to another immune cells, 
including macrophages and NK cells (Taylor-Robinson and Phillips 1998), it seems reasonable that 
their responses would be tightly regulated by a requirement for continued antigen presentation, such 
that other response are indirectly limited.  
 Activated PbTII cells expressed an assortment of chemokine receptors prior to Th 
differentiation. This indicates that they are receptive to competing chemokine signals, which 
increase the likelihood of interacting with different cells in a heterogeneous tissue environment. In 
this way, PbTII differentiation could result from chance events, rather than preprogramming during 
priming. To explore the relationship between PbTII differentiation and spatial intercellular 
interactions, intravital imaging of PbTII cells, myeloid cells and B cells within the spleen could be 
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performed during PcAS infection. Furthermore, sorting PbTII cells from microdissected T cell 
zones, marginal zones and follicles could allow for more in-depth analysis of their phenotype by 
scRNAseq. Results from this research would provide clues for accurate delivery of antigen to the 
right APCs and in the right location to induce appropriate T cell responses to infections or vaccine 
challenges.  
 As demonstrated here and in other studies, scRNAseq can be applied to explore 
heterogeneity between cells and to model biological processes(Jaitin, Kenigsberg et al. 2014, 
Gaublomme, Yosef et al. 2015). Another feature of scRNAseq is that it allows for extensive 
information to be gained from as few as a handful of cells. This is particularly attractive for human 
immunological studies, which are often complicated by ethical constraints limiting the number of 
cells or range of tissues attainable for assessment. Although many studies use peripheral blood 
mononuclear cells (PBMCs) as a surrogate for immune response in peripheral tissues, comparison 
of cellular responses from both sites has revealed striking differences(Strauss, Bergmann et al. 
2007, Czarnowicki, Gonzalez et al. 2015). ScRNAseq has already proven useful in the area of 
human cancer research(Patel, Tirosh et al. 2014, Navin 2015, Kim, Lee et al. 2016) and in studying 
human embryogenesis (Yan, Yang et al. 2013). Future human disease studies could apply 
scRNAseq on cells from biopsies taken during diagnosis and disease management assessments, 
such as for Crohn's disease, to model how cells contribute to changes in disease state. 
 An important caveat of scRNAseq is that transcriptional activity does not necessarily 
correspond to translation into protein, or indeed cellular function. Extensive research into the 
relationship between RNA translation and protein levels has shown only a 50% overlap in the loci 
controlling the expression of these elements, suggesting distinct regulator mechanisms(Wu, 
Candille et al. 2013). Additionally, factors such as microRNAs that regulate translation, as well as 
mRNA synthesis and decay rates modulate the level of protein expressed(Baek, Villen et al. 2008, 
Schwanhausser, Busse et al. 2011).Therefore, the field is moving towards a multi-omics approach, 
in which genomics is combined with proteomics to gain a more holistic picture of the cellular 
activity. To demonstrate how this might be achieved, in a hypothetical study of T cell 
differentiation, phosphoproteomics could be used to monitor phosphorylation signalling of 
transcription factor localisation of such regulatory factors. Transcriptomics would elucidate the 
cohort of genes up or downregulated by activated transcription factors. Finally, proteomics would 
determine which transcripts become proteins at which time. 
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6.3 IRF3 balances Th1 and Tfh-mediated immune responses 
 Following from the observation that monocytes support Th1 differentiation, in Chapter 6 
innate immune signaling pathways were compared for their contribution to Th responses. Although 
STING, TLRs and NLRs have all been implicated in the detection of Plasmodium products 
(Krishnegowda, Hajjar et al. 2005, Parroche, Lauw et al. 2007, Sharma, DeOliveira et al. 2011, 
Kalantari, DeOliveira et al. 2014), no role for isolated PRRs was observed in eliciting an immune 
response. This highlights a caveat of a reductionist approach to immunological studies, since the 
removal of one element from a system does not take into account possible compensation by other 
elements. Thus, it is possible that functional redundancy exists between PRRs in driving Th 
responses, as suggested by the literature for ensuring robustness in innate responses towards 
continually evolving pathogens (Nish and Medzhitov 2011). To circumvent this issue, PbTII 
responses to infection could be followed in mice deficient in two or even three key molecules in 
different signaling pathways.  
 Here, a critical role for IRF3, a regulator of TI IFNs that sits downstream of a number of 
PRR signaling pathways, was identified. IRF3 promoted expansion of antigen-specific CD4+ T cell 
responses and their differentiation into Th1 cells. This contrasts with a recently reported role for TI 
IFN and the master transcription factor IRF7 in impairing Th1 responses during Plasmodium 
infection (Haque, Best et al. 2014, Edwards, Best et al. 2015). Therefore, this data suggests that 
IRF3 displays a diverse array of functions in immune cells. The role for IRF3 in supporting Th1 
responses after their initial activation was associated with MHCII expression by Ly6Chi 
inflammatory monocytes. Together with scRNAseq data reported in Chapter 4, this suggests a 
model in which monocytes upregulate MHCII expression under direction of IRF3 and facilitate 
encounters with CXCR3+ T cells through production of CXCL9/10. Monocytes support Th1 
responses, which assist in clearance of pRBCs(Amante and Good 1997). An obvious question 
arising from this data is whether IRF3 is activated within monocytes. Future work in this area could 
implement phosphoproteomics, to assess the phosphorylation of IRF3 within sorted Ly6Chi 
monocytes as a measure of its activation. Furthermore, chromatin immunoprecipitation followed by 
sequencing (ChIP-seq) analysis could be used to determine where IRF3 is binding to the genome to 
provide mechanistic insight into its function. Advancements in this technology could include single-
cell ChIP-seq (Rotem, Ram et al. 2015) in a single-cell multi-omics analysis as suggested above. 
 B cell-intrinsic IRF3 was shown to suppress the development of GC B cell responses and 
subsequent Plasmodium-specific antibody titres during blood-stage infection. This is consistent 
with previous reports and suggestions of IRF3 activation with B cells (Oganesyan, Saha et al. 2008, 
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Jin, Xiao et al. 2012). Tfh differentiation was also dampened, likely as a direct consequence of 
suppressed GC B cell responses. This suggests that IRF3 acts as a negative regulator of B cells to 
prevent excessive humoral responses. Indeed, IRF3, independently of interferons, has been shown 
to be induced by DNA-damaging agents, and was involved in cell cycle checkpoint control in 
response to these signals (Kim, Kim et al. 1999, Kim, Kim et al. 2000, Weaver, Ando et al. 2001). 
Ectopic expression of IRF3 significantly attenuated cell growth, while expression of mutated IRF3 
facilitated oncogenic transformation of human cell lines (Kim, Lee et al. 2003). Importantly, the 
data presented here showed that in the absence of IRF3 mice were able to clear the infection sooner 
and exhibited greater numbers of memory B cells. Intriguingly, mice deficient in IRF3 cleared a 
lethal infection of PbA, possibly due to improved humoral responses. The mechanism behind how 
IRF3-deficient mice survive cerebral symptoms of PbA infection would be an interesting avenue to 
pursue.  
6.4 Concluding remarks 
 Using a new antigen-specific TCR transgenic tool and cutting-edge scRNAseq technology 
with computational modelling, this thesis has demonstrated novel cellular and molecular 
mechanisms for modulating protective immunity during malaria. These findings have profound 
significance in identifying novel strategies to boost immunity to malaria, for example by using 
suitable adjuvants to induce monocytic responses or carefully alleviating the effects of IRF3 in B 
cells to improve humoral immunity. Future studies utilising the PbTII system and scRNAseq will 
continue to provide a more in-depth picture of the complex immune mechanisms that currently 
hinder the eradication of malaria. 
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